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Germline loss-of-function mutations in BRCA1 are associated with
a high lifetime risk of breast and ovarian cancer. Most mutations in
the gene are ‘truncating’: in the main these induce premature termi-
nation codons, resulting in nonsense-mediated decay, loss of the
transcript and/or the entire protein. The improved screening
methods now in use across the UK will identify many carriers of
unclassified  BRCA1 variants. These are chiefly missense muta-
tions, introducing an amino acid change in the context of an
expressed protein. Indeed more than one-quarter of entries
recorded in the Breast Cancer Information Core dataset of BRCA1
sequence variants collected from patients worldwide are
unclassified missense alterations (http://research.nhgri.nih.gov/bic/).
Currently, discovery of the majority of missense variants leaves
both variant carriers and their families in an ambiguous position.
These variants remain unclassified because in the majority of cases
it is not possible to follow variants by cosegregation analysis, and
the number of appropriate controls required to be certain that a
variant is absent in unaffected individuals is prohibitive. Currently,
in silico algorithms try to distinguish between missense substi-
tutions that are likely to be pathogenic and those that are not.
These algorithms compile a multicomponent likelihood ratio that
integrates assessment methods ranging from conservation analy-
sis, co-occurrence of a deleterious allele in trans, and immuno-
histochemical analysis [1-3]. What is missing from these analyses
is the relationship between loss of protein function and detriment
to patient health.
We have focused on the N-terminal region of BRCA1. This region
has a high density of missense substitutions, including those of
known pathogenic status, and many currently unclassified variants.
We have shown that experimental missense variants, generated
randomly and selected for loss of interaction with the BRCA1
ubiquitin ligase components, BARD1 and the E2 enzyme UbcH5,
identify variants reported within the Breast Cancer Information
Core database of individuals with a personal or family history of
breast cancer [4]. The E2 component is particularly sensitive to
missense alteration in BRCA1, with the majority of currently
unclassified variants in the region inhibiting interaction, whereas
the BARD1 component is disrupted by a smaller, but overlapping,
subset restricted to substitution of the structurally detrimental zinc-
ligation residues. Variants that inhibited the E2 also prevented the
enzymatic activity. These data strongly suggest that the ligase
activity of BRCA1, through interaction with E2 and BARD1, is
related to breast cancer predisposition.
Using yeast two-hybrid analysis for BRCA1:BARD1 and
BRCA1:E2 interaction, we have tested the most chemically
different substitutions achievable by single nucleotide change in all
of the most highly conserved amino acids of the region (invariant
from human to sea urchin), and have also tested all currently
identified patient missense variants. These data have been
combined with Grantham variation and Grantham deviance scores
(a measure of how conserved an amino acid is, together with how
different the protein change is) to assess the relationship between
protein:protein interaction and measures of disease risk. Risk
measures were based on the results of full sequence tests of
BRCA1 and BRCA2 from 68,000 BRACAnalysis subjects (Myriad
Genetics, Salt Lake City, UT, USA), and used estimates of the
odds of developing breast cancer for a carrier of a BRCA1
missense substitution [2], together with enrichment ratios achieved
by comparing the variants observed in the dataset with the variants
expected on the basis of known substitution rates.
Classification methods in the past have attempted to place variants
in either the pathogenic or the little-clinical significance categories.
The results of this analysis suggest that some classes of variant
may confer an intermediate risk. If so, these data have considerable
implications for the counselling and clinical management of women
found to be positive for missense variants in future.S2
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Background  Previous epidemiological studies have investigated
the relationship between individual nutrients such as vitamin D and
vitamin B12 and mammographic density, a strong marker of breast
cancer risk [1], with varied results. There has been limited research
on overall dietary patterns and most studies have focused on adult
dietary patterns [2]. We examine prospective data to determine
whether dietary patterns from childhood to adult life affect
mammographic density.
Methods The Medical Research Council National Survey of Health
and Development is a national representative sample of 2,815 men
and 2,547 women followed since their birth in March 1946 [3]. A
wealth of medical and social data has been collected in over 25
follow-ups by home visits, medical examinations and postal
questionnaires. Dietary intakes at age 4 years were determined by
24-hour recalls and in adulthood (ages 36, 43 years) by 5-day food
records. Copies of the mammograms (two views for each breast)
taken when the women were closest to age 50 years were
obtained from the relevant NHS centres. A total of 1,319 women
were followed up since birth in 1946 for whom a mammogram at
age 50 years was retrieved, and the percentage mammographic
density was measured using the computer-assisted threshold
method for all 1,161 women. Breast cancer incidence for the
whole cohort is being ascertained through the National Health
Service Central Register.
Statistical analysis Reduced rank regression analysis, a relatively
new approach to dietary pattern analysis, is being used to identify
dietary patterns associated with mammographic density [4]. This
approach identifies patterns in food intake that are predictive of an
intermediate outcome of the disease process, such as mammo-
graphic density, and subsequently examines the relationship
between the identified dietary patterns and breast cancer risk.
Results  Preliminary analyses so far suggest that variations in
dietary patterns in adulthood might explain more than 10% of the
variation in percentage mammographic density at age 50 years
(age 36 years: 13%; age 43 years: 14%), with variations in
patterns in childhood explaining slightly less. Further work is being
carried out on the characteristics of these dietary patterns and
their effects on percentage mammographic density and its two
components (that is, absolute areas of dense and nondense
tissues) and on breast cancer risk, after adjusting for socio-
economic status, anthropometric variables and reproductive factors.
Conclusion  The present study will provide for the first time
information on the relationship between dietary patterns across the
life course and mammographic density, and will help to clarify the
pathways through which diet may affect breast cancer risk.
Acknowledgements Breast Cancer Campaign UK–World Cancer
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Loss of oestrogen receptor alpha in long-term
antioestrogen-resistant cells: reversal by a c-src inhibitor
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Background  Tamoxifen still remains the most frequently used
antioestrogen for the treatment of breast cancer. However, its
efficacy is often limited by the emergence of acquired resistance
and it has been suggested that, in some instances, this may involve
oestrogen receptor (ER) loss. This study addresses this issue by
examining long-term tamoxifen treatment of breast cancer cells and
identifies that progressive ER loss does occur, leading to greatly
increased aggressive tumour cell behaviour. Encouragingly, even
after 30 months treatment, ER loss is reversible by a c-src inhibitor.
Our data therefore provide a new model to study the cellular
mechanisms associated with antihormone promoted ER loss and
its possible prevention/reversal by signal transduction inhibitors.
Methods Using quantitative PCR based on SYBR Green fluores-
cence, the expression of total ERα mRNA and its constituent
mRNA variants were quantified in MCF7 cells and in our in vitro
developed tamoxifen-resistant breast cancer cells (TamR), which
have been cultured in the presence of tamoxifen for 30 months.
Specific PCR amplification of all ERα mRNA variants was possible
using forward primers designed to bind specifically to the 5′
untranslated regions of ERα mRNA and used separately with a
common reverse primer that anneals to the 5′ end of the proteinS3
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encoding region of exon 1 of ERα cDNA. Expression of ERα
protein was assessed by western blot and immunohistochemistry.
Results In MCF7 cells, the ERα mRNA isoforms A, B and C were
detected as the most predominant variants, with C ERα mRNA
showing the highest expression level. In TamR cells, about a 40%
fall in total ERα mRNA was observed in comparison with MCF7
cells and was most apparent for the C variant. Extension of the
tamoxifen treatment period to 30 months produced a further
dramatic decrease in ERα mRNA (all variants) and protein levels,
resulting in ER negativity being recorded in >90% of the cells by
immunohistochemistry. These cells show increased levels of
phosphorylated Erk 1&2, AKT, PKCα and src, and are highly
aggressive in their growth behaviour, with increased cell motility
and invasiveness. Treatment of the cells with the demethylating
agent 5-azacytidine did not restore ERα expression, suggesting
that epigenetic alterations are unlikely to be responsible for the
reduced ER levels. However, Affymetrix data in the TamR cells
showed that some positive regulators of ER expression, such as
p53 and Foxo3A, are downregulated during the development of
the resistant phenotype and their continued absence may
contribute to the progressive ER loss. Significantly, pathway
inhibitor studies revealed c-src to be an important regulator of ER
loss, since its inhibition rapidly restored ER levels.
Conclusion Our data indicate that considerable ER loss can occur
during antihormonal treatment of breast cancer cells and that this
can lead to a more aggressive phenotype. Encouragingly, however,
even after 30 months exposure to tamoxifen, the process is
reversible by inhibition of c-src. These data suggest that
combinations of antihormones with signal transduction inhibitors
could retain ER functions in treated cells and prevent a drift
towards more aggressive cancer cell behaviour.
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Suppression of the NF-κ κB cofactor Bcl3 inhibits mammary
epithelial cell apoptosis and, in breast tumours, correlates
with poor prognosis
A Wakefield1, L Piggott1, D Croston1, WG Jiang2, R Clarkson1
1Life Sciences, School of Biosciences, University of Cardiff, UK;
2Angiogenesis and Metastasis Group, School of Medicine,
University of Cardiff, UK
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Background  Several transcription factors have been shown to
play important roles in the regulation of apoptosis at the onset of
murine mammary involution. These include LIF-activated STAT3,
c/ebpdelta, Ap-1 and IKK/NF-κB-mediated regulation of death
receptor ligands. A study of STAT3 and STAT5 transcriptional
targets in mammary epithelial cells in vitro showed that both
c/ebpdelta and c-fos (a component of Ap-1) were upregulated by
STAT3, suggesting a degree of interdependence between these
transcription factor pathways in mediating their apoptotic effects.
Interestingly, while no NF-κB or IKK genes were significantly
regulated by STATs, the NF-κB cofactor gene, Bcl3, was found to
be a principal transcriptional target of STAT3. This factor plays a
role in altering the transcriptional capacity of specific NF-κB
subunits and has previously been described as an oncogene in B-
cell lymphomas. In this study we set out to establish whether Bcl3
had a role in regulating the cell fate of mammary epithelial cells
either in the normal mammary gland or in mammary/breast cancer.
Methods Archived material representing a range of tumour grades
and types was collected from breast cancer patients immediately
after surgery (tumour tissues = 122, normal tissues = 32). The
median follow-up of the patients was 120 months (range 12 to
156 months). QRT-PCR for Bcl3 was performed and this infor-
mation was used to determine statistically significant correlations
with the clinical data on breast pathology. MCF7, T47D and MDA-
MB231 human breast cancer cell lines were subjected to Bcl3-
specific siRNA knockdown and subsequently assessed for cell
motility characteristics using ECIS technology. Bcl3-knockout mice
were assessed histologically for alterations in apoptosis rate during
the adult pregnancy cycle. Western blots, quantitative PCR and
DNA binding assays were used to determine the activity of
molecular markers of apoptosis in these animals. Bcl3-deficient
animals were crossed with mmtv-neu (c-erbB2) mice to establish
the role of Bcl3 in primary (neu-dependent) mammary tumour
growth, and magnetic resonance imaging was performed on
tumour-bearing animals, to establish metastasis rates in the
presence/absence of Bcl3.
Results An analysis of 122 human breast cancer tissues showed
that Bcl3 gene expression was suppressed in a significant
proportion of invasive tumours, which correlated with poor
prognosis. This also correlated with a significant decrease in Bcl3
gene expression in human breast cancer cell lines exhibiting
increased motility characteristics. The effects of siRNA-mediated
knockdown of Bcl3 are ongoing. In the mouse mammary gland,
Bcl3 expression was restricted to epithelial cells during the first 24
hours of involution. Bcl3 deficiency resulted in a transient delay in
the appearance of apoptotic bodies in the early involuting
mammary gland in Bcl3–/– mice, while pSTAT3 levels were
unchanged compared with equivalent timepoints in control
animals. The activities of initiator/executor caspases of both
intrinsic and extrinsic pathways were significantly decreased in
Bcl3–/– tissues at this time, which correlated with decreases in the
expression of key regulators of intrinsic/extrinsic apoptosis. Results
from the ongoing magnetic resonance imaging study of tumour
incidence/progression in mmtv-neu/Bcl3–/– mice will be presented.
Conclusion  These observations suggest that Bcl3 promotes
apoptosis in the mammary gland and provides preliminary evidence
of cross-talk between STAT3 and NF-κB pathways, both of which
have been implicated in breast cancer. Our current data on Bcl3 in
primary breast tumours and breast cancer cell lines contrasts with
other studies, to suggest that Bcl3 suppresses the metastatic
progression of primary breast cancer and has a neutral role in
breast cancer incidence or primary tumour growth.
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Background The onset of metastasis in organs such as the lung,
bone and brain is a major cause of mortality in breast cancer patients.
Many signalling pathways have been implicated in mediating
progression to metastatic disease, including the transforming
growth factor beta (TGFβ) signalling pathway. In many tissues
TGFβ results in a growth inhibitory signal. This is mediated by
transducers of the Smad family, which translocate to the nucleus
and activate transcription. In tumour cells, however, TGFβ-
dependent antiproliferative control is lost and cells acquire the
ability to replicate in TGFβ-rich environments. Despite molecular
and clinical evidence pointing to a role for TGFβ signalling in
cancer progression and metastasis, it is unclear at which points of
the metastatic process TGFβ signalling occurs and whether it is
necessary and/or sufficient to elicit cancer cell motility.S4
Methods To address these questions, MTln3E rat breast cancer
cells were used as a relevant model system. When injected into
the mammary fat pad of nude mice these cells form a primary
tumour from which motile cells will depart to form metastasis in the
lymph nodes and the lungs. To gain insight into TGFβ signalling in
vivo, MTln3E cells were engineered to express either GFPSmad2
or a Smad3 responsive promoter driving the expression of ECFP
(CAGA::ECFP). This allowed the monitoring of Smad-dependent
TGFβ signalling in vivo using multiphoton confocal microscopy.
Results Our results indicate that TGFβ signalling, measured by
cytoplasmic to nuclear translocation of GFPSmad2 and by
activation of CAGA ECFP, does not occur ubiquitously within the
primary tumour. In particular, cells that have acquired a motile
phenotype display active TGFβ signalling. As nuclear localisation
of GFPSmad2 and activation of CAGA ECFP are also observed in
nonmotile cells, however, TGFβ signalling may be necessary but
not sufficient to elicit cell motility in primary tumour cells.
Furthermore, activation of TGFβ signalling in motile cells is
transient, as lymph node metastasis display little activation of the
pathway. In addition, we have uncovered a second role for TGFβ
signalling in the metastatic process. After intravenous injection in
mouse tail vein, TGFβ pretreated cells colonise the lungs more
efficiently than untreated controls and this results from the ability of
these cells to survive clearance from the lungs.
Conclusion Together these data suggest that TGFβ signalling may
positively influence two distinct steps of the metastatic cascade,
first by enabling cells to become motile and second to enhance
their survival during the lung colonisation.
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Background MUC1 is a highly attractive target for immunotherapy
of breast cancer owing to its overexpression, altered glycosylation
and loss of polarity in over 90% of tumours. To exploit this, we are
developing genetic approaches to retarget T-cell specificity to
MUC1 using chimeric antigen receptor (CAR) technology.
Methods  A panel of CARs have been generated using scFv
derived from the SM3 and HMFG2 hybridomas. Using the SFG
oncoretroviral expression vector, gene transfer was achieved in up
to 75% of human T cells.
Results Two parameters proved crucial in engineering an optimized
CAR ectodomain. First, we found that MUC1-mediated activation of
engineered human T cells is subject to steric hindrance. This was
observed using anchored but not soluble MUC1 and was
independent of MUC1 glycosylation status. To circumvent this, we
increased the flexibility and reach of CAR binding arms using the
elongated hinge found in IgD. Second, CAR function was highly
dependent upon strong binding capacity across a broad range of
tumour-associated MUC1 glycoforms, including MUC1 Tn, T and
sialylated derivatives. This was realized using an scFv cloned from
the HMFG2 hybridoma. To optimize CAR signalling, tripartite
endodomains were constructed that contain modules derived from
TNF receptor family members in addition to CD28 and CD3ζ.
Ultimately, this iterative design process yielded a potent MUC1-
specific CAR termed HOX that contains a fused CD28/OX40/CD3ζ
endodomain. HOX-expressing T cells proliferate vigorously in vitro
upon repeated encounter with soluble or membrane-associated
MUC1, mediate production of proinflammatory cytokines (IFNγ and
IL-17) and elicit brisk antigen-dependent killing of MUC1+ tumour
cells. To test function in vivo, a human breast cancer xenograft
model has been established using MDA MB 435 tumour cells
engineered to coexpress MUC1 and firefly luciferase. When
introduced into SCID/Beige mice by intraperitoneal injection, rapid
tumour growth occurs that can be monitored longitudinally and
noninvasively by bioluminescent imaging. Mice bearing established
tumour have been treated intraperitoneally with a single dose of
human T cells grafted with HOX, two control CARs (DOX: lacking
the HMFG2 scFv; HDFTr: lacking a functional endodomain) or
medium alone. We observed that treatment with HOX-expressing T
cells resulted in a significant delay in tumour growth, as measured by
bioluminescent imaging, compared with control mice (Figure 1). In
addition, HOX-grafted T cells confer a significant survival advantage
upon mice bearing MCF7 breast cancer xenografts.
Conclusion Despite its role in tumorigenesis and immune evasion,
we show that the near-ubiquitous breast cancer antigen MUC1
can be targeted using CAR grafted T cells.
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Figure 1 (abstract O6)
*P < 0.05, HOX versus DOX, HOX versus medium if present; **P < 0.05, HOX versus DOX, HOX versus medium, HOX versus HDFTr.S5
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Role of the Hsp90 cochaperone, FKBPL, in oestrogen
receptor signalling and breast cancer growth and survival
H McKeen, C Byrne, A Valentine, M O’Rourke, A Yakkundi, 
K McClelland, K McAlpine, DG Hirst, T Robson
Molecular Therapeutics Group, School of Pharmacy, Queens
University Belfast, UK
Breast Cancer Res 2008, 10(Suppl 2):P1 (doi: 10.1186/bcr 1885)
Hsp90 chaperone complexes are involved in maintaining the
stability and signalling of Hsp90 client proteins such as the
oestrogen receptor (ER). The ER is the primary mediator of breast
cancer proliferation in response to oestrogen. Since increased ER
levels and transcriptional activation are associated with over 50%
of breast cancers, the ER is an attractive target for cancer
treatment strategies. Hsp90 inhibitors such as 17AAG are known
to destabilize these complexes by promoting proteasome-mediated
degradation of the steroid hormone receptor leading to tumour
growth inhibition [1] and sensitization to chemotherapy [2] and
radiotherapy [3]. Using protein interaction assays, we have
identified FKBPL, a novel gene that codes for an immunophilin-like
protein, as an Hsp90 cochaperone associated with the ER and
dynein motor protein complex. Overexpression studies have
demonstrated that FKBPL modulates ER signalling and affects
breast cancer growth and survival. Since most tumours become
refractory to current hormonal therapies within a year of starting
treatment, FKBPL represents a novel drug target that would enable
the disruption of signalling pathways integral in maintaining ER-
mediated tumour growth and survival.
Acknowledgements Funded by Breast Cancer Campaign, Action
Cancer and DEL.
References
1. Solit DB, Scher HI, Rosen N: Hsp90 as a therapeutic target
in prostate cancer. Semin Oncol 2003, 30:709-716.
2. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO,
Karnitz LM: Hsp90 inhibition depletes Chk1 and sensitizes
tumor cells to replication stress. J Biol Chem 2003, 278:
52572-52577.
3. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A,
Markovina S, et al.:  Geldanamycin and 17-allylamino-17-
demethoxygeldanamycin potentiate the in vitro and in vivo
radiation response of cervical tumor cells via the heat
shock protein 90-mediated intracellular signaling and
cytotoxicity. Cancer Res 2003, 63:8984-8995
P2
Two functionally distinct epithelial progenitors exist within
the luminal cell compartment of the mouse mammary gland
J Stingl1, CJ Eaves1,2, CJ Watson1
1Department of Pathology, University of Cambridge, Cambridge,
UK; 2Terry Fox Laboratory, British Columbia Cancer Research
Centre, Vancouver, Canada
Breast Cancer Res 2008, 10(Suppl 2):P2 (doi: 10.1186/bcr 1886)
Background  The organization of the mammary epithelial cell
hierarchy is poorly understood.
Methods To determine the cells that make up this hierarchy and
the relationship between them, we used fluorescence-activated
cell sorting in combination with in vitro colony-forming cell assays
to examine the growth and differentiative properties of pheno-
typically distinct subsets of mouse mammary epithelial cells.
Results Our results indicate that >95% of all colony-forming cells
present within the mammary epithelium are localized within the
luminal cell compartment and that >90% of these have a
CD45–Ter119–CD31–(Lin–)CD24highCD14+ phenotype. This
progenitor cell population can be further resolved into two
functionally distinct subpopulations based on the expression of
Sca1. The Lin–CD24highCD14+Sca1– progenitors, which express
low levels of estrogen receptor alpha and intermediate levels of
keratin 14 (K14), are perceived to be progenitors that produce
Lin–CD24highCD14–Sca1– alveolar cells during pregnancy. The
Lin–CD24highCD14+Sca1+ progenitors, which express intermediate
levels of estrogen receptor alpha and are K14–, are perceived to
be precursors of the steroid receptor expressing cells, of which the
vast majority are terminally differentiated and have a
Lin–CD24highCD14–Sca1+ phenotype.
Conclusion  These results demonstrate the existence of two
functionally distinct progenitor cells within the luminal compartment
of the mammary gland and provide a framework for interpreting
breast tumour gene expression profiles and the possible origins of
breast tumours.
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Interactions between BRCA2 protein and the meiosis-
specific recombinase DMC1
T Thorslund, F Esashi, SC West
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Homologous recombination has a dual role in eukaryotic
organisms. Firstly, it is responsible for the creation of genetic
variability during meiosis by directing the formation of reciprocal
crossovers that result in random combinations of alleles and traits.
Secondly, in mitotic cells, it maintains the integrity of the genome
by promoting the faithful repair of DNA double-strand breaks. In
vertebrates it therefore plays a key role in tumour avoidance.
Mutations in the tumour suppressor protein BRCA2 are associated
with predisposition to breast and ovarian cancers, and loss of
BRCA2 function leads to genetic instability, as BRCA2 is required
for regulation of double-strand break repair by homologous
recombination. BRCA2 protein regulates recombinational repair by
interacting directly with RAD51 recombinase via a series of
degenerate BRC repeat motifs encoded by exon 11 (BRCA2996-
2113), and an unrelated C-terminal domain (BRCA23265-3330).
Recent observations show that BRCA2 is also required for
homologous recombination at meiosis. We show that human
BRCA2 binds directly to the meiosis-specific recombinase DMC1
and define the primary DMC1 interaction domain to a 26 amino
acid region located at BRCA22386-2411. This region is highly
conserved in BRCA2 proteins from a variety of mammalian
species, but is absent in BRCA2 from Arabidopsis thaliana,
Caenorhabditis elegans, and other lower eukaryotes. Within this
region, we demonstrate the critical importance of Phe2406,
Pro2408, and Pro2409 at the conserved motif 2404KVFVPPFK2411,
and define this novel DMC1 interaction domain the PhePP motif.
The PhePP motif promotes specific interactions between BRCA2
and DMC1, and no interactions take place between this region of
BRCA2 and RAD51. Thus, the RAD51 and DMC1 interaction
domains on BRCA2 are distinct from each other, allowing
coordinated interactions of the two recombinases with BRCA2 at
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meiosis. These results lead us to suggest that BRCA2 is a
universal regulator of RAD51/DMC1 recombinase actions.
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Lineage commitment in mammary epithelium is regulated
by type 2 cytokines and Stat6
WT Khaled1, SE Nicholson2, FO Baxter1, N Sprigg2, JP Stingl1,
ANJ McKenzie3, CJ Watson1
1Department of Pathology, University of Cambridge, UK; 2Division
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Breast Cancer Res 2008, 10(Suppl 2):P4 (doi: 10.1186/bcr 1888)
Naïve T-helper cells differentiate into Th1 and Th2 subsets that
have unique cytokine signatures, activators, and transcriptional
targets. The Th1/Th2 cytokine milieu is a key paradigm in T-cell
lineage commitment and IL-4/IL-13 and Stat6 are known to be
important mediators of Th2 development. We have now
demonstrated that this paradigm applies also to mammary
epithelial cells, which undergo a switch from Th1 to Th2 cytokine
production upon the induction of differentiation. Thus, the Th1
cytokines IL-12, IFNγ, and TNFα are downregulated concomitantly
with the upregulation of the Th2 cytokines IL-4, IL-13 and IL-5 as
epithelial cells commit to the luminal alveolar lineage. Moreover, we
show that Th2 cytokines play a crucial role in mammary gland
development in vivo, because differentiation and alveolar morpho-
genesis are reduced in both Stat6 and IL-4/IL-13 doubly deficient
mice during pregnancy. This unexpected discovery demonstrates a
role for immune cell cytokines in epithelial cell fate and function,
and adds an unexpected tier of complexity to the previously held
paradigm that steroid and peptide hormones are the primary
regulators of mammary gland development.
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Background Elevated chromosomal radiosensitivity in lymphocytes
of breast cancer patients is thought to be an indicator for the
presence of one or more as yet unidentified genes of low
penetrance that promote susceptibility to the disease in up to 60%
of cases [1,2]. One such gene may be TOPO2A, encoding for the
DNA processing enzyme topoisomerase IIa. The involvement of
topoisomerase IIa is predicted from the author’s model for formation
of chromatid breaks [3]. In the model the DNA double-strand break
is not directly involved in the chromatid break, but acts as an initiator
in a sequence of events leading to a chromatid break. It is thought
that a chromatid break may be formed by a misjoining of chromatin
ends during topoisomerase IIa decatenation of chromatids as the
cell progresses through G2 towards mitosis. Topoisomerase IIa is
known to be vulnerable to perturbation by oxidative stress during
the precise process of cutting and joining DNA strands [4].
Methods Gamma-radiation-induced chromatid breaks are scored
for chromatid breaks in colcemid-blocked chromosome spreads of
metaphase HL60 and mitoxantrone-resistant variants: MX1 and
MX2 cells with reduced topoisomerase II expression. Topoiso-
merase IIa expression levels were measured using western
blotting. SiRNA was used to knock down expression in normal
exponentially growing human cells that are irradiated with a low
dose of γ-rays and scored for the presence of chromatid breaks.
The chromatid break frequency and topoisomerase IIa expression
(ELISA assay) are being compared in 3-day-stimulated peripheral
blood T lymphocytes from a group of breast cancer patients and
control individuals exposed to a low dose of γ-radiation.
Results We show that chromatid radiosensitivity (based on the
frequency of metaphase chromatid breaks in irradiated G2 cells) is
significantly lower in a topoisomerase IIa underexpressing variant
cell lines [5], and preliminary results show that reducing expression
with SiRNA also reduces chromatid radiosensitivity. In a pilot study
we are currently comparing the chromatid radiosensitivity and
topoisomerase IIa expression in stimulated peripheral blood
lymphocytes of a group of Tayside breast cancer patients and a
similar number of normal noncancer control individuals.
Conclusion Our data support the hypothesis that topoisomerase
IIa expression is a determinant of chromatid break frequency in
irradiated G2 cells, and thus could be an underlying cause of the
observed variability of chromatid radiosensitivity among both
sporadic breast cancer cases and normal control individuals.
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Background  Genome rearrangement is a major mechanism of
gene alteration in cancer. Chromosome translocations and
inversions can result in gene fusion, promoter insertion or gene
inactivation. In the past it has been assumed that such rearrange-
ments are not significant players in the common epithelial cancers,
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as they are in leukaemias and sarcomas. However, this view is now
being challenged. In particular, Tomlins and colleagues found that
around 70% of prostate cancers have translocations or inversions
of the ETS family of transcription factors [1]. In breast cancer, we
have shown that the NRG1/heregulin gene is translocated in 6%
of primary cases [2] and Soda and colleagues described fusions of
ALK in 7% of lung cancers [3].
Methods and results We present a comprehensive analysis by
array painting of the chromosome translocations of breast cancer
cell lines HCC1806, HCC1187 and ZR-75-30. In array painting,
chromosomes are isolated by flow cytometry, amplified and
hybridized to DNA microarrays [4]. A total of 200 breakpoints were
identified and all were mapped to 1 Mb resolution on BAC arrays,
then 40 selected breakpoints, including all balanced breakpoints,
were further mapped on tiling-path BAC arrays or to around 2 kb
resolution using oligonucleotide arrays. Many more of the
translocations were balanced than expected, either reciprocal
(eight in total) or balanced for at least one participating
chromosome (19 paired breakpoints). Many breakpoints were at
genes that are plausible targets of oncogenic translocation,
including CTCF and P300. Two gene fusions were also demon-
strated, TAX1BP1-AHCY and RIF1-PKD1L1.
Conclusion  Our data establish that array painting is a very
effective way to map substantial numbers of translocation
breakpoints and support the emerging view that chromosome
rearrangements that fuse, activate or otherwise alter genes at their
breakpoints may play an important role in common epithelial
cancers.
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Regulation of gene expression by the estrogen receptor (ER)
requires the coordinated recruitment and dissociation of trans-
criptional coactivator complexes and concomitant chromatin
remodelling and histone modification. In addition to the well-
characterised recruitment of coactivator proteins, a number of
corepressor proteins can also be recruited to the liganded ER,
including RIP140 and L-CoR.
We have recently identified a new ER interacting protein, ZNF366,
which is recruited to the liganded ER, through interactions
involving the zinc finger domains of both proteins. We show that
repression of ER-regulated genes by ZNF366 involves recruitment
of the well-described corepressor CtBP. This interaction is
mediated by two sequence motifs in ZNF366, conforming to the
consensus CtBP-binding motif (PXDLS). Mutation of these motifs
in ZNF366 reduces, but does not abolish, the corepressor activity
of ZNF366. Additionally, ZNF366 interacts with RIP140, raising
the possibility that RIP140 and ZNF366 may act synergistically in
regulating ER activity [1].
Finally, we show that although ZNF366 is expressed in normal
breast epithelial cells, its expression is not detected in breast
cancer cells. This raises the possibility that regulation of ER activity
by ZNF366 may be important in breast cancer development.
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C-terminal binding proteins (CtBPs) (CtBP1 and CtBP2) are dual-
function proteins that act in the nucleus as transcriptional co-
repressors and in the cytoplasm as regulators of mitotic Golgi
fissioning. They have been implicated in the process of cellular
transformation through their physical and functional interactions
with the viral oncoproteins adenovirus E1A, and EBNA3C. Studies
in which the expression or function of CtBPs has been suppressed
in mammalian cells have independently identified both a role in
suppressing apoptosis, through their regulation of transcription of
proapoptotic genes, and a requirement for cell-cycle progression,
dependent on their role in the Golgi. Here we have undertaken a
holistic analysis of the phenotypic consequences of ablating CtBP
expression in breast cancer-derived cell lines. We find that loss of
CtBPs suppresses the proliferation of these lines through a
combination of induction of apoptosis, reduction in cell-cycle
progression into mitosis, and aberrations in transit through mitosis
itself. This third phenotype includes errors in mitotic chromosome
segregation, activation of, but failure to sustain, the spindle
assembly checkpoint, diminished localisation of spindle checkpoint
proteins at kinetochores, and a high rate of failure to complete
cytokinesis. These represent novel roles for CtBPs in the regulation
of critical stages of the cell division cycle.
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Background RASSF2 is located at 20p13, a region frequently lost
in human cancers. RASSF2 is a recently identified member of the
ras association domain of family tumour suppressor genes, and
many other members of this family are inactivated in human
tumours by promoter methylation.
Methods Methylation-specific PCR and combined bisulphite and
restriction analysis were used to analyse the methylation status of
the RASSF2 promoter CpG island in a series of breast tumours
and cell lines. Bioinformatic approaches were used to study
RASSF2 and a highly conserved putative bipartite nuclear localisa-
tion signal (NLS) was identified. Colony formation, growth in soft
agar and growth in immunocompromised mouse assays were used
to assess the tumour suppressive activities of RASSF2.
Results RASSF2 was frequently methylated in breast tumour cell
lines, 65% (13/20), and in primary breast tumours, 38% (15/40).
In the 10 samples for which corresponding normal DNA was
available this methylation was tumour specific. RASSF2 expression
could be switched back on in methylated breast tumour cell lines
after treatment with 5-aza-2dC. Endogenous RASSF2 localised to
the nucleus and mutation of the putative nuclear localisation signal
abolished the nuclear localisation. RASSF2 suppressed breast
tumour cell growth in vitro and in vivo, while the ability of NLS-
mutant RASSF2 to suppress growth was much diminished.
Conclusion  These data indicate that RASSF2 is frequently
methylated in breast tumours, and thus RASSF2 is a novel
methylation marker that has the potential to be developed into a
valuable epigenetic marker for screening. We also demonstrate
that RASSF2 acts as a tumour suppressor gene and that it
contains a functional NLS that is important for its tumour
suppressor gene function.
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Background CTCF is a conserved, ubiquitous and multifunctional
transcription factor with features of a tumour suppressor. We have
previously reported that CTCF function is modulated by post-
translational poly(ADPribosyl)ation [1,2]. Poly(ADPribosyl)ation of
CTCF protein results in two isoforms: a highly poly(ADPribosyl)ated
form (called CTCF180) and a hypopoly(ADPribosyl)ated form
(called CTCF130). In this study we assessed the presence of both
CTCF isoforms in normal and cancer breast tissues and
investigated their function using immortalised cell lines.
Methods  CTCF expression was analysed in breast tissues and
breast cancer cell lines by western blotting, immunohistochemistry
and immunofluorescence, using antibodies that specifically
recognise different CTCF isoforms. Functional investigations of
CTCF isoforms in cell culture included induction of apoptosis,
senescence and cell-cycle arrest using various chemical
treatments and analysis of cells by flow cytometry.
Results We discovered, using a large panel of breast tumours and
paired peripheral tissues, that only the CTCF180 isoform was
present in normal breast tissues, whereas CTCF130 was
exclusively detected in breast tumour tissues and immortalised cell
lines. Immunohistochemical staining revealed that 91% of the
breast tumours contained CTCF130. In addition, correlations were
found between the levels of CTCF130 and tumour grade, lymph
node metastases and neoadjuvant chemotherapy treatment. In
breast cancer cell lines, induction of cell death by apoptosis and
senescence resulted in a transition from the CTCF130 to the
CTCF180 isoform. This shift was not observed following cell-cycle
arrest.
Conclusion  The present study demonstrates that CTCF180 is
characteristic for normal breast tissues, whereas CTCF130 is
specific for breast tumours and breast cancer cell lines. The
CTCF130 isoform may therefore be used as a specific biological
marker for breast tumourigenesis. Our data indicate that loss of
CTCF poly(ADPribosyl)ation may be involved in breast tumour
development. Poly(ADPribosyl)ation of CTCF, on the other hand,
correlates with induction of cell death in breast cancer cell lines.
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Background It has long been suspected that there is an important
breast cancer tumour suppressor gene on the short arm of
chromosome 8, 8p, and our array CGH data suggest that it may be
close to NRG1 [1]. NRG1 encodes growth factors that bind to
tyrosine kinases ErbB3 and ErbB4, and can both stimulate cell
proliferation and apoptosis. NRG1 is also quite frequently broken
by chromosome translocations [2].
Methods and results By quantitiative PCR, NRG1 expression was
repressed or abolished in many breast cancer cell lines and
tumours as compared with normal breast. Methylation analysis by
sequencing or pyrosequencing bisulphite-treated DNA showed
striking DNA methylation at a CpG island in NRG1, which is
correlated with an absence of NRG1 transcripts. Treatment of
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cancer cell lines with 5-aza-2-deoxycytidine reactivated the
expression of NRG1 by 7 to 100 times. NRG1 was also methy-
lated in tumour tissue samples while it was not in uncultured
normal breast epithelium. Knocking down NRG1 expression by
siRNA led to an increase in net cell proliferation.
Conclusion NRG1 could be the 8p tumour suppressor gene. It is
located in the right place. It is silenced by methylation or other
mechanisms in many breast cancer cell lines and tumours.
Functionally, NRG1 expression is antiproliferative – shown both by
our siRNA experiments and older work that showed expression to
be proapoptotic to breast cancer cell line MCF7 [3].
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We recently established that the p53 gene expresses nine
different p53 protein isoforms. The p53 isoforms bind preferentially
to some p53-responsive promoters and modulate differentially p53
transcriptional activity [1]. We characterized further p53β activity.
p53β is differentially recruited to p21 and bax promoters in the
absence or in the presence of DNA-damaging drugs.
p53β enhances p53 transcriptional activity on the p21 promoter in
a dose-dependent manner in the absence of cellular stress but
inhibits p53 transcriptional activity on the p21 promoter in the
presence of DNA-damaging agents. On the contrary, p53β has no
effect on p53 transcriptional activity on the bax promoter in the
absence of stress but enhances p53 transcriptional activity on the
bax promoter in response to stress without increasing the p53
protein level.
Our data indicate that p53β is involved in the choice of p53 target
gene expression in response to cellular signals, switching cell fate
outcome from G1 arrest/DNA repair to cell death.
The present finding supports our hypothesis that differential
expression of the p53 isoforms in primary breast tumours may help
to link p53 status to biological properties and drug sensitivity.
Reference
1. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A,
Xirodimas DP, Saville MK, Lane DP: p53 isoforms can regu-
late p53 transcriptional activity. Genes Dev 2005, 19:2122-
2137.
P13
Inhibitor of apoptosis proteins as a therapeutic target in
breast cancer
FM Foster, NJ Bundred, CH Streuli
Faculty of Life Sciences, University of Manchester, UK
Breast Cancer Res 2008, 10(Suppl 2):P13 (doi: 10.1186/bcr 1897)
Background Apoptosis is the process of programmed cell death
by which damaged or unhealthy cells are normally destroyed.
Cancer cells are able to avoid apoptosis and thereby survive
inappropriately. Inhibitor of apoptosis proteins (IAPs) are a family of
proteins that block apoptosis in normal cells, by binding to active
caspases, the proteases that mediate cell death. There are eight
human IAPs, including NAIP, XIAP, cIAP1, cIAP2, livin, survivin and
apollon. An upregulation of IAPs could cause resistance to
apoptosis. Targeting IAPs in cancer therapy may therefore improve
the clinical effectiveness of apoptosis-inducing chemotherapeutics.
A number of studies have shown that XIAP and survivin are up-
regulated in cancer, and inhibiting these IAPs increased the
apoptotic response induced by some chemotherapeutics. We aim,
first, to examine the expression profile of all IAPs in breast cancer
and, second, to determine whether inhibiting IAPs will enhance the
apoptotic response to traditional chemotherapeutics and newly
developed targeted therapies, such as Herceptin.
Methods IAP levels were detected in patient and cell line samples
by immunoblotting with validated antibodies using the Li-Cor
Odyssey system (Li-Cor Biosciences, Lincoln, NE, USA). IAPs
were inhibited using siRNA or cell-permeable mimics of endo-
genous inhibitors. Control cells and cells with XIAP knocked down
or inhibited were exposed to TNF-related apoptosis inducing
ligand (10 ng/ml), Herceptin (100 μg/ml), Iressa (10 μM), or
Lapatinib (100 nM) for 48 hours. Apoptosis was scored by examin-
ing nuclear morphology (DAPI) or active caspase 3 staining.
Proliferation was examined by Ki67 staining.
Results We have found that IAPs are widely upregulated in breast
cancer. In particular cIAP2, XIAP and survivin were more prevalent
in breast cancer cells than normal breast epithelium. Knock down
of XIAP or inhibition with small molecule inhibitors resulted in an
increased apoptotic response to TNF-related apoptosis inducing
ligand, in both sensitive and resistant cell lines. Knocking down
XIAP also increased the apoptotic response to a number of growth
factor receptor-targeted therapies such as Herceptin, Iressa and
Lapatinib.
Conclusion  Inhibiting IAPs in combination with both chemo-
therapeutic agents and targeted therapies, such as Herceptin and
Lapatinib, which act as receptor antagonists, will improve clinical
outcome.
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Background Proteomic technologies verified AGR-2 as a protein
family overexpressed in human cancers, including breast, prostate
and oesophagus cancers, with the ability to inhibit the tumour
suppressor protein p53 [1]. The AGR-2 gene is a hormone
responsive gene with an unexpected induction by the anticancer
drug tamoxifen highlighting the proto-oncogenic role of this
protein. The hAGR-2 gene was first described in the MCF-7 breast
Available online http://breast-cancer-research.com/supplements/10/S2S10
carcinoma cell line, and was found to be coexpressed with the
estrogen receptor (ER), in ER-positive cell lines [2,3]. Moreover, it
was recently revealed that AGR-2 is secreted from androgen-
inducible cell lines in prostate cancer cell lines [4].
Methods  Localization studies of AGR-2 were performed using
fluorescence microscopy in order to determine in which
compartment the protein functions. Yeast two-hybrid analysis has
identified potential nuclear and cytoplasmic binding proteins for
AGR-2, essential for the upstream or downstream regulation of the
AGR-2 pathway.
Results Anterior gradient 2 encodes one protein that gives rise to
two forms: the full-length and the mature. Full-length AGR2wt,
which bears the leader sequence, localizes to the ER and the
Golgi compartment whereas the mature protein requires the C-
terminal KTEL sequence for strong nuclear localization. Deletion of
the KTEL, putative ER retention, sequence does not alter the
localization of the wt full-length form to a large extent but has a
strong effect on the localization shift of the mature form.
Subcellular fractionation data verified the difference in the
localization patterns of the wt forms and their mutants. Moreover,
the localization of the protein and each of the mutants differs
significantly in various cell lines, suggesting a multipotent role of
the protein when it comes to activation pathways and localization
patterns within the cell. Furthermore, we present data showing
models of how the AGR-2 family might function as a drug-
resistance survival factor in cancer as well as a p53 inhibitor.
Conclusion All of the above suggest a multipotent role of AGR-2
when it comes to trafficking, cellular localization and activation or
inhibition pathways in cancer. The localization of the protein can
therefore determine the level of p53 inhibition.
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We have been investigating a novel link between two independent
processes linked to breast cancer: Wnt signalling and h-Prune
overexpression. The canonical Wnt signalling pathway was
activated in 40% to 60% of human breast cancers through
mechanisms that are not understood. Similarly, the phospho-
diesterase h-Prune was overexpressed or amplified in 54% of
breast cancers and was linked to breast tumour progression
through unknown mechanisms.
We have shown that overexpression of xenopus Prune induced
formation of a secondary axis in a standard assay to identify
activators of the Wnt signalling pathway. In HEK293 cells, xenopus
Prune overexpression induced a 300-fold increase in Wnt/TCF-
dependent transcription. Whilst human prune does not appear to
be able to activate Wnt signalling as potently as its xenopus
homologue, it does synergise with other activators of the pathway
to increase TCF-dependent transcription.
Here we show whether there is a correlation between over-
expression of h-Prune and active Wnt signalling in breast cancer,
and whether the synergistic responses described are mediated
through the enzymatic activity of prune, or through binding to GSK-3.
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We have previously demonstrated that the DEAD-box RNA
helicase p68 is an important regulator of gene expression [1,2],
whilst other groups have shown that p68 interacts with and
coactivates estrogen receptor alpha (ERα) [3,4]. The main focus of
our project is to investigate the molecular mechanism of ERα
coactivation by p68 and to examine the potential consequences for
breast cancer development.
We have established that the interaction of p68 and ERα requires
the DNA binding domain of ERα and the C terminus of p68.
Importantly, this region of p68 lies outside the conserved helicase
core and was previously shown by us to be essential for
transcriptional regulation by p68. Additionally, coactivation of ERα
by p68 requires the ligand binding/AF2 region of ERα and is
consistent with the model that p68 is recruited to ERα-responsive
promoters in response to estrogen [4]. We have also shown that
p72, a helicase that is very highly related to p68 and that had
previously been suggested to act in an analogous fashion to p68
[3], poorly coactivates ERα in standard transcriptional coactivation
assays, using ER-responsive promoters. This is underscored by our
finding that overexpression of p68, but not of p72, in cell lines
results in stimulation of expression of physiological target genes of
ERα.
Interestingly, siRNA-mediated knockdown of endogenous p68 has
little effect on the expression of ERα target genes. This observation
is consistent with the idea that p68 has little effect on ERα function
physiologically, but that the elevated p68 levels found in tumours
may stimulate ERα-mediated gene expression in a pathological
context. Strikingly, however, in contrast to p68, knockdown of
endogenous p72 results in a marked inhibition of both baseline
and estrogen stimulated-expression of these genes. These findings
suggest, firstly, that p72 is important physiologically for ERα
activity in the cell and, secondly, that p68 and p72 may be acting
in an opposing rather than analogous fashion (as had been
previously suggested [3]). Moreover, our preliminary data suggest
that overexpression of p68 in cells may additionally coactivate ERα
in an estrogen-independent manner, a finding that may have implica-
tions in the development of resistance to endocrine therapies.
We are currently developing inducible p68/p72 overexpression
and siRNA cell lines with a view to examining the effect of
augmenting or suppressing p68/p72 expression in mouse
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xenograft models. Additionally we are screening a large panel of
breast cancers to examine p68 and p72 expression/localisation in
the context of ERα expression.
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Mammary gland involution is characterised by a high degree of
apoptosis. By identifying genes that are upregulated at this
developmental stage, we aimed to discover key factors that are
involved in the induction of mammary epithelial cell death and
therefore present potential tumour suppressors for breast cancer.
Among 96 genes recently identified as specifically upregulated
early during involution were the transforming growth factor beta
(TGFβ)-stimulated clone 22 homologue (TSC-22/TGFβ1-induced
transcript 4) and TGFβ3 [1]. TGFβ3 has recently been shown to be
necessary for induction of apoptosis during mammary gland
involution, while TSC-22 overexpression can lead to cell death. We
have therefore tested whether TSC-22 mRNA expression can be
induced by TGFβ3 and whether it is involved in or necessary for
TGFβ-induced apoptosis. We further show that TSC-22 can
enhance TGFβ3-induced Smad response and epithelial cell death.
In addition, overexpression of TSC-22 alone can induce a Smad
response and apoptosis in mammary epithelial cell cultures, which
is independent of p53. Further, we have performed tests to study
the necessity for Smad proteins during TSC-22-induced
apoptosis, and to establish the intracellular localisation of TSC-22.
A pilot study on a small cohort of archival breast cancer cases,
representing all stages of malignant progression, shows that TSC-
22 protein was reduced or undetectable in 60% of breast
carcinomas when compared with adjacent normal breast tissue,
suggesting that TSC-22 could indeed be a potential novel tumour
suppressor gene. We shall present data showing that methylation
of the TSC-22 promoter is not involved in the reduction of TSC-22
protein in breast cancer.
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Background Germline mutations in BRCA1 and BRCA2 genes
predispose women to an increased risk of breast/ovarian cancer.
Both genes have important roles in DNA damage repair and are
implicated in gene expression regulation. We have previously
shown that normal fibroblasts from mutation carriers can be distin-
guished from noncarriers following radiation-induced DNA damage.
In this new study we used lymphocytes to determine whether these
also show differential response to induced DNA damage and
whether expression profiling using microarray technology could be
used to accurately predict the BRCA genotype.
Methods  Short-term lymphocyte cultures were established from
fresh blood samples from 20 BRCA1 and 20 BRCA2 mutation
carriers and from 10 negative controls (individuals tested negative
for the mutation present in the family). Lymphocytes were
subjected to 8 Gy ionizing irradiation to induce DNA damage and
RNA was extracted 1 hour post γ-irradiation. For expression pro-
filing, genome-wide (30 K) spotted cDNA microarrays manufac-
tured by the Cancer Research UK Microarray Facility were used.
We then applied the support vector machine (SVM) classifier with
statistical feature selection to determine the best feature set for
predicting BRCA1 and BRCA2 heterozygous genotypes. We also
investigated the prediction accuracy using a nonprobabilistic
classifier (SVM) and a probabilistic classifier (Gaussian process
classifier).
Results and conclusion We achieved high accuracy (92% to
96%) in predicting the mutation carrier status. We shall present
the detailed outcome of using the SVM classifier and the Gaussian
process classifier in the task of distinguishing between the three
classes, BRCA1 and BRCA2 mutation carriers and noncarriers,
and evaluate whether this microarray technology can be used to
facilitate the clinical detection and classification of mutations.
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Background CCCTC binding protein (CTCF) is a highly conserved
and ubiquitous transcription factor with versatile functions. It is
involved in transcriptional regulation, chromatin insulation and
epigenetic control [1]. Although CTCF has features of a tumour
suppressor gene, it is overexpressed in breast cancer cells; this
phenomenon is associated with the resistance of these cells to
apoptosis [2]. The aim of the present study is to investigate the
molecular mechanisms of the CTCF-dependent resistance of breast
cancer cells to apoptosis.
Methods A proteomics approach was used to generate protein
profiles of breast cancer cells, ZR75.1, with normal and reduced
levels of CTCF. In the latter cells CTCF was knocked-down using
siRNA and iRNA. Cell extracts were analysed using two-dimen-
sional PAGE, and differentially expressed proteins were identified
by matrix-assisted laser desorption/ionization time-of-flight or liquid
chromatography/mass spectrometry/mass spectrometry.
Results  More than 20 putative candidates have so far been
obtained; they belong to various protein families involved in the
control of signalling, metabolic, apoptotic, stress response and
mammary gland specific regulatory pathways. One of the
candidates, the proapoptotic protein Bax, was further validated as
a target for negative regulation by CTCF. We demonstrated that
expression of Bax correlated inversely with CTCF levels.
Furthermore, Bax promoter was negatively regulated by CTCF in
reporter assays. Two putative CTCF binding sites were identified
within the promoter of Bax gene; contact nucleotides were
determined by footprinting and methylation interference assays.
Conclusion Our data suggest that high levels of CTCF may cause
repression of Bax and inhibition of apoptosis. Lower levels of
CTCF lead to activation of Bax, resulting in apoptosis. Selective
reduction of CTCF can therefore be an attractive option in the
development of antibreast cancer therapies.
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Background  Aberrant Notch signalling has been shown to be
involved in many cancers. We have recently observed accumu-
lation of the Notch intracellular domain (NICD) in breast cancer cell
lines and tissue samples in comparison with normal cell lines and
tissues. Moreover, Notch activation has been shown to inhibit
apoptosis induced by chemotherapeutics that activate the p53
pathway. We are thus investigating the role of Notch signalling in
breast cancer by studying the molecular mechanisms that underlie
its suppression of apoptosis.
Methods  Notch signalling was activated in the normal breast
epithelial cells MCF10A by expression of NICD or a fusion protein
CBF1-VP16. To inhibit Notch signalling in MCF7, BT474 and
Hs578t cancer cells we expressed NUMB, a natural inhibitor of the
pathway or a dominant-negative Mastermind protein. Signalling
through apoptotic pathways and extent of cell death were
monitored by western blot analysis and chromatin condensation by
Hoechst staining, respectively. Apoptosis was induced by
melphalan treatment (100 μM). Pretreatment with SH6 (10 μM) or
SP600125 (10 μM) was used to inhibit AKT pathways or JNK
activity, respectively. Nutlin-3 (10 μM) was used to inhibit p53–
MDM2 interaction.
Results Activation of Notch signalling in MCF10A cells caused
resistance to p53-dependent apoptosis induced by DNA damage.
Conversely, inhibiting Notch signalling in MCF7, BT474 or Hs578t
cancer cell lines led to a sensitization to apoptosis. We further
showed that AKT was phosphorylated on serine 473 and that the
AKT targets ASK1 and MDM2 were phosphorylated on serine 83
and 166, respectively, in Notch-activated MCF10A cells. Further-
more, AKT inhibition by treatment with SH6 restored sensitivity of
NICD-expressing or CBF1-VP16-expressing cells to DNA-damage-
induced apoptosis, showing that AKT activation is sufficient to
confer resistance to apoptosis. We thus investigated the role of
AKT-mediated MDM2 phosphorylation. Inhibition of p53–MDM2
interaction by treatment with Nultin-3 restored neither NOXA or
PUMA accumulation nor sensitivity of NICD-expressing or CBF-1-
VP16-expressing MCF10A cells following DNA-damaging agent
treatment. We next showed that, following DNA-damaging agent
treatment, Notch activation prevented JNK phosphorylation and
PUMA and NOXA accumulation. Furthermore, JNK activation in
NICD-expressing or CBF1-VP16-expressing cells is sufficient to
induce cell death, and inhibition of JNK signalling by treatment with
SP600125 is sufficient to prevent cell death in normal MCF10A
cells.
Conclusion  Notch activation of the AKT pathway inhibits DNA
damage-induced apoptosis by inhibition of JNK via ASK1
phosphorylation.
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TopBP1 is a nuclear protein with eight BRCT domains and is
involved in many aspects of nucleic acid metabolism: it is involved
in the initiation of DNA replication in the Xenopus in vitro
replication system by assisting loading of polymerase onto the
replication complex; it is a substrate for ATM/ATR and is essential
for the ATR DNA damage signalling pathway, and is also probably
involved in the actual DNA repair process; it acts as a
transcriptional cofactor for E2F1 where it regulates the apoptotic
function of this protein. In addition, the yeast homologues of
TopBP1, Dbp11 (Saccharomyces cerevisiae) and Cut5 (Schizo-
saccharomyces pombe), are also involved in replication and repair
processes. TopBP1 also shares functions with BRCA1; both are
involved in regulating an intact G2/M checkpoint, they colocalise to
sites of DNA damage, they share sequence homology (even
outside the BRCT domains), they are substrates for ATM/ATR, and
they can regulate expression of the c-myc gene. All of these
properties of TopBP1 led to us investigating whether TopBP1
plays a role in breast cancer.
There is a polymorphism in TopBP1 that gives an increased risk of
breast cancer [1], and work from our laboratory has demonstrated
that TopBP1 is aberrantly expressed in a significant number of
human breast cancers [2]. Clearly the role of TopBP1 in replication
and genome maintenance would mean that disturbance of expres-
sion could result in genomic instability contributing towards
cancer. Our studies have focused on an additional aspect of
TopBP1 that could contribute to the transformed phenotype; gene
regulation. We have identified several chromatin modification
domains on TopBP1 that could contribute not only to trans-
criptional regulation but also to the replication and repair functions
of this protein [3]. Using siRNA knockdown of TopBP1 in MCF7
cells, we identified genes that are regulated by TopBP1. Following
knockdown of TopBP1, the short-term growth of the MCF7 cells
was not affected. This was surprising as it has been predicted that
TopBP1 is essential for DNA replication and our results demon-
strate that this is not the case in all cell lines (we have tested other
lines in which TopBP1 is essential for S phase). However, even
though these cells cycled for several days, they did not survive long
term, presumably due to accumulated damage following replication
in the absence of TopBP1. Using this MCF7 system we carried out
microarray experiments that revealed the absence of TopBP1
alters the expression of genes involved in many cellular pathways
implicated in breast cancer, including the oestrogen signalling
pathway, and the mitogen-activated protein kinase signalling network.
Future work will focus on determining how TopBP1 regulates
these pathways and what cellular interacting partners TopBP1
requires for chromatin modification. Such studies will increase our
understanding of breast cancer and assist in developing diagnostic
and prognostic gene profiling for breast cancer management.
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Background BRCA1 and cyclin D1 are both essential for normal
breast development and mutation or aberration of their expression
is associated with breast cancer [1,2]. Cyclin D1 is best known as
a G1 cyclin where it regulates the G1 to S phase transition by
acting as a rate-limiting subunit of CDK4/6 kinase activity. More
recently, however, Stacey has demonstrated that cyclin D1 levels in
G2/M determine whether a cell continues to proliferate or exits the
cell cycle [3]. The majority of BRCA1 in the cell is bound to
BARD1 through their N-terminal RING domains. Hetero-
dimerization is essential for the stability and correct localization of
the complex and confers ubiquitin ligase activity to BRCA1. The
importance of the ligase activity of BRCA1 to breast cancer
development is inferred from the fact that N-terminal disease-
associated mutations are proposed to reduce ligase activity [4].
Methods  Protein–protein interactions were demonstrated using
yeast-two-hybrid and coimmunoprecipitation. Protein levels were
altered through overexpression, siRNA and antisense technology.
The effect of proteasome inhibitors and cycloheximide treatment
was also examined.
Results  We initially identified cyclin D1 as a binding partner of
BARD1 in a yeast-two-hybrid screen and defined the minimal
binding region as the N-terminus of BARD1. This interaction was
confirmed  in vivo by coimmunoprecipitation. The N-terminus of
BARD1 also binds BRCA1 and imparts ubiquitin ligase activity to
the complex. Covalent modification of proteins with ubiquitin is a
common regulatory mechanism in eukaryotic cells. Traditionally,
polyubiquitin chains linked through lysine 48 target proteins for
degradation by the 26 S proteasome. We have demonstrated that
cyclin D1 protein levels are inversely related to BRCA1 and
BARD1 levels in several model systems. Furthermore, regulation of
cyclin D1 levels occurs through a post-transcriptional mechanism
and requires the ligase activity of BRCA1. Interestingly, this
phenomenon is cell-cycle regulated, occurring in G2/M.
Conclusion We propose that cyclin D1 is a potential substrate for
BRCA1 ubiquitination and that this targets cyclin D1 for
proteasomal-mediated degradation. Future work will focus on
ascertaining the functional consequence of cyclin D1 regulation by
the BRCA1–BARD1 complex; in particular, the impact of BRCA1,
mediated through regulation of cyclin D1, on the proliferation
versus differentiation decision.
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Two-thirds of breast cancers express estrogen receptor alpha
(ERα) and are estrogen-dependent for growth, yet the unavailability
of accurate in vivo models has long impeded the characterisation
of critical events that lead to the development of these luminal
subtypes of the disease. Previously, our group successfully created
an ERα-positive breast cancer model by quantitative transfor-
mation of normal human mammary epithelial cells (HMECs) derived
from reduction mammoplasties. HMECs were grown as mammo-
spheres in suspension to enrich for progenitor cells, which were
then transformed using lentiviral vectors encoding ERα and TERT
as well as the polycomb gene BMI1 and MYC, both of which have
been implicated in ERα-positive breast cancer. Injection of
transformed HMECs into mammary fad pads of NOD/SCID mice
resulted in the formation of estrogen-dependent tumours that
metastasised to multiple organs [1], confirming the creation of a
model that mirrors the characteristics of human estrogen-
dependent breast cancer. Somewhat surprisingly, we observed
islands of squamous differentiation in the tumours that formed in
the NOD/SCID mice, whereas the large majority of human breast
tumours are adenocarcinomas. To address this discrepancy, we
are currently testing a combination of our established protocol with
new HMECs in vitro culture conditions that have recently been
shown to abrogate the squamous phenotype of the resulting
tumours in mice [2]. Our model system is a powerful tool for the in
vivo characterisation of candidate genes that have been implicated
in development of ERα-positive breast cancer. Genes of interest
include  TNRC9, which has recently been identified in genome-
wide association studies as a potential novel breast cancer
susceptibility gene [3], as well as TBX3, which is known to play a
role in mammary gland development as well as breast tumouri-
genesis. We are currently testing these genes in our model using
overexpression and knockdown approaches.
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Background  Estrogen receptor (ER) expression is a key
determinant of breast tumour behaviour. While the role of ERα in
carcinogenesis is relatively well understood, the role of ERβ, the
more recently identified receptor, remains uncertain. This is partly
because analyses have been confused by a consistent
discrepancy between ERβ expression at mRNA and protein levels
[1]. Recently, evidence has accumulated that deregulation of gene-
specific  translation occurs during carcinogenesis in breast and
other tissues. Regulation of ERβ translation could therefore be
responsible for nonconcordance of its mRNA and protein levels,
and could provide an important level of modulation of ER activity
during breast cancer development.
Regulation of translation occurs mainly during initiation. Most
initiation occurs by cap-dependent scanning, which requires
binding of the initiation complex to the mRNA cap and recruitment
of other proteins. These scan along the 5′ untranslated region
(UTR) of the mRNA to the reading frame, where they recognise an
initiation codon, recruit more factors, and initiate protein synthesis.
5′ UTRs vary greatly in length and sequence with some containing
elements that allow regulation of factor recruitment or scanning,
and thereby allow regulation of translation of their specific mRNAs
[2]. It is thought that deregulation of translation, via 5′-UTR
sequences, is responsible for a significant proportion of the
expression changes in cancer cells and that this has a role in
carcinogenesis.
We identified three alternative 5′ UTRs for ERβ – UTRa (including
upstream exon 0K), UTRa long (UTRa containing an additional 5′
sequence) and UTRb (including upstream exon 0N) – from the
literature [3] and EST databases (Figure 1). Our hypothesis is that
these alternative 5′ UTRs allow differential post-transcriptional
regulation of ERβ expression, thereby providing critical regulation
of ER function.
Methods We investigated the properties of these three ERβ 5′
UTRs using established reporter assays [4]; each 5′ UTR was
cloned upstream of a GFP reporter. Breast cell lines (MCF7, MDA-
MB-453, MDA-MB-231, BT-20 and HB2) were transiently
transfected with either an unmodified GFP reporter as a control
(this is identical to experimental vectors except for its non-
specialised 5′ UTR), or with equal copy numbers of specific 5′-
UTR reporters.  Effects of each 5′ UTR on translation were
assessed by measurement of relative GFP protein and mRNA
expression from each plasmid using flow cytometry and
quantitative PCR, respectively. Semi-quantitative PCR was also
used to analyse ERβ 5′ UTRa and UTRb expression in matched
normal/tumour breast tissues.
Results Our results are the first to show that these alternative 5′
UTRs do, in fact, allow the differential regulation of ERβ translation.
The UTRa and UTRa long 5′ UTRs strongly inhibited translation of
the GFP reporter whilst UTRb had little effect. In addition, our
preliminary data suggest that these alternative 5′ UTRs are
differentially expressed between breast normal and tumour tissue.
The expression of UTRa mRNA was found to be upregulated in a
panel of breast tumours compared with matched normal tissue. This
may have important implications in breast cancer development.
Work is currently ongoing to investigate the stability of these mRNA
messages and to identify important regulatory sequences.
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Conclusion Post-transcriptional regulation plays an important role
in determining the level of ERβ protein expression and may
therefore have an influence on overall estrogen receptor activity.
This may have important implications on our understanding of
breast cancer biology and treatment.
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Background Reelin is a secreted signalling protein whose major
function has so far been described in the developing brain, where
it is involved in cell positioning of neuronal progenitor cells.
Recently, the Reelin promoter has been found to be methylated in
pancreatic cancer and this was associated with increased
migratory ability [1], whereas in the prostate Reelin expression is
associated with high-grade cancers [2].
Methods  We measured the Reelin expression and promoter
methylation status in breast cancer-derived cell lines and in a
cohort of 64 breast cancer cases. We further stained sections of
normal, benign, and cancerous human breast, as well as two tissue
arrays of 168 and 2,200 breast cancer patients, respectively.
Reelin staining was analysed with regards to other clinical
parameters and survival.
Results Promoter methylation status in breast cancer cell lines, as
well as in primary cancers, corresponds with reduced expression
of Reelin. In the normal breast, Reelin is expressed in the luminal
epithelium and myoepithelium, but is lost during breast cancer
progression. Reelin expression correlates with increased survival
(P = 0.01) and negative lymph node status. Treatment of breast
cancer cell lines with the demethylating agent decitabine leads to
re-expression of Reelin RNA.
Conclusion  Reelin expression in the breast is associated with
increased survival and negative lymph node status, and is
controlled at least in part by promoter methylation. Reelin is
therefore a novel potential tumour suppressor gene in the breast.
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Background  Normal mammary epithelial cells, like all other
nucleated cells in the body, have the innate capacity to undergo
programmed cell death by apoptosis. This process is controlled by
external factors such as hormones and growth factors, as well as
by cell–cell contacts and recognition of damaged DNA, and plays
an essential role in maintaining stable cell numbers. In breast
cancer cells, in common with most other cancer cells, the control
of apoptosis is defective, so that the rate of cell death falls below
that required to maintain a stable cell population size. The analysis
of the molecular control of apoptosis is therefore very important in
understanding breast cancer development and in producing novel
therapies.
We have successfully used functional expression cloning [1] to
identify novel genes playing controlling roles in the apoptosis
process. We have used the effects of the genes on cell survival
itself to isolate those genes that act at rate-limiting steps in the
control of this process, and whose level of activity therefore
Available online http://breast-cancer-research.com/supplements/10/S2
Figure 1 (abstract P24)
5′ end of the human ERβ gene (14q23) aligned with mRNAs
containing different ERβ 5′ UTRs. UTR exons (filled boxes),
transcriptional (black arrows) and translational (ATG) start sites, intron
sizes, and primers used for PCR analysis (grey arrows, specific UTRs;
open arrows, exon 1) are shown. Sequences strongly suggestive of
translational regulation are described: uORFs and stable RNA
structure, quantified as change in free energy, ΔG; for comparison, ΔG
of the nonregulatory β-actin 5′ UTR is only –24 kcal/mol.S16
determines whether the cell lives or dies. The genes we have
identified include protein phosphatase 4 [2], Fau [3], vATPase E,
PLAC8 and GAS5 [4]. Subsequently we have studied the effects
of upregulation and downregulation of the activity of these genes
on breast cancer cells. We have also analysed the levels of
expression of these genes in normal breast epithelium and in
breast cancer tissue in order to determine which of the genes are
involved in the development of these cancers.
Methods  Gene expression in breast cancer cell lines was
upregulated by transfection of full-length cDNAs in pcDNA3 or
pCMVSPORT expression vectors. Downregulation was achieved
by transfection of siRNAs (Ambion; Applied Biosystems, Warring-
ton, UK). Real-time quantitative RT-PCR was used to monitor gene
expression levels in the breast cancer cell lines, and also in breast
cancer and matched normal breast tissue.
Results  Modulation of expression of several of the candidate
genes, particularly Fau, altered the sensitivity of breast cancer cell
lines to apoptosis. While expression of PLAC8 was not signifi-
cantly altered in the breast tumour samples as a whole, several of
the other genes, including Fau and  vATPase E, did show
significant changes in their levels of expression in breast tumour
tissue, when compared with normal matched breast epithelial
tissue from the same patients.
Conclusion Several of the apoptosis-controlling genes identified
by functional expression cloning affect the sensitivity of breast
cancer cells to apoptosis, including that caused by DNA-damaging
agents. Those genes that show differential expression may play
particularly important roles in the development of breast cancer
and in determining breast cancer resistance or sensitivity to
cytotoxic therapy.
Acknowledgement Breast Cancer Campaign funded this project.
References
1. Williams GT, Farzaneh F: The use of gene function to iden-
tify the rate-limiting steps controlling cell fate. Cancer
Immunol Immunother 2004, 53:160-165.
2. Mourtada-Maarabouni M, et al.:  Functional expression
cloning reveals pro-apoptotic role for protein phosphatase
4. Cell Death Differ 2003, 10:1016-1024.
3. Mourtada-Maarabouni M, et al.: Regulation of apoptosis by
Fau revealed by functional expression cloning and anti-
sense expression. Oncogene 2004, 23:9419-9426.
4. Williams GT, et al.: Isolation of genes controlling apoptosis
through their effects on cell survival. Gene Ther Mol Biol
2006, 10:255-262.
P27
D133p53 isoform is a direct p53 target gene that
modulates p53 tumour suppressor activity
M Aoubala
Breast Cancer Res 2008, 10(Suppl 2):P27 (doi: 10.1186/bcr 1911)
Abstract not available at time of publication.
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Myoepithelial cells (MEC) are essential to the maintenance of
normal breast function, and loss of normal MEC function is
commonly associated with breast cancer. Most established
invasive breast carcinomas develop through an in situ phase
known as ductal carcinoma in situ (DCIS). We have identified up-
regulation of β6 integrin on MEC in a subset of DCIS. Normal MEC
exhibit potent tumour suppressor function, but it is not clear
whether this is compromised in DCIS. The aim of the present study
is to investigate the effect of β6 expression on myoepithelial tumour
suppressor function.
Immunohistochemical analysis of DCIS of different grades with and
without an invasive breast cancer was carried out to determine the
β6 status. For in vitro studies magnetic bead sorting was used to
isolate a pure normal-like myoepithelial cell line from the immorta-
lised 1089 cell line (N-1089 MEC). These were used to generate
β6 overexpressing myoepithelial cells (DCIS-modified MEC) by
retroviral transduction. The lines were characterised by immuno-
fluorescence and flow cytometry, and the tumour suppressor
function of both lines was compared with primary normal and DCIS
MEC in coculture with breast cancer cell lines.
Analysis of a series of primary DCIS tissues (n > 400) demon-
strated induction of β6 in MEC in a subset of cases, predominantly
high grade. Upregulation was almost universal in DCIS associated
with invasive disease. Initial characterisation of the 1089 line
revealed a mixed phenotype from which pure MEC were selected
on the basis of β4 integrin. This population exhibited all charac-
teristic myoepithelial markers. Coculture assays demonstrated that
N-1089 MEC could produce the same tumour suppressor effect
as primary MEC, leading to significant reduction in tumour invasion
(P < 0.001) and proliferation (P < 0.001). N-1089 MEC trans-
duced with αvβ6 (DCIS-1089 MEC) demonstrated enhanced
binding and migration to the β6 ligand LAP, and activation of a
transforming growth factor beta reporter, indicating that the αvβ6
was functional. Whilst primary DCIS MEC showed loss of
suppressor function (P < 0.05), DCIS-1089 MEC exhibit altered
behaviour with a more migratory phenotype then the normal
counterpart, but at least some of the tumour-suppressor function
was maintained.
We have shown that MEC exhibit an altered phenotype in DCIS
with de novo expression of αvβ6. We have generated normal-like
cell lines that exhibit all the characteristics of primary MEC and
recapitulate primary MEC tumour suppressor function. Primary
DCIS MEC show loss of suppressor function whereas β6-
overexpressing MEC (which resemble DCIS-like MEC) promote or
suppress breast cancer cell invasion in a cell-type-specific manner.
These findings suggest that changes in MEC during DCIS may
influence disease progression, and these cell lines provide a
powerful model to study further the mechanisms involved.
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The differences in glycosylation patterns seen in breast malignancy
strongly influence the final structure of membrane and secreted
glycoproteins, and these novel tumour-associated glycoforms can
modify the behaviour of the malignant cell and its interaction with
immune effector cells. Changes in mucin type O-glycosylation
occur in breast carcinomas and are the result, at least in part, of
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changes in the expression of specific glycosyltransferases [1]. A
similar change in the expression of glycosyltransferases resulting in
the change of glycans attached to O-linked glycoproteins is seen
when normal dendritic cells mature and migrate to the lymph nodes
[2]. As 70% to 80% of metastatic breast cancers metastasize via
the lymphatics, a particular pattern of O-linked glycans may be
required for cells to migrate and/or settle in the lymph nodes.
Changes in O-linked glycosylation have a considerable influence
on the structure of mucin glycoproteins that carry hundreds of O-
linked glycans. The MUC1 membrane mucin is expressed by over
90% of breast carcinomas and in the change to malignancy
truncated O-glycans are added to this mucin. In vitro synthesis of
MUC1-based glycoproteins and glycopeptides carrying specific
tumour-associated glycans has allowed an investigation of how
individual glycoforms affect the immune response and interact with
immune effector cells [3,4]. It is becoming clear that some glyco-
forms of MUC1 can induce an immune response while others are
immunosuppressive. Understanding how the different tumour-
associated glycoforms induce or inhibit the immune response is
important for the design of clinical studies using MUC1-based
antigens.
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Background Tamoxifen has been the principal endocrine therapy
for estrogen receptor alpha (ERα)-positive breast cancer patients
and still remains the therapy of choice in the premenopausal
setting. However, resistance and recurrence remain a serious
problem. Our previous work has indicated that 15-hydroxyprosta-
glandin dehydrogenase (15-PGDH) was significantly down-
regulated in two, independently derived, tamoxifen-resistant (TAMr)
MCF-7 derivatives compared with sensitive controls [1]. 15-PGDH
is the key enzyme for the biological inactivation of prostaglandins,
and has been shown to be a tumour suppressor in breast cancer.
However, a role for 15-PGDH downregulation in endocrine resis-
tance has not previously been identified.
Methods and results Downregulation of 15-PGDH mRNA and
protein in TAMr MCF-7 was confirmed by quantitative RT-PCR and
western blotting. To determine the role of 15-PGDH in TAMr, we
stably transfected TAMr MCF-7 cells with human 15-PGDH cDNA.
Overexpression of 15-PGDH partially restored sensitivity of TAMr
cells to 4-hydroxytamoxifen by the MTT assay, demonstrating that
15-PGDH downregulation plays a functional role in the acquisition
of TAMr. Treatment of TAMr MCF-7 cells with a DNA methyl-
transferase inhibitor (5-azacytidine), and a histone deacetylase
inhibitor (trichostatin A), led to re-expression of 15-PGDH mRNA
(by quantitative RT-PCR), suggesting that 15-PGDH is silenced via
epigenetic mechanisms during the acquisition of TAMr. To address
whether 15-PGDH downregulation is involved in clinical TAMr, we
assembled a tissue microarray comprising 89 relapsed primary
human breast cancers and 234 tamoxifen-sensitive controls. We
are currently optimizing 15-PGDH immunohistochemistry on our
tissue microarrays, and results will be presented.
Conclusion Our data suggest that the acquisition of TAMr in vitro
involves epigenetic silencing of 15-PGDH. Moreover, our data
show that 15-PGDH downregulation has a novel, functional role in
endocrine resistance.
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Elevated levels of matrix metalloproteinases (MMPs) have been
found to associate with poor prognosis in various carcinomas. This
study aimed at evaluating plasma levels of the collagenases
MMP1, MMP8 and MMP13 as diagnostic and prognostic markers
of breast cancer. Using ELISA, plasma levels of MMP1, MMP8 and
MMP13 were measured in 42 control individuals and in 208
patients – of which 21 were inflammatory breast cancer patients –
and were correlated with standard clinicopathological data. Plasma
MMP1 levels were higher in breast cancer patients than in control
individuals, while the opposite was true for MMP8. Plasma MMP13
levels could not be detected. We found a negative correlation of
plasma MMP1 with tumour size (P = 0.07); and a positive associa-
tion of MMP8 with the premenopausal status (P = 0.06),
Nottingham Prognostic Index (P = 0.06) and Her2 expression
(P = 0.07). Further, a twofold decrease in MMP1 (P = 0.025) and
MMP8 (P = 0.007) levels was observed in inflammatory breast
cancer patients, a very rare and not well understood aggressive
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disease. Most interestingly, we observed a peculiar relation
between plasma MMP8 levels and lymph node metastasis. We
found that both control individuals and patients without lymph node
involvement (pN0) have lower plasma MMP8 levels than patients
with moderate lymph node involvement (pN1, pN2) (P = 0.001);
and that they show a trend for higher MMP8 levels as compared
with patients with extensive lymph node metastasis (pN3) and a
strong predisposition to distant metastasis. In summary, we
observed differences in MMP1 and MMP8 plasma levels between
distinct breast cancer patient groups. As it is not clear to date
whether MMPs in blood and body fluids have a physiological
function per se, we hypothesize that altered levels in blood reflect
local changes in the extracellular microenvironment. As such, a
positive association of blood MMP levels with clinical
characteristics and tumour features reflects a negative association
with tissue MMP levels and vice versa. Therefore, our results
suggest that both MMP1 and MMP8 in the tumour may contribute
to the aggressive phenotype of inflammatory breast carcinomas.
Interestingly, our results suggest that tumour MMP8 expression
may affect the metastatic behaviour of breast cancer cells with a
greater protective effect against lymph node metastasis than
against distant metastasis.
Acknowledgement  Supported by the EU Cancerdegradome
Project Grant LSHC-CT-2003-503297.
P32
Association of MMP8 gene variation with breast cancer
prognosis
J Decock1,2, JR Long3, RC Laxton4,5, XO Shu3, C Hodgkinson4,
W Hendrickx1, EG Pearce5, YT Gao6, AC Pereira7, R Paridaens1,
W Zheng3, S Ye4,5
1Laboratory for Experimental Oncology, KU Leuven, Belgium;
2Biomedical Research Centre, School of Biological Sciences,
University of East Anglia, Norwich, UK; 3Department of Medicine,
Vanderbilt Epidemiology and Cancer Centre, Vanderbilt University
School of Medicine, Nashville, TN, USA; 4William Harvey Research
Institute, Barts and The London School of Medicine, London, UK;
5Human Genetics Division, University of Southampton, UK;
6Department of Epidemiology, Shanghai Cancer Institute,
Shanghai, China; 7Departamento de Biociencias e Diagnostico
Bucal, Faculdade de Odontologia de São José dos Campos –
UNESP, São José dos Campos, Brazil
Breast Cancer Res 2008, 10(Suppl 2):P32 (doi: 10.1186/bcr 1916)
Animal and cell line studies indicate an inhibitory effect of matrix
metalloproteinase 8 (MMP8) on tumorigenesis and metastasis [1-
3]. We investigated whether MMP8 gene variation was associated
with breast cancer metastasis and prognosis in humans. We first
studied nine tagging single nucleotide polymorphisms (SNPs) in
the MMP8 gene in 140 clinically and pathologically well-charac-
terized breast cancer patients. Four of the SNPs were found to be
associated with lymph node metastasis, the most pronounced
being a promoter SNP (rs11225395) with its minor allele (T)
associating with reduced susceptibility to lymph node metastasis
(P = 0.02). This SNP was further evaluated for association with
cancer relapse and survival among a cohort of approximately 1,100
breast cancer patients who had been followed for cancer
recurrence and mortality for a median of 7.1 years. The T allele was
associated with reduced cancer relapse and greater survival,
particularly among patients with earlier stage cancer. Among
patients of tumour-node-metastasis stage 0-II, the adjusted hazard
ratio of disease-free survival was 0.7 (95% CI, 0.5 to 0.9) for
patients carrying T allele compared with those homozygous for the
C allele (P = 0.02). In vitro experiments showed that the T allele
had higher promoter activity than the C allele in breast cancer
cells. Electrophoretic mobility shift assays showed binding of
nuclear proteins to the DNA sequence at the SNP site of the T
allele but not that of the C allele. The data suggest that MMP8 gene
variation may influence breast cancer prognosis and support the
notion that MMP8 has an inhibitory effect on cancer metastasis.
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Background Bone metastasis is a frequent and often incurable
complication of breast cancer causing severe bone pain, patho-
logical fractures, spinal cord compression and hypercalcaemia. We
have focused on establishing the significance of the cell surface
hyaluronan receptor CD44 in underpinning the preferential meta-
stasis of breast cancer cells to bone. In prior in vitro studies we
have demonstrated that depletion of CD44 expression in breast
cancer cells attenuates their adhesion to bone marrow endothelial
cells (BMECs). Our recent experiments have also determined that
the expression of CD44 is elevated in a bone-homing breast
cancer subline MDAMB231BO relative to that detected in the
parental MDAMB231 breast cancer cell line. Together these
experiments suggest a physiological role for this receptor in
promoting the entry of breast cancer cells into the bone micro-
environment.
Methods To further understand the potential significance of CD44
signalling to breast cancer metastasis, we established a tetra-
cycline-regulated CD44 expression system in the minimally
invasive, CD44-negative MCF7F cell line. Removal of tetracycline
from the growth media resulted in time-dependent increases in
CD44 expression in MCF7F cells, promoting increased cell
invasion and migration responses in addition to potentiating the
adhesion of MCF7F cells to BMECs. Subsequent microarray
analysis was conducted using this expression system to identify
CD44/HA-regulated genes in breast cancer cells.
Results The expression and activation of CD44 was associated
with increased expression of a subset of genes implicated in
metastasis including proteolytic enzymes, growth factors and
cytoskeletal proteins (for example, cortactin). Interestingly, the
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cysteine protease cathepsin K and the matrix metalloprotease
MT1MMP were identified as CD44/HA-regulated genes. These
proteases target collagen I, a major component of the bone matrix
whose degradation is a major consequence of osteolytic meta-
stasis of breast cancer. Quantitative real-time PCR, immuno-
blotting and ELISA-based experiments have demonstrated that the
transcript and protein expression of cathepsin K and MT1MMP
increase in response to CD44/HA signalling in a panel of CD44-
expressing breast cancer cell lines (MDA231, MDA157 and
MCF7F). Further experiments conducted using a parental and bone-
homing subclone of the MDAMB231 cell line (MDAMB213BO)
have shown that the expression of CD44, cathepsin K and
MT1MMP is elevated in the MDAMB231BO cells relative to their
parental counterparts. Furthermore, CD44/HA signalling was
shown to increase cathepsin K and MT1MMP mRNA and protein
expression in the MDAMB231BO cells. Consistent with their
increased metastatic phenotype, MDAMB231BO cells displayed
enhanced invasion on HA-supplemented Matrigel and collagen I
and demonstrated enhanced collagenolytic activity as demon-
strated using an in vitro fluorescence-based assay. RNAi mediated
depletion of CD44 and MT1-MMP expression and pharmacological
inhibition of cathepsin K attenuated CD44 promoted invasion
through a collagen I matrix. We are currently investigating the
mechanistic basis underpinning the transcription of these
proteases in breast cancer cells, and using the MDA231BO cell
line to determine the in vivo significance of CD44 expression to
osteolytic metastasis of breast cancer.
Conclusion  Our studies demonstrate that CD44 signalling
regulates collagenase activity in breast cancer cells underpinning
their invasion through matrix substrates that are enriched within
breast tissues and organs to which this disease preferentially
metastasises. The long-term objective of our research will be to
determine whether CD44 expression and that of its transcriptional
targets may be predictive for those breast cancer patients at higher
risk of developing skeletal disease and/or may potentially lead to
the development of novel and more effective therapeutic strategies
to attenuate bone metastasis.
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Background Acquired endocrine resistance in breast cancer cells
is accompanied by altered growth factor receptor signalling [1]
and a highly migratory cell phenotype [2]. Interestingly, in
tamoxifen-resistant (TamR) MCF7 cells, our microarray analysis has
demonstrated elevated levels of CD44, a transmembrane
glycoprotein known to interact with, and modulate the function of,
growth factor receptors [3]. Here we have explored the role of
CD44 as a modulator of heregulin beta-1-induced migratory
signalling in TamR cells.
Methods Expression of CD44 (standard and v3 isoforms) were
confirmed by RT-PCR and western blotting and their association
with erbB family members determined by both immuno-
fluorescence microscopy and immunoprecipitation. Activation of
intracellular signalling following heregulin beta 1 treatment
(10 ng/ml) in the presence or absence of CD44 (using siRNA-
mediated inhibition) was determined by western blotting using
phosphospecific antibodies. Cellular migration was determined by
seeding cells (control and CD44 siRNA-treated) into fibronectin-
coated transwell chambers (8.0 μm pore size) in the presence or
absence of heregulin beta 1. After 24 hours, migratory cells were
fixed, stained with crystal violet and counted.
Results  Both standard and v3 isoforms of CD44 were
overexpressed in TamR cells at both gene and protein levels (mean
fold increase in CD44s protein (TamR versus MCF7): 4.26 ± 1.2,
P < 0.05). Moreover, CD44s and v3 colocalised with Her2 and
Her3 receptors at the cell surface and were also detectable in
Her2/Her3 cellular immunoprecipitates. Treatment of TamR cells
with heregulin resulted in phosphorylation of erbB receptors
together with a number of downstream signalling intermediates,
including Akt, Src and FAK, and resulted in enhanced cellular
migration. Significantly, heregulin-induced intracellular signalling
was dramatically reduced in cells in which the expression of CD44
was suppressed (via siRNA), with a corresponding loss of
heregulin-induced migratory behaviour (mean fold change in cell
migration versus untreated control: 6.7 ± 1.1, P < 0.05 (heregulin
beta 1); 1.8 ± 0.9 (CD44 siRNA); 1.47 ± 0.6, P < 0.05 (heregulin
beta 1 + CD44 siRNA)).
Conclusion  These data demonstrate a role for CD44 as a
modulator of erbB receptor function in endocrine-resistant breast
cancer cells, where it augments heregulin beta 1 migratory signalling.
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The role that the novel lymphatic-associated adhesion molecule
CLEVER-1 plays in breast cancer metastasis has been examined
by assessing its expression in human breast tumour specimens
and by conducting in vitro experiments to monitor its involvement in
regulating cell adhesion to human umbilical vein endothelial cells
(HUVEC) and hTERT immortalised lymphatic endothelial cells
(LEC).
CLEVER-1 expression was examined in tonsil, lymph node and
148 formalin-fixed paraffin-embedded archival breast carcinoma
specimens using standard immunohistochemistry protocols. In
vitro CLEVER-1 expression was studied, in HUVEC and LEC, via
fluorescence-activated cell sorting. Tumour cell (breast MCF-7 and
MDA-MB-231, and melanoma SKMEL-30) adhesion and leukocyte
adhesion to parental and CLEVER-1 siRNA knockdown endothelial
cells was also examined.
The results show that, in tissue specimens, CLEVER-1 is present
in blood and lymphatic vessels and in certain leukocyte sub-
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populations (macrophage or dendritic cells). Although expression,
in tumours, is higher in blood vessels than in lymphatic vessels
(62.4% versus 18.2%), only lymphatic expression is associated
with lymph node metastasis (P = 0.027). CLEVER-1 expression in
blood vessels and lymphatic vessels correlates with the density of
inflammatory infiltrate (P < 0.001 and P = 0.004, respectively) and
expression in macrophages (P < 0.001). In vitro results show that
although CLEVER-1 is expressed intracellularly in both HUVEC
and LEC, only LEC exhibit surface expression. Interestingly,
adhesion assays show that tumour cells adhere preferentially to
LEC with maximal adhesion exhibited at 30 to 40 minutes. Tumour
cells adhere less to CLEVER-1 knockdown LEC than to control
LEC. The role of CLEVER-1 in cellular adhesion is being further
investigated, using tumour cells and different leukocyte
populations, to determine its involvement in adhesion and migration
of different cell types across lymphatics.
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Background Bone metastasis is a frequent complication of breast
cancer. It is estimated that up to 85% of breast cancers will
metastasize to the bone. The selective metastasis of breast cancer
to the bone is thought to result from the preferential adhesion of
breast cancer cells to the bone marrow endothelial cells (BMECs)
lining the bone marrow sinusoids. Our studies have shown that
CD44 promotes the primary adhesion of breast cancer cells to
bone marrow endothelium in vitro. The aim of the present study
was to further explore the cascade of events underpinning CD44-
initiated adhesion.
Methods  Experiments using parental and bone-homing (BO)
clones of the MDA-MB-231 breast cancer cell line established the
importance of CD44 to integrin-mediated adhesion to BMECs.
Results  MDA-MB-231BO cells displayed increased CD44
expression and adhesion to both BMECs and fibronectin, relative
to parental cells. MDA-MB-231BO cells also displayed increased
expression and activation of the β1-integrin subunit. In addition, the
bone-homing cells exhibited elevated constitutive phosphorylation
of the kinases Src and FAK and the cytoskeletal proteins cortactin
and paxillin relative to the parental cells. Stimulation of MDA-MB-
231BO cells with the CD44 ligand hyaluronan (HA) induced an
increase in the expression of the β1-integrin chain, FAK and paxillin;
and, furthermore, promoted a rapid increase in the activation status
of the β1-integrin subunits, Src, cortactin and paxillin in these cells.
The HA-induced phosphorylation of paxillin was attenuated by
depletion of CD44 and cortactin expression using selective RNAi
strategies, suggesting that it is a downstream target of HA-CD44-
cortactin signaling. MDA-MB-231BO cell adhesion to fibronectin
or to hBMECs was attenuated by RNAi-mediated suppression of
CD44, cortactin and paxillin expression or following administration
of two neutralizing antibodies that inhibit β1-integrin and α 4β1-
integrin receptor signaling. Antibody-based inhibition of integrin
signaling also attenuated the HA-induced phosphorylation of
cortactin and paxillin, suggesting that these proteins constitute a
signaling cascade activated downstream of a CD44-initiated,
integrin-dependent process.
Conclusion Our results describe a molecular pathway promoting
cytoskeletal reorganization that is activated downstream of a
CD44-induced, integrin-dependent event and that is critical to
efficient breast cancer cell adhesion to hBMECs.
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Background  Lymph node metastasis is associated with
considerable morbidity and is linked to poor prognosis in breast
cancer. We have developed experimental models of lymphatic
metastasis from the human breast carcinoma cell lines GI 101a
and MDA-MB-435. Several sublines of cells derived from lymph
node metastases in vivo have been developed. When injected into
mammary fat pads (MFP) of athymic mice, all cell lines produced
spontaneous lymph node metastases. These cell lines also
generated lymph node metastases (in addition to the expected
lung metastases) when injected intravenously. In the latter, the
tumour cells need to traverse the pulmonary capillary bed and
either show tropism for, or adaptation to, the lymph node
environment. These distinct patterns of spread – due respectively
to direct (intralymphatic) and indirect (haematogenous) colonisa-
tion of nodes – will enable us to explore determinants of both putative
passive and active (nodal tropism) mechanisms independently.
Methods  RNA was extracted from frozen primary tumours and
lymph node metastases derived from the different cell lines, after
MFP or intravenous injection, and was used to generate gene
expression profiles. A supervised learning method from the BRB
ArrayTools 3.5.0 software was used to identify the genes that were
differentially expressed between the lymph node metastases
obtained from the two routes of dissemination, as well as between
matched primary tumours and their lymph node metastases.
Results Microarray results indicate that it is possible to distinguish
between the lymph node metastases and matched primary
tumours. Additionally, the nodal metastases derived from the MFP
primary site segregate from those derived from the peripheral
circulation. These samples cluster together irrespective of the cell
line of origin. We have now identified genes upregulated and
downregulated in each cluster, and are validating their expression
at the protein level.
Conclusion The presented results will provide more information
about the molecules involved in the generation of lymph node
metastases. Furthermore, the identification of genes differentially
expressed between metastases originating from MFP and
intravenously suggests that at some level distinct molecular
mechanisms may be in operation in active and passive modes of
dissemination.
Acknowledgement  Funded by the European Framework 6
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Protease genes are involved in multiple steps of cancer
progression, including cell growth, migration and angiogenesis.
These genes are valuable as prognostic and/or diagnostic markers
of disease and are potential therapeutic targets.
We used TaqMan® real-time quantitative PCR to conduct the first
detailed quantitative expression profiling of the entire family of
metalloprotease and serine protease genes and their inhibitors in
breast cancer (over 380 genes). Using a bank of 60 samples (50
cancer and 10 normal mammary tissue) collected at the Norfolk
and Norwich University Hospital [1] we have identified a number of
genes that show significant disregulation in tumour samples
compared with normal breast tissue. Expression correlates either
positively or negatively with tumour grade in many genes.
A further cohort of 229 Dutch patients with more extensive clinical
history [2] was profiled in a subset of the metalloproteinase genes.
Among the genes that showed significant aberrant expression,
Matrix metalloproteinase-8 (MMP8) emerged as a candidate to
play a protective role during tumour progression. MMP8 was found
to have significant prognostic value and was strongly correlated
with prolonged survival. MMP8 is prognostic as a continuous
variable for relapse-free survival (hazard ratio = 0.76, P = 0.045)
and for overall survival (hazard ratio = 0.69, P = 0.025). Expression
of MMP8 also correlated with lymph node involvement, reduced
expression equating to greater nodal spread (P = 0.001).
Expression of MMP8 was independent of tumour grade. These
data show that MMP8 is prognostic in breast cancer, and suggest
that the function of MMP8 antagonizes metastasis.
Acknowledgement Supported by Breast Cancer Campaign.
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Introduction  Obesity will soon be the leading preventable risk
factor for many cancers. The insulin-like growth factors (IGFs) have
been strongly implicated as important risk factors for many
epithelial cancers, including breast cancer, and for mediating the
link between nutrition and these cancers. Obesity-related
increases in circulating fatty acids cause insulin resistance with
consequent morbidity but, despite the considerable overlap
between insulin and IGFs, there have been no studies of the
effects of fatty acids on IGF activity.
Objective To examine the effects of the most abundant circulating
fatty acids (oleate – unsaturated; palmitate – saturated) alone and
in combination with IGF-I on MCF-10A nonmalignant breast and
MCF-7 breast cancer epithelial cells.
Methods  Following 24 hours in serum-free media, cells were
exposed to albumin-bound fatty acids (100 to 400 μM) for 48
hours with or without IGF-I (20 to 25 ng/ml). Cell growth and death
were assessed by cell counting and the trypan blue dye exclusion
assay, respectively. Data were analysed by ANOVA.
Results  For MCF10-A and MCF-7 cells, IGF-I increased cell
growth (P < 0.01 and P < 0.001) whereas oleate (100 to 400 μM)
alone had no effect. However, IGF-induced growth was
differentially affected in combination with oleate: being enhanced
in the MCF-10A cells (by 57% at 400 μM; P < 0.001) but inhibited
in the cancer cells (by 28% at 400 μM; P < 0.05).
For both cell lines, palmitate alone only inhibited growth at the
highest dose (400 μM), which was coincident with the induction of
apoptosis. Palmitate did not affect IGF-induced proliferation in
either cell line. The cells were differentially sensitive to palmitate-
induced death (at 400 μM a 1.5-fold increase of MCF-7 cells; an
eightfold increase of MCF-10A cells). Palmitate-induced death in
MCF10-A cells was inhibited by a ceramide synthase inhibitor,
fumonisin B1 (0.1 μM) (61%), and by oleate (96% at 400 μM) but
was unaffected in the presence of IGF-I.
We are currently investigating the signalling pathways underlying
the differential effects of oleate on IGF-induced growth of MCF-
10A and MCF-7 cells.
Conclusion Palmitate had no effect on IGF-induced cell growth,
whereas oleate enhanced that of normal cells but inhibited that of
cancer cells. Unlike oleate, palmitate induced apoptosis although
cancer cells were relatively resistant to this. This apoptosis was via
ceramide production and was inhibited by oleate but not IGF-I.
Saturated and unsaturated fatty acids have differential effects on
IGF-induced growth and the survival of human breast epithelial
cells, supporting the notion that nutrition is a major environmental
influence on breast cancer progression.
Acknowledgement  Funded by American Institute for Cancer
Research.
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Introduction Insulin-like growth factor binding protein 3 (IGFBP-3)
is the most abundant insulin-like growth factor binding protein in
human serum and is able to modulate cell proliferation inde-
pendently of its ability to bind insulin-like growth factor. Tumour-
associated increases in IGFBP-3 levels relate to upregulation of
epidermal growth factor receptor (EGFR) and HER-2 with
increasing oestrogen independence. Remodelling of the extra-
cellular matrix with increased fibronectin expression in poor
prognostic tumours further enhances EGFR levels and signalling.
Objective To explore the potential interactions of IGFBP-3 with the
EGFR/HER-2 pathways.
Methods  Normal breast epithelial cells (MCF-10A) and breast
cancer cells (T47D) were dosed with EGF (5 ng/ml and 10 ng/ml),
IGFBP-3 (100 ng/ml), an EGFR/HER-2 tyrosine kinase inhibitor,
(Iressa, 0.25 μm) and a ROCK inhibitor (Y-27632, 5 μM) either
alone or in combinations on either plastic, laminin or fibronectin
(0.25 μg/ml). Cell growth was evaluated by cell counting and
tritiated thymidine incorporation. Internalisation of the EGFR and
Available online http://breast-cancer-research.com/supplements/10/S2S22
HER-2 was assessed by biotinylation and affinity purification using
a Pin Point Cell Surface Isolation Kit (Pierce, Northumberland, UK)
on whole cell lysates followed by western immunoblotting for the
EGFR and HER-2. Statistical significance was determined using
ANOVA.
Results  On plastic and laminin with MCF10A cells, EGF and
IGFBP-3 each increased cell proliferation alone (by 55.2%,
P < 0.001 and 31.7%, P < 0.01, respectively), and together there
was a synergistic increase of 278% (P < 0.001). In addition, the
proliferative effect of IGFBP-3 alone, like that of EGF, was
completely abrogated in the presence of Iressa. With T47D cells,
EGF increased cell proliferation (by 33.9%, P < 0.001), IGFBP-3
alone had no effect, but in combination, in contrast to the normal
cells, IGFBP-3 completely blocked EGF-induced growth
(P > 0.01). These actions of IGFBP-3 on EGF-induced growth
were reversed when the cells were cultured on fibronectin. Further-
more, we found that the modulation of EGF-induced proliferation
by IGFBP-3 was not mediated by changes in the phosphorylation
status of EGFR or HER-2. It was, however, associated with modu-
lation of the internalisation of the EGFR and activation of Rho.
Conclusion  We found that IGFBP-3 had differential, matrix-
dependent effects on EGF-mediated proliferation in normal and
breast cancer cells, which was achieved through modulation of
EGFR internalisation and the activation of Rho. Breast tumour
levels of IGFBP-3 may determine their dependence on EGFR/
HER-2 activity and their response to therapies targeting these
receptors.
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Background  Previous studies in the Tenovus Centre have
demonstrated that the development of antioestrogen resistance in
vitro is accompanied by unfavourable changes in the breast cancer
phenotype leading to increase tumour cell growth rate. Here
evidence is presented to suggest that this is in part due to
antihormones causing the epigenetic silencing of oestrogen-
induced genes involved in the negative regulation of cell growth.
Importantly, we show that reversal of this process using the
demethylation agent 5-azacytidine (5AZA) allows oestrogen-
induced cell kill by a previously unrecognised mechanism.
Methods  The breast cancer cell lines used in this study were
MCF7, MCF7-derived tamoxifen-resistant variant (TamR) and
TamR sublines that had been withdrawn from tamoxifen (TamRwd)
for up to 6 months. Cells were challenged by oestradiol (E2),
antihormones and 5AZA. Cell growth responses were assessed by
anchorage-dependent growth assays and alterations in
expression/activity of oestrogen receptor (ER) and ER-regulated
genes were analysed by real-time PCR, western blotting and/or
immunocytochemistry.
Results  Compared with the parental MCF7 cells, TamR cells
showed a significant upregulated basal rate of growth that was
maintained on tamoxifen withdrawal for 6 months. Following the
tamoxifen withdrawal, the cells remained ER-positive and showed a
slight growth response to E2. In contrast, they showed no growth
inhibitory response to tamoxifen. Examination of the methylation
status of the promoters of two classically ER-regulated genes
switched off in TamR and TamRwd cells, pS2 and progesterone
receptor (PR), confirmed their increased methylation and that
5AZA was able to reverse this process, allowing the re-expression
of pS2 and PR on E2 treatment. Although pS2 and PR are not
thought to play a role in the regulation of cell growth, these data
provide proof of principal that gene silencing occurs in TamR cells
and that it can be reinstated by 5AZA plus E2. To determine
whether tamoxifen was capable of inducing the methylation of ER-
regulated genes involved in cell growth, TamRwd cells pretreated
with 5AZA were subject to an E2 dose–response challenge. In
contrast to TamRwd cells treated with E2, which promoted a
growth response, E2 in combination with 5AZA was strongly
inhibitory at physiological doses of the steroid (10–9 M), with this
action being reversed by tamoxifen. An Affymetrix analysis of the
TamR cells has revealed multiple E2-regulated genes that are
switched off in the resistant cells whose ontology indicates tumour
suppressor/proapoptotic functions.
Conclusion Our data suggest that antihormone resistance may be
associated with the epigenetic silencing of growth inhibitory genes
leading to enhanced growth rates. We propose that reinstatement
of the expression of such genes using demethylation agents in
combination with E2 may provide a previously unrecognised
therapeutic opportunity in breast cancer.
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Background Oestrogen receptor-positive breast cancers develop
resistance to anti-oestrogens by utilising alternative growth factor
pathways as observed in our tamoxifen-resistant cell line (TAMR).
These include EGFR, IGF1-R and Src signalling as well as
increased growth and invasion. Zinc is elevated in breast cancer
tissue and has been demonstrated to activate certain growth factor
signalling pathways. We have tested the expression level of
members of the LIV-1 family of zinc influx transporters and
discovered that HKE4 (SLC39A7, ZIP7), previously shown by us
capable of increasing the intracellular zinc levels, has increased
expression in TAMR. We have therefore investigated whether the
development of the more aggressive phenotype observed in our
TAMR cells, including activation of these signalling pathways as
well as increased growth and invasion, is due to an increase of
intracellular zinc and as a direct result of increased expression of
HKE4.
Methods  All nine members of the LIV-1 subfamily of ZIP
transporters were measured in our model of tamoxifen-resistant
breast cancer using Affymetrix arrays. Zinc-induced activation of
growth factor signalling pathway components was investigated by
western blot and/or fluorescent microscopy. Short-term (15-min)
treatments with 20 μM zinc included ionophore, whereas long-term
(hours/days) did not. Recombinant LIV-1 family members with a V5
tag were expressed using pcDNA3.1/V5-His-TOPO vector, and
siRNA (Dharmacon smartpools with relevant controls) was used to
reduce endogenous expression.
Results  HKE4 (SLC39A7), a ZIP transporter from the LIV-1
subfamily, was discovered to be elevated in TAMR cells by
Affymetrix analysis and confirmed by PCR and western blot. We
have observed that our TAMR cells have a twofold increase in
intracellular zinc compared with wild-type cells, using the zinc-
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specific fluorescent dye Newport Green. Short-term zinc treatment
of TAMR cells activates the signalling pathways implicated in
antihormone-resistant proliferation and is reduced by both the zinc
chelator TPEN and the Src kinase inhibitor SU6556. The same
effects are observed after longer term (6 days) zinc treatment with
additional increases in cell growth and invasion through Matrigel.
Since we have previously demonstrated that HKE4 is capable of
increasing intracellular zinc in cells and, more recently, that these
TAMR have elevated intracellular zinc levels, we have tested the
hypothesis that elevated HKE4 expression is directly responsible
for the aggressive phenotype observed in our TAMR cells. Reduc-
ing HKE4 levels by siRNA demonstrated a role for this molecule in
driving the zinc-induced activation of multiple signalling pathways.
In the presence of siRNA for HKE4, the previously observed zinc-
induced activation of EGFR, Src, and IGF1-R was eradicated and
the EGF-stimulated activation was also decreased. Additionally, we
have demonstrated the converse by transfecting recombinant
HKE4 into wild-type cells and/or treating them with zinc to observe
the activation of these signalling pathways and increases in
invasive capability. Interestingly, we have observed a similar role of
HKE4 in our model of faslodex-resistant breast cancer.
Conclusion The presented results propose that HKE4, a member
of the LIV-1 subfamily of ZIP transporters, is directly involved in the
activation of the aggressive phenotype observed with the
development of antihormone resistance, and as such is a potential
new target for the prevention of resistance to antihormones in
breast cancer progression.
P43
Stromal fibroblasts with nuclear β β-catenin are present
within breast tumours and increase proliferation and
invasion of epithelial breast cancer cells
E Verghese1,2, HG Shenoy2,3, AM Shaaban1,2, A Waterworth2,
MB Peter2,3, K Horgan3, V Speirs2, AM Hanby1,2, TA Hughes2
1Department of Pathology, St James University Hospital, Leeds,
UK; 2Leeds Institute of Molecular Medicine, Wellcome Trust
Brenner Building, University of Leeds, UK; 3Department of Breast
Surgery, Leeds General Infirmary, Leeds, UK
Breast Cancer Res 2008, 10(Suppl 2):P43 (doi: 10.1186/bcr 1927)
Background β-catenin, when located within the nucleus, acts as
an oncoprotein by activating TCF/LEF transcription factors, which
in turn regulate transcription of a wide range of growth and
proliferation-associated genes. Nuclear β-catenin is frequently
seen in epithelial cancer cells as a result of either inappropriate
Wnt signalling or inactivating mutations in genes for key β-catenin
regulators or for β-catenin itself. Breast tumours are unusual,
however, in that nuclear β-catenin is relatively rare in epithelial
breast cancer cells. On the other hand, nuclear β-catenin expres-
sion has been documented in fibroblasts within breast fibro-
adenomas and benign phyllodes tumours [1]. Preliminary
observations within our laboratory indicated that stromal fibroblasts
in and around breast carcinomas also frequently express nuclear β-
catenin. Our aim in the present work was to validate this
observation, and to determine how fibroblasts with nuclear β-
catenin might influence cancer behaviour.
Methods  We performed immunohistochemistry for β-catenin on
whole sections of breast cancers from 200 individual cases. A
scoring system based on the number of fibroblasts expressing
nuclear β-catenin was devised and fibroblasts around tumour and
normal breast tissue were scored. To examine the potential
influence of nuclear β-catenin-positive fibroblasts on breast tumour
behaviour, we have developed a tissue culture model. With
appropriate controls, fibroblasts (MRC5/immortalised primary
breast fibroblasts) were transfected to overexpress β-catenin and
the influence of these cells on breast cancer cells (MCF7/MDA-
MB-231) in vitro was determined. First, proliferation rates of breast
cancer cells treated with conditioned media from transfected
fibroblasts were determined (MTT assays). Secondly, invasion
assays were carried out in transwell plates; fibroblasts were β-
catenin or control transfected in lower chambers and breast
cancer cells were seeded into upper chambers onto membranes
coated with extracellular matrix (Matrigel/ECMatrix). Epithelial cells
invading through membranes were quantified (cell counting/
fluorometric assay using CyQuant GR dye).
Results and conclusion We found that fibroblasts expressing
nuclear β-catenin are frequent in and around breast tumours, while
they are very rare around normal breast. In our tissue culture
model, β-catenin-transfected fibroblasts stimulated both prolifera-
tion and invasion of breast cancer cells. In conclusion, nuclear β-
catenin within stromal fibroblasts may have a potent influence on
breast cancer behaviour. This influence further highlights the
importance of stromal–epithelial interactions in breast carcino-
genesis.
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Adhesion to the extracellular matrix is fundamental in cell survival,
proliferation and differentiation. In the absence of correct signals
from the extracellular matrix, normal cells die by a form of apoptosis
termed anoikis. These mechanisms are abrogated in invasive
breast cancer. The BH3-only protein Bid is involved in anoikis. The
full-length protein translocates to the mitochondria following cell
detachment from the matrix and this is not dependent on Bid
cleavage by caspase 8. Understanding the regulation of full-length
Bid during apoptosis will help identify ways to manipulate the
apoptotic machinery to prevent cell survival during metastasis. Bid
can be phosphorylated following a number of stimuli. We have
shown that Bid becomes dephosphorylated in epithelial cells
undergoing anoikis. We have also identified Bid as being
phosphorylated during normal cell cycle. Arresting the cell cycle at
G1/S results in accumulation of nonphosphorylated Bid.
Conversely, arresting cells during mitosis results in an increase in
the phosphorylated form of Bid. Mutant forms of the protein in
which potential phosphorylation sites were removed were used to
identify serine 66 as a critical site of phosphorylation. Inhibition of
the cell cycle kinase cdk1 in fibroblasts blocks Bid phosphorylation
and is therefore a potential regulatory kinase acting to control Bid
during the cell cycle. Our results indicate a novel site of regulation
in Bid at serine 66. This residue is phosphorylated during mitosis
and may act to control the sensitivity to apoptosis during this part
of the cell cycle.
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With a few exceptions, the number of new breast cancer cases
among women is increasing in almost all western countries.
Although lifestyle, life choices, genetics and the diet are shown to
contribute to the increase in breast cancer, the sheer number of
newly diagnosed cases cannot solely be explained by these
factors. The present review aims to evaluate evidence that environ-
mental factors, including chemical exposure, also play a role.
Studies among identical twins have shown that the most important
contributor to the causation of breast cancer is the environment
not shared by the pair, even under circumstances where the
genetic predisposition is very similar. Similarly, in families with a
heritable predisposition to breast cancer, time of birth, physical
activity and obesity can profoundly influence risk.
There is overwhelming evidence that oestrogens are strong
determinants of breast cancer risks. This is not limited to natural
oestrogens formed in a woman’s body, but extends to synthetic
hormones used as pharmaceuticals, such as those used for the
alleviation of menopausal symptoms. The demonstration of breast
cancer risks from oestrogen-only and, more pronounced, from
combined oestrogen–progesterone regimens is a case in point.
Very recent decreases in breast cancer incidence in the USA and
in parts of Germany could even be linked to a dropping off of
hormone therapy use.
To date, studies carried out to examine whether certain environ-
mental chemicals are implicated in breast cancer could neither
prove nor rule out a possible link. But to avoid wrongly dismissing a
role for chemicals in breast cancer, two issues must be addressed.
First, the available studies have largely focused on single
chemicals and have ignored the possibility that large numbers of
agents may act in concert. Recent evidence from Spain strongly
suggests that cumulative exposure to oestrogenic chemicals is
associated with breast cancer risks. Second, instead of looking at
exposures later in a woman’s life, when the breast tissue is less
vulnerable, critical periods of vulnerability during puberty and
development in the womb must be considered. Very recent studies
demonstrating breast cancer risks from exposure to the pesticide
DDT during puberty and from exposure to the oestrogenic anti-
miscarriage drug DES further underline the importance of chemical
exposure in breast cancer.
Taken together, there is a case for abandoning the view of breast
cancer as solely a lifestyle and genetic disease. It is necessary to
take account of the role of environmental factors, especially
chemical exposures. With UK breast cancer incidence at an all
time high, risk reduction will not be achievable without considering
preventable causes, such as exposure to chemicals.
P46
Assessment of angiogenesis in the hyperplasia
preinvasive, invasive breast carcinoma sequence
JE Bluff1, SS Cross2, NJ Brown1, MW Reed1, CA Staton1
1Microcirculation Research Group, Academic Unit of Surgical
Oncology, School of Medicine and Biomedical Sciences, University
of Sheffield, UK; 2Department of Pathology, School of Medicine
and Biomedical Sciences, University of Sheffield, UK
Breast Cancer Res 2008, 10(Suppl 2):P46 (doi: 10.1186/bcr 1930)
Background Tissue factor (TF), the primary initiator of coagulation,
has been shown to stimulate angiogenesis, which is crucial for the
development and metastasis of solid tumours, in part by
upregulating vascular endothelial growth factor A (VEGF).
Angiogenesis in invasive breast cancer is well documented, but
little is known about the role of angiogenesis in premalignant
breast disease, or when the angiogenic switch occurs during the
development of breast malignancy. This study therefore quantifies
angiogenesis, VEGF and TF in the hyperplasia, preinvasive,
invasive breast carcinoma sequence.
Method One hundred and eighty-seven serial sections of normal
human breast (n = 12), benign hyperplastic breast (usual ductal
hyperplasia;  n = 35), premalignant hyperplastic breast (atypical
ductal hyperplasia; n = 31), preinvasive cancer (ductal carcinoma
in situ; low/intermediate grade, n = 23; high grade, n = 43) and
invasive breast cancer specimens (n = 43) were immunohisto-
chemically stained for CD31 (pan endothelial cell (EC) marker),
endoglin (proliferating EC marker), VEGF and TF. The microvessel
density (MVD), a surrogate marker for angiogenesis, was quantified
using Chalkley grid analysis. VEGF staining was assessed semi-
quantitatively and TF expression was graded as present or absent.
Results CD31 staining was observed in ECs in all of the breast
specimens observed. There was a significant increase in MVD
between normal and hyperplastic/preinvasive breast cancer tissue
(P < 0.005) and between preinvasive and invasive carcinomas
(P < 0.0005), which was associated with a significant increase in
VEGF expression in breast epithelial (P < 0.0005) and tumour
cells, respectively (P < 0.0005). The significant increase in MVD
observed between preinvasive and invasive cancers was also
associated with a significant increase in TF expression in invasive
tumour cells (P < 0.0005). In contrast to CD31 staining, endoglin
was not expressed in normal breast, but was expressed by ECs in
11% of usual ductal hyperplasia cases, 13% of atypical ductal
hyperplasia cases, 17% and 26% of ductal carcinoma in situ
cases (low/intermediate grade and high grade, respectively) and
81% of invasive breast cancer specimens. A significant increase in
the number of proliferating ECs was seen in invasive cancers
compared with all the classes of breast tissue examined
(P < 0.0005). Moreover, the significant increase in proliferating
ECs seen between preinvasive and invasive carcinomas was
associated with a significant increase in VEGF and TF expression
in invasive tumour cells (P < 0.0005). There was evidence for a
close association between VEGF and TF in tumour cells of invasive
cancers (P = 0.007) and between VEGF and TF in ECs
(P < 0.0005), suggesting a role for both in angiogenesis.
Conclusion These data indicate that angiogenesis is initiated at
the earliest stages of dysplasia and increases rapidly between
preinvasive and invasive cancer. VEGF and TF expression patterns
suggest these factors play a role in this process.
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We have previously identified that the noninvolved tissue from
breasts that contains a cancer (NTCCB) differs from age-matched
normal breast from women without cancer, having lower apoptotic
indices [1] and altered expression of epidermal growth factor
receptor [2] and β4 integrin [3]. Both of the latter are proteins
expressed by myoepithelial cells. The myoepithelial cell is now
recognised as being important in the regulation of growth, apoptosis
and differentiation of luminal epithelial cells. Our hypothesis is that
altered myoepithelial cell function could lead to reduced apoptosis
and therefore a lower ability of the breast to remove cells with DNA
damage, predisposing to cancer development.
To investigate the expression of myoepithelial proteins, immuno-
histochemistry was used to examine two series of NTCCB and
equal numbers of age-matched normal breast controls, with a total
of 180 tissues assessed. FGF2, IGF1, oestrogen receptor beta,
p63, 14-3-3σ, glucocorticoid receptor and maspin were
investigated. There was a significant difference in the expression of
FGF2 (P = 0.02), with NTCCB having greater staining in both
series of tissues. p63 was significantly different (P = 0.008) in one
series but not the other. None of the other proteins showed a
significant difference between the NTCCB and controls.
Myoepithelial cells are isolated from reduction mammoplasties and
noninvolved tissue from mastectomies using positive selection [4].
Purity and changes in expression with passage have been checked
by RT-PCR and immunocytochemistry for myoepithelial and luminal
markers. Expression of FGF2 is being examined by quantitative
PCR and western blotting. A limited study of the effects of
conditioned media from myoepithelial cells from NTCCB and
controls on breast cancer cell line growth and apoptosis has
shown reduced induction of apoptosis by NTCCB, and these
studies are being extended.
Myoepithelial cells from cancer-containing breast are different,
particularly in expression of FGF2, which is being investigated
further.
Acknowledgement Supported by Breast Cancer Campaign.
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Many studies of normal cells in vitro, of transgenic mouse models
and of somatic mutations in human cancers have provided
evidence that the cytokine transforming growth factor beta (TGFβ)
acts as a suppressor of primary tumour initiation. However, studies
of transformed cells in vitro and of mouse models have also
implicated TGFβ as a promoter of the later stages of tumour
development. A hypothesis that has been proposed to account for
this dual action is that TGFβ acts as a tumour suppressor through
the ubiquitous ALK5 receptor signalling via SMAD2 and SMAD3
to inhibit proliferation of primary tumour cells, but acts sub-
sequently through the endothelial-specific ALK1 receptor via
SMAD1 and SMAD5 to promote angiogenesis, which is required
for tumour progression [1].
In a recent meta-analysis we showed that a single nucleotide
polymorphism (SNP) generating a leucine to proline substitution in
the signal peptide of the TGFB1 protein is associated with an
increase in the risk of invasive breast cancer (OR per additional
proline allele = 1.08 (95% CI = 1.04 to 1.11), Ptrend = 2.8 × 10–5)
[2]. We have also reported that this SNP increases the amount of
TGFB1 protein secreted in vitro by threefold [3]. These data suggest
that higher levels of TGFB1 may promote the invasive breast tumour
phenotype. To determine the effect of host TGFB1 levels in an in
vivo model,  Tgfb1+/– and Tgfb1+/+ mice have been compared in
which the mice carry one or two TGFB1 alleles with the ancestral
SNP form encoding proline in the signal peptide. These studies have
revealed major effects of TGFB1 in controlling the site of metastatic
seeding and the number of metastases that develop.
The TGFB1 SNP association with breast cancer suggested that
other genes in the TGFβ signalling pathways might be associated
with altered risk. We have conducted association studies with
SNPs in 16 further genes encoding proteins directly implicated in
TGFβ signalling.  LTBP1, LTBP2, LTBP4, TGFB1, TGFB2,
TGFB3, ALK1, ALK5, TGFBR2, Endoglin, SMAD1, SMAD2,
SMAD3, SMAD4, SMAD5, SMAD6 and SMAD7 were analysed.
A comprehensive SNP tagging approach was used to select
variants for genotyping in a staged study design using up to 6,900
cases and 6,900 controls, all collected from the East Anglia region
of the UK (>98% of northwestern European ancestry). From 1,254
common SNPs (minor allele frequency >0.05) in these genes
identified from the International HapMap project data, we defined
and genotyped 354 tagging SNPs in the East Anglia cases and
controls. Statistically significant associations were followed up by
genotyping in a Polish set of 2,215 cases and 2,374 controls.
Meta-analysis of these results identified associations with cancer
susceptibility of a variant in ALK5 (OR per additional rare G allele =
0.88 (95% CI = 0.81 to 0.95), Ptrend = 0.001) and in TGFBR2 (OR
per additional rare G allele = 0.96 (95% CI = 0.92 to 1.00), Ptrend =
0.039). Data from two genome-wide studies have been examined
to search further for associations in these genes. The haplotype
risks and interactions between two or more loci have been
investigated and survival analyses have been conducted.
From this comprehensive study we have identified tagging SNPs in
two TGFβ receptor genes that are significantly associated with risk
of invasive breast cancer. Identification of the causative SNPs
Available online http://breast-cancer-research.com/supplements/10/S2S26
within the LD blocks tagged by the two SNPs and their effects on
signalling via the ALK1 and ALK5 pathways remain to be
determined.
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We identified five novel breast cancer susceptibility loci in a recent
Genome Wide Association Study [1] using 227,876 single
nucleotide polymorphisms (SNPs) and up to 50,000 female breast
cancer cases and controls from 22 studies.
One of these loci, tagged by SNP rs3803662, lies in a large
linkage disequilibrium (LD) block on chromosome 16q12. This
region encompasses the largely uncharacterised TNRC9 gene
(also known as TOX3/CAGF9) as well as a hypothetical gene
LOC643714. This association is robust and has recently been
independently verified [2]. The aim of the present study is to map
the associated locus and ultimately identify the causal variant(s)
responsible for the increased risk of breast cancer.
There are 101 common variants in the 165 kb LD block covering
the entire footprints of both genes catalogued by the International
HapMap Project. These are efficiently tagged by 19 tagging SNPs
(tagSNPs) that were genotyped in 2,270 breast cancer cases and
2,280 controls from the East Anglian region of the UK. Using
these, we were able to exclude the coding region of TNRC9 and
reduce the associated region to a 133 kb LD block including both
the 5′ end of the TNRC9 gene and the 3′ end of LOC643714.
This block was re-sequenced in 45 European subjects. Three
hundred and forty-four SNPS were found, of which 170 were not
previously recorded and 175 were common (minor allele frequency
>0.05). Twenty-two of these SNPs are strongly correlated
(r2 > 0.9) with the best tagSNP and have been genotyped, where
possible, in an East Anglian case–control study set of increased
size. Thus there are 23 potential causative variants, which are
distributed across both genes.
In an attempt to reduce this set of candidate causative SNPs and
to further narrow the region of interest, they are being genotyped in
breast cancer case–control sets from Asian and African-American
populations. These populations exhibit greater haplotype diversity
than the more closely related East Anglians, thus providing greater
power to separate the causative variant(s) from the other
candidates.
To complement this work, a further study to determine the
functional properties of the gene region in human breast cells has
been initiated.
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Regulation of cytochrome P450s in breast cancer and their role for
tumour growth and anticancer chemotherapy are studied.
Mammary cancer can develop for many reasons, one of which is
the exposure to environmental carcinogens and/or steroid
hormones. The cytochrome P450 enzyme family not only catalyses
the metabolism of a wide range of carcinogens but is also involved
in metabolism of steroids. This process alters their steroidogenic
properties, a mechanism important for mammary carcinogenesis.
At the centre of this research stand cytochrome P450 1B1
(CYP1B1) and cytochrome P450 CYP1A1. Unlike many other
P450s, these isoforms are expressed extrahepatically. CYP1B1
protein is found to be overexpressed in tumours compared with the
corresponding healthy tissues. Special regulatory mechanisms are
likely to cause this difference.
In the present study we employed TaqMan analysis, immuno-
blotting and reporter assays to investigate the expression patterns
of CYP1B1 and CYP1A1 in a panel of breast cancer cell lines
derived from different stages of mammary carcinomas. Further-
more, we investigated the expression of these P450s in cell lines
derived from primary human mammary epithelial cells that have
been transfected with various combinations of oncogenes and
telomerase. In the transformed human mammary epithelial cells we
found that the expression of CYP1B1, CYP1A1 and their
inducibility by TCDD was differentially affected by the different
oncogenes. Presently, we investigate the regulatory mechanisms
that cause this response.
In a second investigation, we analysed the relevance of P450
expression for mammary-tumour development and tumour therapy.
For this purpose we have developed MCF-7-derived cell lines in
which the expression of CYP1A1 and CYP1B1 could be switched
on/off by treatment with low doses of doxicycline. We
demonstrated that expression of these P450s altered the effects of
estrogens and antiestrogens on cell cycle and apoptotic markers.
The MCF-7-derived cell lines were grown in xenografts. P450
expression was induced by doxicycline in the drinking water. We
were able to demonstrate that P450 expression in our xenograft-
model was tightly regulated by tetracycline. In future, animals will
be treated with or without tamoxifen. Subsequently, the effects of
P450 expression on tumour growth, angiogenesis and apoptosis
will be measured.
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It is anticipated that the results of these investigations will greatly
enhance our understanding about the aetiology of breast cancer
and may provide strategies to improve treatment.
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One approach to improve our understanding of the aetiology of
breast cancer is to identify the genes involved in inherited
susceptibility. These range from the rare high-penetrance
mutations of the BRCA1 and  BRCA2 genes to common low-
penetrance variants, which are just beginning to be identified by
means of whole-genome and candidate gene association studies.
Owing to their small effect, these common variants are difficult to
identify, requiring studies with large sample sizes. The Breast
Cancer Association Consortium recently identified a single nucleo-
tide polymorphism (SNP) in the CASP8 gene that is associated
with a reduction in risk of breast cancer (rs1045485; D302H;
Ptrend = 1.1 × 10–7) in a large multicentre cohort [1].
To further investigate the association between the CASP8 gene
and breast cancer, we genotyped 15 haplotype-tagging SNPs
across a 60 kb region spanning CASP8 in 1,200 cases and 1,200
controls from Sheffield. Two further SNPs demonstrated a
significant association with breast cancer; rs6435074 (Ptrend =
0.042) and rs6723097 (Ptrend = 0.024). These markers were
therefore genotyped in two additional case–control cohorts based
in Utah and Germany. The rs6723097 SNP displayed the
strongest association with odds ratios of 1.15 (95% CI = 1.02 to
1.29) and 1.35 (95% CI = 1.15 to 1.59), for the heterozygous and
rare homozygous genotypes respectively, compared with the
common homozygous genotype (Ptrend = 0.0002).
At present there is no functional explanation for the observed
associations. Therefore it is possible that the associated SNPs are
in linkage disequilibrium with other causative variants; haplotype
analysis and further sequencing of the region will be needed to
identify these.
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Abnormal expression of p53 isoforms can be associated
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Abstract not available at time of publication.
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Background  Postmenopausal breast cancer risk increases
twofold in women who gain significant amounts of weight [1] and
there is evidence that energy restriction may reduce risk [2]. Animal
studies indicate that intermittent energy restriction (IER) reduces
risk and may be superior to continuous energy restriction (CER)
[3]. We have shown that CER reduces breast cancer risk
biomarkers in women but is hard to maintain. We hypothesise that
IER may be superior to CER in reducing biomarkers of breast
cancer risk and may also be more acceptable to women.
Methods One hundred and eight premenopausal women, mean
age 40.0 years (SD = 4.0), mean adult weight gain 20.1 kg (SD =
11.0), were randomised to either CER (75% estimated energy
requirements: ~1,500 kcal 7 days/week) or IER (75% estimated
energy requirements: 650 kcal for 2 days and ~1,800 kcal
5 days/week) over 6 months. The study endpoints are weight and
body composition (waist/hip circumference, fat free and total fat
mass by bioelectrical impedence), measures of insulin sensitivity
(HOMA, SHBG, testosterone), potential breast cancer growth
factors (IGF axis, leptin adiponectin), inflammatory markers (C-
reactive protein and sialic acid) and oxidative stress markers
(serum isoprostane). The relative acceptability of IER and CER will
be assessed using a quality of life questionnaire (RAND SF-36)
and scales of behaviour change and adherence.
Results Nineteen participants (17.6%) have withdrawn from the
study (IER = 12, CER = 7; main reasons: stress = 4, pregnancy =
3, change in employment = 3, could not stick to diet = 3). Baseline
to 6-month results for weight and body composition are reported in
Table 1.
Table 1 (abstract P53)
Six-month results
IER (n = 42) CER (n = 47) P value
Baseline weight (kg) 81.5 (1.97) 84.4 (2.35) 0.39
Weight loss (kg) 7.8 (0.77) 6.4 (0.64) 0.18
Percentage weight loss 9.4 (0.85) 7.5 (0.69) 0.09
Fat loss (kg) 6.0 (0.68) 4.9 (0.56) 0.24
Waist decrease (cm) 7.6 (0.82) 5.7 (0.54) 0.05
Percentage of weight  75.6 (68.7 to 87.5) 79.1 (60.4 to 95.6) 0.69
lost that is fata
Data presented as mean (SE), P values for t test; or as amedian
(interquartile range), P value for Mann–Whitney test.
Conclusion  Significant decreases in weight, fat and waist
occurred in both groups over 6 months, with the IER group doing
slightly better. Greater proportions of the IER group achieved 5%
weight loss (IER 79% cf. CER 66%, P = 0.19) and 10% weight
loss (IER 43% cf. CER 28%, P = 0.13). We await results for
Available online http://breast-cancer-research.com/supplements/10/S2S28
biochemistry and relative acceptability, which will be presented at
the meeting.
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Since genetic testing became a possibility for breast cancer
predisposition in the mid-1990s, research attention has focused
on the impact of predictive genetic testing for people who are told
they are at significantly increased risk of developing breast cancer.
The present study will review research evidence for the impact of
testing in terms of distress experienced and risk management
strategies adopted to manage risk of developing breast cancer
[1,2]. In addition to the psychosocial implications and impact on
risk management behaviour, research has uncovered dilemmas
that people face in talking to their family members. This presen-
tation will highlight some of the dilemmas that genetic testing and
associated research has raised for families who are living with a
family history of breast cancer [3,4]. With the evidence base that
now exists, the challenge for the future is to develop interventions
to support people undergoing genetic testing. In Southampton we
are developing an intervention to support discussions within
families about genetic testing and associated risks.
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Background Phytoestrogens are a group of compounds found in
plants that structurally resemble the hormone estradiol, and thus
have the potential to act as estrogen agonists or antagonists. Their
potential effects may alter the risk of breast cancer, but only a
limited range of phytoestrogens has been examined in prospective
cohort studies.
Methods  Serum and urine samples from 237 incident breast
cancer cases and 952 controls (aged 45 to 75 years) in the Euro-
pean Prospective into Cancer (EPIC) Norfolk cohort were analyzed
for seven phytoestrogens (daidzein, enterodiol, enterolactone,
genistein, glycitein, o-desmethylangolensin, and equol) using liquid
chromatography/mass spectrometry. Data on diet, demographics,
anthropometrics, and medical history were collected upon
recruitment. All models were adjusted for weight, fat and energy
intake, family history of breast cancer, social class, analytical batch,
and factors related to estrogen exposure.
Results With a few exceptions, urinary or serum phytoestrogens
were not associated with breast cancer risk in the EPIC Norfolk
cohort. Breast cancer risk was marginally increased with higher
levels of total urinary isoflavones (OR = 1.08 (95% CI = 1.00 to
1.16), P = 0.055); this association was stronger when restricted to
premenopausal and perimenopausal women (OR = 1.30 (95% CI =
1.04 to 1.64), P = 0.022). Among the 105 women with estrogen
receptor-positive tumours, the risk of breast cancer was increased
with higher levels of urinary equol (OR = 1.07 (95% CI = 1.01 to
1.12), P = 0.013).
Conclusion There was limited evidence of an association between
phytoestrogens and breast cancer risk in the EPIC Norfolk cohort.
Further study is required to determine whether the observations
from the present study are replicated in other populations with
similarly low relative intake of phytoestrogens.
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Background  Nonadherence to oral medication exists amongst
women with breast cancer [1] and those participating in
randomised clinical trials [2]. There is also evidence to suggest
that nonadherence is more prevalent in chemoprevention trials than
in adjuvant trials, with between 20% and 46% of patients in
chemoprevention trials not adhering to medication [3]. The
purpose of this study is to examine adherence amongst a
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subgroup of women participating in the International Breast
Cancer Intervention Study (IBIS II) cognitive subprotocol. IBIS II is
a randomised double-blind chemoprevention clinical trial of
anastrozole versus placebo in postmenopausal women at high risk
of breast cancer.
Methods  Two hundred and seven women participating in the
cognitive subprotocol of the IBIS II trial are having cognitive and
quality-of-life assessments conducted at three time points (prior to
receiving the trial tablets, at 6 months and at 24 months post
randomisation). Following the final assessment, a short semi-
structured interview is conducted to elicit information regarding
trial medication-taking behaviours.
Results Fifty-three out of 207 women who participated in the IBIS
II cognitive substudy had dropped out by 24 months (primarily due
to side effects) and adherence data on 124 women who had a final
assessment have been collected and are reported here. Seventy-
one per cent (89 participants) were taking allopathic medication
aside from the trial tablets, and 47% (58/124) were also taking
supplements, for example multivitamins, ginkgo biloba, omega 3,
and glucosamine. The total number of tablets taken a day ranged
from 1 to 14, with a mean of 4.8 tablets per day. Only 15 women
said they had ever experienced difficulty swallowing tablets and 10
of those were taking medication aside from the trial tablets. When
participants were asked to indicate whether they had ever
forgotten to take their trial tablets 50% (62 participants) said yes,
but 37% (46 participants) stated only rarely. When asked whether
participants ever chose not to take their trial tablets, for whatever
reason, only 6/124 (5%) reported occasions when they had done
so. Reasons included going away for holiday, not wanting to mix it
with painkillers, and stomach upsets. When asked whether taking
the trial tablets interfered with their daily life, the majority (90%,
111 participants) said never.
Conclusion  Adherence data from the IBIS II trial participants
contrast with those found in the first IBIS trial (tamoxifen versus
placebo). Early indications are that, contrary to previous findings,
women receiving an aromatase inhibitor to prevent breast cancer
appear on self-report to have little problem with daily tablet taking
during the first 2 years of this 5-year clinical trial. Reasons for the
differences may be due to sampling; women participating in the
cognitive substudy may be a more motivated group, and it should
be noted that almost one-third of women who dropped out did so
because of vasomotor symptoms. Further monitoring of this group
over a longer period is warranted.
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Objective To establish the significant factors that impact upon the
likelihood of women attending breast cancer screening. These
factors include ethnicity, ethnicity and socioeconomic status, the
season of the appointment and the travelling distance for each
woman.
Method All women screened in the Borough of Oldham in 2006
were investigated (n = 5,490). Ethnicity was attributed by analy-
sing their names. Socioeconomic status was designated through
their area’s average house price. The distance to the screening van
was measured from their postcode.
Results There was a significant difference between Asian (43.7%)
and non-Asian (73.7%) attendance (P < 0.05). The difference
remained significant when socioeconomic status was accounted
for (P < 0.05). Both Asian and non Asian women showed a
reduced uptake in poorer areas. Asian women were less likely than
non-Asian women to attend breast screening irrespective of their
socioeconomic area. Significantly more women attended during
autumn (P < 0.05). The travelling distance to the screening van
had no effect upon attendance (P = 0.38).
Conclusion Since the Forrest Report, improvements in diagnosing
and treating breast cancer have advanced while improvements in
uptake of screening have not. The present study shows that
inequalities still exist within the breast cancer screening system.
Increasing levels of immigration is resulting in a more diverse
nature of our population, thus these inequalities are set to increase.
One fundamental objective is to abolish these inequalities. There
must be a substantial increase in the uptake rate in both non-Asian
and Asian women in all socioeconomic areas so the benefits of
better treatment can be accessed. Well structured and funded
qualitative research is required to establish why such high levels of
nonattendance exist. With the government lengthening the ages
women are eligible for screening to 47 to 73 years old, an extra
200,000 women per year are eligible for screening. Unfortunately
as has been shown, eligibility does not correlate with attendance –
resulting in increasing administration costs and wastage of
valuable resources.
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Background  We previously identified MCPH1, a DNA damage
response protein involved in the regulation of the breast cancer
tumour suppressor gene BRCA1, as the defective protein in one
form of microcephaly [1]. We found that reduced expression of
MCPH1 causes premature chromosome condensation (PCC) [2].
PCC is a hallmark of mammalian cells that begin mitosis before
completing DNA replication. The MCPH1 locus (8p22–p23) is
frequently deleted in many tumour types and this is associated with
a poor prognosis and a reduced response to chemotherapy in
breast cancer [3]. Many chemotherapeutic agents such as taxanes
(for example, Taxol) require a functional spindle checkpoint for the
induction of apoptosis in cancer cells.
Methods  Using time-lapse imaging we have studied mitotic
progression in MCPH1-deficient cells. The presence of a
functional spindle assembly checkpoint was tested for using two
different spindle poisons – for example, Taxol and nocodazole – in
MCPH1-deficient cells. Immunohistochemistry using a MCPH1
antibody was performed on 54 breast cancer samples and was
correlated with pathology data.
Available online http://breast-cancer-research.com/supplements/10/S2S30
Results We have identified a number of mitotic defects including
slower mitotic progression displaying aberrant chromosomal
congression and micronuclei formation in MCPH1-deficient cells.
MCPH1-deficient cells displayed a reduced mitotic arrest in
response to spindle poisons, indicating impairment of the spindle
checkpoint. Our immunohistochemistry data have identified
reduced MCPH1 expression in 32% (17/54) of breast cancers,
particularly in higher grade tumours.
Conclusion The mitotic phenotype suggests that loss of MCPH1
function in tumours could cause mitotic errors resulting in
aneuploidy development. Our data indicate MCPH1 plays a role in
resistance to chemotherapeutic agents such as Taxol through its
involvement in the spindle checkpoint and apoptosis. We therefore
hypothesise that, while germline defects in MCPH1 cause
microcephaly, somatic defects may cause aneuploidy development
and resistance to chemotherapy in breast cancer.
Acknowledgement Supported by Yorkshire Cancer Research.
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Background  Resistance to radiotherapy may be a significant
factor in the development of local recurrence following surgical
resection and radiotherapy. We aimed to develop a novel in vitro
model of radioresistance using a breast cancer cell line and to
subsequently identify molecular biomarkers that may be associated
with the radioresistant phenotype. We utilised a quantitative
proteomics technique (iTRAQ; Applied Biosystems, Warrington,
UK) based on matrix-assisted laser desorption/ionisation (MALDI)
time-of-flight (TOF)/TOF mass spectrometry to identify differentially
expressed proteins.
Methods We established three novel breast cancer cell sublines
that were significantly resistant to radiotherapy when compared
with the parental cells. The radioresistant sublines were created by
irradiating cells in fractionated doses of 2 Gy up to a total dose of
40 Gy. Sufficient time was allowed for the cells to recover between
subsequent irradiations. A dose–response curve was assessed at
the end of treatment to demonstrate a statistically significant
increase in radioresistance for each novel cell subline when
compared with parental cells. One radioresistant/parental cell pair
was first analysed using in-solution digestion and liquid
chromatographic separation with protein identification by MALDI-
TOF/TOF (LC-MALDI analysis) on an Applied Biosystems 4800
Plus instrument (Applied Biosystems, Warrington, UK). Quanti-
tative iTRAQ was then performed on the same instrument for all
three radioresistant/parental cell pairs.
Results A total of 586 and 652 proteins were identified in T47D
and T47DRR cells, respectively, by LC-MALDI. Those proteins
identified in both cell lines and any redundant entries were
removed to reveal those proteins that were unique to each cell line.
In total, 244 unique proteins were identified in T47D cells and 311
unique proteins were identified in T47DRR cells. Comparison of
the three pairs of radioresistant/parental cell samples by iTRAQ
revealed a number of differentially expressed proteins. Using a
standard  ≥2-fold change in expression, these iTRAQ analyses
revealed significant changes in the expression of 51 proteins in
one or more of the radio-resistant derivatives. Further confirmation
by immunoblotting is underway. Currently the decrease in
expression of 26S proteasome associated subunits has been
confirmed by this method.
Conclusion LC-MALDI and iTRAQ analysis has revealed a large
number of candidate proteins that may be associated with a
radioresistant phenotype. These now require further confirmatory
studies. These mass spectrometry-based techniques offer a
powerful proteomic approach to identify candidate biomarkers that
may be involved in radioresistance.
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Background Radiotherapy is one of the major modalities in breast
cancer treatment. However, resistance to radiotherapy may be a
significant factor in the development of local recurrence following
surgical resection and radiotherapy. In addition, if patients with
radioresistant breast cancers can be identified, harmful side effects
from exposure to unnecessary ionizing radiation could be
prevented. We aimed to develop novel in vitro models of radio-
resistance using breast cancer cell lines and to subsequently
identify molecular biomarkers that may be associated with the
radioresistant phenotype. We used a combined proteomic (two-
dimensional gel electrophoresis/mass spectrometry) and trans-
criptomic (expression microarrays) screening approach.
Methods We established three novel breast cancer cell sublines
that were significantly resistant to radiotherapy when compared
with the relevant parental cells (MCF-7, T47D, MDA-MB-231).
Radioresistant sublines were created by irradiating cells in
fractionated doses of 2 Gy up to a total dose of 40 Gy. Sufficient
time was allowed for the cells to recover between subsequent
irradiations. A dose–response curve was assessed at the end of
treatment to demonstrate a statistically significant increase in
radioresistance for the novel cell sublines when compared with
parental cells. Each radioresistant/parental cell pair was analysed
using two-dimensional gel electrophoresis. The protein profiles
were compared and differentially expressed proteins were
identified by matrix-assisted laser desorption/ionisation time-of-
flight mass spectrometry. Immunoblotting was used to confirm the
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identities of a subset of proteins. A 3k cancer-related oligonucleo-
tide microarray was also used to identify targets that were differ-
entially expressed between each novel radioresistant derivative and
its parental cell line. Real-time quantitative PCR was used to
confirm the difference in expression of a subset of genes that
demonstrated significant (at least twofold) differential expression.
Results Using the proteomic approach, 47 differentially expressed
proteins were identified from one or more cell line pair. These
proteins include glutathione S transferase mu 3 (GSTM3),
proteasome activator subunit 1 (PSME1), PSME2, PSMA7, L-
plastin, cytokeratin 17, TRAP-1 and aldolase A. The differential
expression of GSTM3, PSMA7, L-plastin, cytokeratin 17, TRAP-1
and aldolase A have so far also been confirmed by western
blotting. Using expression microarray analysis, the expression of 69
genes was found to be significantly altered in one or more
radiotherapy-resistant cell sublines. Real-time quantitative PCR
expression was also used to confirm the differential expression of
GSTM3, PSME1 and PSME2.
Conclusion The development of these novel radiotherapy-resistant
breast cancer cell sublines and a combined proteomic/
transcriptomic complementary approach has identified candidate
biomarkers that may be associated with radiotherapy resistance. In
particular, proteasome activator subunits and GSTM3 appear to be
of interest from both screening approaches. Further validation,
functional and clinical evaluation is required, but this
complementary screening approach has identified candidate
biomarkers that may be involved in radioresistance and may reveal
novel therapeutic targets in breast cancer.
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Background  Resistance to radiotherapy may be a significant
factor in the development of local recurrence following surgical
resection and radiotherapy. In addition, if patients with
radioresistant breast cancers can be identified, harmful side effects
from exposure to unnecessary ionizing radiation could be
prevented. We aimed to develop a novel in vitro model of radio-
resistance using a breast cancer cell line and to subsequently
identify molecular biomarkers that may be associated with the
radioresistant phenotype. Antibody microarrays offer a
complementary approach for proteomic analysis in conjunction
with standard screening methods such as two-dimensional gel
electrophoresis/mass spectrometry. We have previously utilised
the Panorama Cell Signalling Antibody Microarray Kit (Sigma-
Aldrich, Poole, UK) consisting of 224 antibodies [1]. In the present
study we assessed a novel high-density 725-antibody microarray
to screen for proteins associated with radioresistance.
Methods We established a novel breast cancer cell subline that
was significantly resistant to radiotherapy when compared with the
parental cells (T47D). The radioresistant subline was created by
irradiating cells in fractionated doses of 2 Gy up to a total dose of
40 Gy. Sufficient time was allowed for the cells to recover between
subsequent irradiations. A dose–response curve was assessed at
the end of treatment to demonstrate a statistically significant
increase in radioresistance for the novel cell subline when
compared with parental cells. The radioresistant/parental cell pair
was analysed using the Panorama Antibody Microarray XPRESS
Profiler725 Kit (Sigma-Aldrich). The microarray comprised 725
different antibodies on nitrocellulose-coated microscope slides.
The antibodies were selected from a wide variety of pathways,
including apoptotic and cell signalling pathways.
Results Utilising a Cy3/Cy5 labelling strategy, the antibody micro-
array approach yielded a number of possible targets for further
study. These include zyxin, growth factor independence 1 and
lysine-specific demethylase 1, which were differentially expressed
between the radioresistant subline and parental cells. Immuno-
blotting has confirmed the identities and differential expression of
some candidate protein targets.
Conclusion The use of a novel high-density antibody microarray
has successfully identified a number of protein targets that may be
associated with a radioresistant phenotype. These proteins require
further study to validate the results. High-density antibody
microarrays potentially offer a powerful new proteomic technique
to allow the global analysis of many proteins simultaneously. These
could be invaluable in the identification of candidate biomarkers
that may be involved in radioresistance and may reveal novel
therapeutic targets in breast cancer.
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Background  Aptamers have shown great potential as novel
targeted radiopharmaceutical entities for the diagnosis and
imaging of disease. They offer reduced immunogenicity, good
tumour penetration, rapid uptake and clearance compared with
their monoclonal antibody counterparts. In previous work we have
reported the labelling of such aptamers against breast-cancer-
related biomarkers with radionuclide ligands.
Methods We have now conjugated previously selected aptamers
against the protein core of the MUC1 glycoprotein tumour marker
with chelating agents and labelled them with 99mTc, for the
diagnostic imaging of breast cancer. The conjugation is achieved
using standard peptide coupling reactions between an amino
modification on the aptamer and the carboxylic group on the
ligands. Labelling with 99mTc used tin chloride as the reducing
agent, and analysis was by HPLC where both the UV and the
gamma emission was monitored. Radiolabelled aptamer conju-
gates were separated from free, unconjugated 99mTc using
microcon filters. For the analysis of the pharmacokinetic properties
of the aptamer–radionucleotide conjugate we used gamma-camera
imaging in MCF-7 breast cancer tumour model systems.
Results We coupled the aptamer with the highest affinity for the
MUC1 glycoprotein to different ligands (MAG2 or meso-2,3-
dimercaptosuccinic acid) and labelled it with active 99mTc to obtain
stable complexes that were used in pharmacokinetic studies. This
allows us to compare the properties of a single conjugate with a
biaptamer conjugate, as two of the DMSA–aptamer conjugates
Available online http://breast-cancer-research.com/supplements/10/S2S32
can coordinate the metal core. An efficient and convenient labelling
of the aptamer with short half-life radioisotopes was achieved as
the last step of the synthesis (postconjugation labelling). The
labelled aptamers were separated from free 99mTc using microcon
filter separation and were monitored by HPLC at all stages, to
ensure that only radiolabelled aptamers were injected and imaged
for their pharmacokinetic properties.
Conclusion The aptamer–chelator conjugates have strong 99mTc
binding properties and the resulting complexes are highly stable in
vivo both in terms of nuclease degradation and leaching of the
metal. The presence of more than one molecule of aptamer per
complex alters the binding and pharmacokinetic properties of the
radiolabelled products, allowing the complex to remain longer in
circulation and thus offering improved tumour imaging properties,
without affecting the tumour penetration of the aptamer. Further-
more, different ligands affect accumulation of the aptamer in
different organs, as they alter the lipophilic properties of the
conjugate. These results aim to open new possibilities for the
diagnostic imaging of, and potentially the targeted radiotherapy of,
breast cancer.
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Background  Advances in the understanding of the molecular
basis of breast cancer has necessitated a definition of more
sensitive and specific indicators of prognosis that are central to the
underlying cancer biology and that reflect the complicated and
heterogeneous nature of the disease. The present study investi-
gates the pattern of expression of the steroid receptor coregulators
NCOA1/SRC1, NCOA3/RAC3, NCOR2/SMRT, and CBP/p300
in breast cancer. The aims were to identify whether their expres-
sion was related to patient outcome, their relationships to known
prognostic factors and to provide a basis for further research to
investigate the mechanistic significance of such associations.
Method The protein levels of steroid receptor coregulators were
assessed using immunohistochemistry in a large well-character-
ised series of breast carcinomas prepared as tissue microarrays.
Relationships between these targets, other clinicopathological
variables and patients’ outcome were examined.
Result The most important finding was that NCOR2/SMRT was an
independent prognostic indicator of overall patient survival and the
disease-free interval and was significantly correlated with distant
metastases and local recurrence, whereas tumours expressing
NCOA1/SRC1 had significantly longer overall patient survival and
disease-free interval. There were also significant correlations
between coregulator expression of NCOA1/SRC1, CBP/p300
and NCOA3/RAC3 that were associated with lower tumour grade.
NCOA1/SRC1 was also correlated with smaller tumour size.
Furthermore, the coactivators had a significant association with
steroid receptors, particularly estrogen receptor alpha.
Conclusion  The corepressor NCOR2/SMRT is associated with
poor patient outcome, independent of other prognostic factors. In
contrast, steroid receptor coactivator expression is generally
associated with a good prognosis. Further investigations are
needed to establish the mechanisms of these links between the
steroid receptor coregulator system and patient outcome.
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Background  Breast cancers that appear similar by stage and
grade are not identical in terms of outcome for each patient
affected. Heterogeneity would be better understood using genomic/
proteomic profiles to predict for relapse. Risk estimation could be
truly individualised and treatment personalised. Proteomics goes
beyond possession of an abberrant gene by assessing post-
translational modifications such as phosphorylation and measuring
protein–protein interactions. Optical proteomics uses fluorescence
lifetime imaging microscopy (FLIM) to quantify associations
between signalling proteins in tissues beyond the spatial resolution
of light microscopy by measuring Förster resonance energy
transfer (FRET). These technologies improve understanding of how
extracellular signals are sensed by cancer cells and transduced to
trigger invasion. Protein kinase C alpha (PKCα) is a signalling
protein that can oppose apoptosis. The actin-binding protein ezrin
provides a direct link between the cytoskeleton and plasma
membrane, necessary for cell migration and metastasis. Ezrin–
PKCα interaction has been demonstrated in breast cancer cell line
experiments [1].
Methods Fluorophore-conjugated antibodies to PKCα and ezrin
were applied to breast cancer tissue microarrays (TMA), obtained
from a well annotated tissue bank with a rich complement of
clinical data. Each TMA was created from 84 invasive breast
carcinoma samples, formalin fixed and paraffin embedded.
Immunofluorescence enables imaging of both proteins
simultaneously at two different wavelengths from the same section
of tissue. As intensity is proportional to concentration, proteins can
be accurately quantified. FLIM analysis was performed. Where anti-
ezrin-Cy2 and anti-PKCα-Cy3 are located within nanometre
proximity intracellularly, measurable energy transfer occurs (FRET).
Controls were matched tumour areas of noninteracting proteins.
Results We imaged six TMAs (histopathological grades I to III) in
triplicate to generate epifluorescence images and FRET/FLIM data.
We have demonstrated a wide spectrum of distribution for both
ezrin and PKCα in human breast cancer tissue. We have reported
on the activation state of ezrin and the colocalisation of both
proteins (Figure 1). We have measured FRET between anti-ezrin-
Cy2 and anti-PKCα-Cy3. The present study is the first to
demonstrate ezrin–PKCα interaction in human breast tissue
(Figure 2). In a subset, the FLIM assay was complemented by an
independent intensity method. Tissue data are further corroborated
by parallel assays performed on cultured cancer cells. All
parameters are undergoing multivariate analysis and further
statistical comparison with respect to time to relapse of disease.
Conclusion  The present study has established several optics-
based parameters to be used in a multivariate correlation with
breast cancer patient outcome. The goal is to derive multiple high-
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throughput optical proteomic markers that could be applied to
tumour tissue at first diagnosis to better predict risk for individual
patients. This project aims to translate advanced optical proteomic
science into real-life benefit, assisting patients and physicians in
the difficult decisions regarding treatment.
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Background Cancer Research UK (2007) [1] stated that the most
common cancer for women in the United Kingdom is breast
cancer. In 2004, about 20% of all breast cancer cases diagnosed
would lead to death [2]. The accepted prognostic factors fail to
establish accurately the outcome for breast cancer patients as a
large proportion of those diagnosed with invasive breast
carcinomas are given aggressive treatments even though many of
them are unlikely to develop a life-threatening cancer even without
therapies. Over the past decade, many genetic and molecular
pathways have been associated with breast cancer. To progress
towards personalized therapies, there is a need for novel bio-
markers for diagnosis, for the detection of metastasis and as
targets for new selective immunotherapies. The BUC genes
(Breast UniGene Cluster) are novel breast-associated genes
identified on the basis of their specific expression spectrum, which
includes testis, normal breast and breast cancer tissue. During in
silico analysis of the BUC gene sequence, we discovered that the
BUC11 gene sequence shares significant similarity with the gene
sequence of an unpublished gene that codes for a predicted
protein (source data obtained from the NCBI website [3]).
Methods  siRNA was designed for specific BUC11 silencing.
BUC11 siRNA efficacy was first tested using real-time RT-PCR
following transfection and mRNA isolation. The transfection of
breast cancer cell line MDA231 was carried out using INTERFERin
siRNA Transfection reagent (Autogen Bioclear, Calne, UK). The
experiment was performed in duplicate wells. Each experiment
comprised cells with BUC11 gene-specific siRNA, cells with
negative control siRNA, cells with INTERFERin alone and cells
alone. On day 2, 3H-thymidine (Sigma-Aldrich, Gillingham, UK) was
added to the cells. On day 3, cell suspensions were transferred to
a filter plate, Microscint solution (Packard, Meriden, CT, USA) was
added and the reading of the plate was performed. The procedure
was repeated on day 7 and on day 10. To quantify gene expression
at the mRNA level in breast tumours, conventional RT-PCR as well
as real-time quantitative RT-PCR were carried out. Samples used
in this study come from various invasive and noninvasive histo-
logical subtypes of breast cancer, different malignancies (for example,
melanoma, testis cancer, mesothelioma) and normal tissues.
Results Regarding BUC11 gene knockdown, 72 hours following
transfection, 89.7% of specific inhibition of BUC11 mRNA
expression was observed (real-time RT-PCR results). Three days
following transfection of MDA231 with BUC11 siRNA, cell
proliferation was inhibited by 98%. This result is still observed
7 days following transfection. However, the inhibition of
proliferation is no longer observed 10 days following transfection,
which is not surprising due to the transient nature of transfection.
The  BUC11 gene was expressed in 90% of the breast cancer
tissues tested. BUC11 mRNA was not (or at very low levels)
expressed in the normal tissues tested (heart, liver, prostate, brain,
uterus, spleen, skeletal muscle, lung, kidney, placenta, trachea,
thyroid, spinal cord, salivary gland, thymus and peripheral blood
mononuclear cell) except for normal testis and normal breast
tissues.  BUC11 mRNA was expressed in varying levels in the
breast cancer samples tested. BUC11 mRNA was expressed at
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Figure 1 (abstract P64)
Ezrin and PKCα colocalised in normal breast ducts. Ezrin–PKCα
colocalisation is demonstrated but with a long fluorescent lifetime and
a blue pixel-by-pixel fluorescence lifetime (τ) map. The fluorescent
lifetime of Cy2 does not reduce. There is no interaction between the
proteins. Controls were matched tumour areas in the same tissue core
(3 to 5 μm deeper in the TMA block) stained for noninteracting proteins.
Figure 2 (abstract P64)
Ezrin and PKCα colocalised in grade II invasive breast cancer. The
fluorescent lifetime has shortened and a the pixel-by-pixel fluorescence
lifetime (τ) map shows areas of red. There is interaction between the
proteins in these areas when compared with the control. In this section
of invasive ductal breast cancer, ezrin–PKCα interaction is
demonstrated as FRET has occurred.S34
similar levels in the normal testis and testicular cancer tissues
tested. BUC11 mRNA was only expressed in the breast cancer
cell lines T47D and MDA231. Furthermore, BUC11  mRNA
appears to be overexpressed in breast tumour compared with the
normal counterpart in the early stages of the disease and down-
regulated in more advanced aggressive breast cancers. Finally,
BUC11 mRNA was not expressed in any of the other cancer
samples tested (oesophageal, mesothelioma, melanoma, gastric
and kidney).
Conclusion BUC11 could potentially be a good candidate for the
diagnosis and prognosis of breast cancer due to the correlation of
BUC11 gene expression with the stage of breast cancer. siRNA
silencing of BUC11 led to the inhibition of the proliferation of
MDA231 breast cancer cells. This suggests that BUC11 might
have a role in the proliferation of cancer cells in the breast. The
tissue specificity of the BUC11 expression profile provides a
rationale to consider BUC11 as a tissue-specific gene involved in
the differentiation of breast and testis tissues. If the restricted
expression spectrum is confirmed in a larger cohort of samples,
BUC11 could be useful to detect micrometastasis in the lymph
nodes or peripheral blood of breast cancer patients. Finally,
BUC11 gene is not expressed in vital organs; thus it could
potentially be a good target for vaccine strategies.
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Background  Migration stimulating factor (MSF) is a 70 kDa
truncated isoform of fibronectin containing a unique intron-derived
10 amino acid C-terminal sequence not present in any previously
described full-length (250 to 280 kDa) fibronectin isoform. Unlike
fibronectin, MSF is not an extracellular matrix component, but a
soluble factor showing potent bioactivities relevant to cancer
development, such as stimulation of cell migration, matrix
remodelling and angiogenesis. MSF motogenic activity is mediated
by its constituent IGD (isoleucine–glycine–aspartate) motifs. Two
isoforms of MSF have been cloned. These differ by a 15 amino
acid deletion and are referred to as MSF+aa (AJ535086) and
MSF–aa (AJ276395). The term MSF will be used to denote both
isoforms. We have identified an inhibitor of MSF+aa (MSFI) that is
present in serum and in approximately 50% to 65% of breast
carcinomas. MSF+aa and MSF–aa differ in their functional inter-
action with this inhibitor: MSF+aa is inhibited by MSFI, whereas
MSF–aa is not. Both isoforms contain the same MSF-specific
sequence and IGD functional domains; consequently, they are
equally active in the absence of MSFI [1-4] (K. Kankova, S.J. Jones,
I.R. Ellis, M.M. Florence, S.L. Schor, A.M. Schor, unpublished data,
2008).
Objective To examine the expression of MSF isoforms and their
possible role in breast tumours.
Methods  Three types of monoclonal and polyclonal antibodies
were raised and characterised: identification antibodies (VSI) that
recognise the MSF-unique sequence; function-neutralising anti-
bodies (pepQ) that recognise the IGD functional domain; and
antibodies (TYN) that recognise MSF–aa but not MSF+aa. MSF
expression in paraffin-embedded archival specimens of breast
tumours was examined by immunohistochemistry using VSI and
TYN antibodies. The expression of MSF mRNA and protein by four
breast carcinoma cell lines (MCF-7, T47D, MDA-MB435 and
MDA-MB-231) and their response to rhMSF was determined by
molecular, biochemical and functional assays.
Results Immunostaining with VSI and TYN antibodies indicated that
approximately 80% of breast carcinomas (n = 85) overexpressed
total MSF and MSF–aa. High expression was associated with poor
prognosis. One of the breast carcinoma cell lines (MCF-7) did not
produce MSF. The remaining three lines secreted bioactive MSF
into their conditioned medium. Analysis of the type of MSF
produced indicates that T47D, MDA-MB435 and MDA-MB-231
cells produce both MSF+aa and MSF–aa; the latter representing
approximately 50% to 60% of total MSF. rhMSF stimulated the
invasion of tumour cells through three-dimensional gels of type I
collagen or through collagen-coated membranes. Conversely, cell
invasion by MSF-producing tumour cells was effectively abolished
by MSF-function-neutralising antibodies (pepQ).
Conclusion MSF isoforms are present in most breast tumours and
are secreted by breast tumour cell lines. MSF stimulates tumour
cell invasion in an autocrine and paracrine manner, modulated by
the type of isoform expressed and by the presence of MSFI.
Acknowledgements The authors thank Breast Cancer Campaign,
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Background  The breast cancer susceptibility gene, BRCA1, is
mutated in a high percentage of hereditary breast and ovarian
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cancers. It is a large gene containing 5,592 nucleotides, and since
its discovery over 1,500 distinct mutations have been identified
throughout the entire coding region. While genetic screening can
be informative it is frustratingly ambiguous, as a complete
spectrum of mutation types are presented and, while those that
result in the introduction of a premature stop codon or a frame shift
can be predicted to adversely affect protein function, there is
considerable uncertainty regarding the functional outcome of the
majority of the missense mutations. Evaluating the functional
significance of such mutations is challenging due to the difficulties
in purifying such a large protein. The identification of functional
domains in BRCA1 will therefore be critical to the development of
functional assays to evaluate their pathogenicity. Prior to our
studies only two domains had been identified – the N-terminal
RING domain and the C-terminal BRCT domain – and while the
structures of both these domains provide a platform from which the
structural consequences of missense mutations can be predicted,
they only account for 16% of the total protein and hundreds of
mutations of unknown pathogenicity remain to be characterised.
Our work aims to identify domains in BRCA1 that can be used to
determine the functional outcome of missense mutations.
Methods BRCA1 (230 to 534), identified as a soluble fragment
[1], was overexpressed in Escherichia coli BL21 (DE3) codon plus
and purified to homogeneity from crude cell extracts by ion
exchange and Ni2+-nitrilotriacetate affinity chromatography. The
purified fragment was digested with trypsin at an enzyme to
substrate ratio of 1:500 and a resistant domain identified using a
combination of N-terminal sequencing and MALDI mass
spectrometry (Bruker REFLEX III). The domain identified as amino
acids 340 to 554 was purified and characterised as described
previously [2]. The DNA binding affinity and selectivity were
determined by surface plasmon resonance and gel retardation
assays. Heteronuclear single quantum coherence NMR spectra of
free and bound protein were recorded on a Varian INOVA 600
MHz spectrometer. Site-directed mutagenesis was carried out
using the Quik change site-directed mutagenesis kit (Stratagene,
La Jolla, CA, USA), and the ability of the resultant proteins to bind
to DNA was assessed. All mutant proteins were purified by a
simple one-step procedure using nickel chelate affinity chromato-
graphy.
Results and discussion A host of reports implicate a role for
BRCA1 in the repair of damaged DNA, in particular that of double-
strand breaks by homologous recombination. The formation of
DNA crossovers (four-way junctions) is a central feature of this
repair process, and the ability of BRCA1 to specifically recognise
these structures is an important part of its function, as it potentially
targets it to sites of DNA repair. Using a combination of limited
proteolysis and mass spectrometry we have identified and
characterised a domain in BRCA1 that binds specifically to these
DNA structures [1,2]. This region is comprised of amino acids 340
to 554 and contains one polymorphic and 42 unclassified mis-
sense variants. Analysis of the residues involved in DNA binding by
NMR spectroscopy reveals that three of four arginine residues
(R507, R506, R504 and R496) are potentially involved in binding;
which three remains to be identified but R507, R506 and R496
are known to be mutated in some cancer patients (R507I, R504H,
R496C and H). It is therefore tempting to speculate that the three
involved in DNA binding are R507, R506 and R496. To determine
whether this is the case, and indeed the value of using the DNA
binding activity as a functional screen, each of these have been
changed to their respective mutations, and also to glutamic acid
and alanine, by Quik change site-directed mutagenesis. R506 has
also been changed to E and A. All mutant proteins contain a C-
terminal hexahistidine fusion, which has allowed a simple one-step
purification procedure using nickel chelate affinity chromatography
to be developed. The ability of each mutant domain to bind to four-
way junction DNA is currently under investigation. These studies
will allow us to determine whether the DNA binding activity of
BRCA1 can be used as a potential functional assay for BRCA1
missense mutations.
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Background Changes in the incorporation of [18F]Fluoro-2-deoxy-
D-glucose (FDG) determined using positron emission tomography
(PET) is a highly sensitive technique for the early detection of
tumour response to therapy [1]. Using serial FDG-PET scans,
tumours responding to therapy generally show a decrease in FDG
incorporation compared with pretreatment. How FDG incor-
poration at the tumour cell level is modified by treatment and the
mechanisms involved is poorly understood and is the subject of the
present study.
Methods  [18F]FDG incorporation, glucose transport, hexokinase
activity and ATP content were determined in breast tumour
(MCF-7, T47D), colorectal (SW620, HCT-8) and gastric (AGS)
tumour cell lines during response to typical and novel agents
utilised in the treatment of the respective tumour types. Treatment
doses causing 50% growth inhibition (IC50 determined by MTT
assay) over a 72-hour period were utilized.
Results All 72-hour treatment/cell line combinations (breast tumour
cells – MCF-7 and T47D – with tamoxifen, doxorubicin or docetaxel;
colorectal cells – SW620 with 5FU, oxaliplatin or irinotecan – and
HCT8 with irinotecan, cetuximab or both; gastric tumour cells – AGS –
with cisplatin, 5FU or epirubicin) resulted in decreased FDG
incorporation compared with untreated cells. Decreased FDG
incorporation most closely reflected changes in glucose transport by
the HCT-8 and AGS cells, ATP content by the breast tumour cells
and hexokinase activity by the SW620 cells. Apoptosis was evident
in epirubicin-treated AGS cells, which showed the greatest
decrease in FDG incorporation, but was also apparent in irinotecan-
treated cells, which showed declines in FDG incorporation
comparable with treatments without apoptotic fractions.
Conclusion  FDG incorporation in tumour cells responding to a
wide variety of chemotherapy agents is decreased compared with
untreated cells, suggesting that the decrease in FDG incorporation
observed in the clinical setting reflects changes at the tumour cell
level. The rate-limiting step varies with the tumour cell line and can
be glucose transport, hexokinase activity or ATP content. Large
decreases in FDG incorporation may in some tumours be
indicative of the presence of apoptotic fractions.
Acknowledgement  Funding of this work by grants from the
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Background Breast cancer is a heterogeneous disease for which
several forms have recently been identified on the basis of their
gene expression characteristics [1]. We have previously demon-
strated that protein expression characteristics can be used to
identify comparable classes [2]. In the present study we extend
this approach using improved biostatistical methods to confirm the
validity of such an approach and to further define the key criteria
for class membership.
Methods  Expression of 25 proteins, with known relevance to
breast cancer, have been assessed in a series of 1,076 patients.
This large dataset has been examined by four alternative
computational data clustering techniques. Concordance between
techniques was used to elucidate core classes of patients that
could be well characterised.
Results A total of 663/1,076 (62%) patients were assigned to six
different core classes, while 413 (38%) patients were of
indeterminate or mixed class. Three of these core classes
correspond to well known clinical phenotypes (luminal A, luminal B
and HER2). Two classes correspond to the well known basal
phenotype, but exhibit a novel differentiation into two subgroups.
The last class appears to characterise a novel luminal subgroup.
Conclusion The present study serves to confirm that key clinical
phenotypes of breast cancer can be identified. It has identified that
both the luminal and basal breast cancer phenotypes appear to be
heterogeneous and contain distinct subgroups. Of importance is
the observation that only 62% of breast cancer cases in this cohort
have been assigned to the determined phenotypes, while the
remaining 38% of cases express mixed or indeterminate
characteristics. This latter observation, although previously
recognised, has not been emphasised in the past. It has important
clinical implications should either cDNA expression or protein
expression assays be used for stratification of patients into
treatment groups either in clinical trails or for routine clinical
management. The clinical phenotypes determined in this study are
a new luminal group, luminal N, the new basal subgroups, basal X
and basal Y, and the previously well-established luminal A, luminal
B and HER2 groups.
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Background  The aim of the present study was to determine
whether tumour-specific gene amplification is detectable in
circulating cell-free DNA isolated from the plasma of breast cancer
patients. Four loci, known to show amplification in breast cancers,
were chosen for investigation of paired plasma and tumour DNA:
Her-2 and C35 on chromosome 17, and FGFR1 and RAB11f1P1,
which map to chromosome 8. Both gene pairs are frequently, but
not exclusively, coamplified in breast tumours.
Methods  Lymphocyte, tumour and plasma DNA from 21
unselected breast cancer cases were analysed for amplification by
a real-time quantitative PCR assay. Primers and a minor groove
binder (MGB) TaqMan probe were targeted to the four genes and
to an unamplified reference gene selected from each of the two
intervals (CNTNAP1 and UNC5ND, respectively). A normal
lymphocyte DNA sample was included in each experiment to
examine interassay reproducibility and as an experimental
calibrator. A ratio above 2.0 was regarded as positive for gene
amplification [1].
Results Amplification was detected in tumour and plasma DNA at
all four loci, with frequencies ranging from 19.1% to 52.3%. Five of
21 cases showed concordant amplification of Her-2 in plasma and
tumour DNA, compared with four, one and two of 21 cases for
C35, FGFR1 and RAB11f1P1 amplification, respectively. No
amplification was seen in the lymphocyte DNA samples.
Conclusion  Taken together, these data confirm that tumour-
specific amplification, including Her-2 amplification, is detectable
in circulating cell-free DNA isolated from the plasma of breast
cancer patients. This suggests the possibility of developing a rapid
and simple blood screening tool for identification of gene
amplification in breast cancer cases.
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Background  The Prospective Study of Outcome in Sporadic
versus Hereditary Breast Cancer (POSH) first started recruiting in
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June 2001 and will stop recruiting in December 2007. Follow-up is
funded until December 2009. There are 2,665 participants
recruited to the study by 10 October 2007. All participants were
diagnosed with a first primary invasive breast cancer since January
2000 and were ≤40 years old at diagnosis. Eligibility criteria also
allow inclusion of those with known BRCA gene diagnosed at ≤50
years of age.
Method Recruitment has been mainly through oncology centres
across the UK and was greatly facilitated by adoption into the
National Cancer Research Network in November 2002. Data
collection points are at diagnosis, 6 months, 12 months and
annually to 5 years.
Results Pros
￿ Patients like the study, as it usually only involves patient
contact at the point of consent and at the first annual follow-up.
Very few decline to participate.
￿ Clinical trials practitioners like the study as it is easy to recruit
to, and fits with routine follow-up regimes.
￿ The study gives enormous potential for translational studies
improving the understanding of not only genetic aspects but
the basic pathobiology of young-age breast cancer.
Cons
￿ It can be difficult to obtain funding for cohort studies.
￿ Some clinical trials practitioners dislike the follow-up forms and
the quantity of data requested.
￿ Postal strikes have an impact on recruitment timing and can
lead to additional patient appointments for blood donation.
￿ Changes in ethics regulations over a 6-year period have
resulted in inconsistent and confused responses to protocol
amendments with consequent delays.
￿ The UK Cancer Research Network point system changed, with
treatment trials given higher points.
Conclusion The mechanics of running this study and some early
summary data about the cohort will be presented and will be of
interest to researchers already involved in the study or who may be
considering starting a similar study or with a specific interest in
collaborative studies around young-onset breast cancer.
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Background  The presence of vascular invasion (VI), encom-
passing both lymphovascular invasion (LVI) and blood vascular
invasion (BVI), in breast cancer has been found to be a poor
prognostic factor. It is not clear, however, which type plays the
major role in metastasis.
Methods To distinguish between LVI and BVI, sections from 177
consecutive paraffin-embedded specimens of primary breast
cancers, with known long-term follow-up, were immuno-
histochemically stained with two blood vascular markers (CD34
and CD31) and with a lymphatic marker (podoplanin/D2-40). BVI
and LVI were identified and the results correlated with clinico-
pathological criteria and patient survival.
Results VI was detected in 56/177 specimens (32%); 54 (96%)
were LVI and two (4%) were BVI. The presence of LVI was
significantly associated with the presence of LN metastasis,
development of distant metastasis, regional recurrence, and a
worse disease-free interval and overall survival. In multivariate
analysis, LVI retained a significant association with decreased
disease-free interval and overall survival. When assessment of LVI
using H&E was compared using the lymphatic marker, VI was
missed in 30/177 (16.9%) and was falsely positive in 12/177
(6.8%) using H&E.
Conclusion VI in breast cancer is predominantly of lymph vessels
and is a powerful independent prognostic factor. The use of
immunohistochemical staining with podoplanin/D2-40 increases
the accuracy of identification.
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Background Over the past 30 years, there has been a dramatic
change in the local management of breast cancer, with radical
operations being replaced by more conservative surgical proce-
dures, together with the widespread use of radiotherapy. This shift
has been prompted by results from randomised clinical trials that
have clearly demonstrated breast-conserving surgery followed by
radiotherapy is equivalent to more radical procedures in terms of
local control and overall survival [1]. However, although the surgery
is now conservative, the radiotherapy remains radical and may be
overtreatment. Evidence for this comes from large studies of
breast-conserving therapy where more than 90% of early breast
recurrences were found to occur at the site of the original primary
tumour site, whether or not radiotherapy was given and/or the
margins were involved [2,3]. The development of a novel
radiotherapy device enabled the launch of an international
randomised controlled trial designed to compare intraoperative
versus conventional external beam radiotherapy in women with
early breast cancer [4].
Methods Intrabeam® (Carl Zeiss, Germany) is a miniature electron
beam-driven X-ray source that provides low-energy X-rays directly
into the area of interest immediately after excision of the tumour, to
provide intraoperative radiotherapy accurately targeted to the
tissues with the highest risk of local recurrence. Following treatment
delivery in the operating theatre, women can then proceed to have
chemotherapy and/or adjuvant hormonal therapy as required. An
equivalence trial, the main outcome objective is risk of local relapse
within the treated breast. Secondary objectives are to compare the
treatment arms with respect to the site of relapse within the breast;
relapse-free survival and overall survival; and local toxicity/morbidity.
Results With centres in eight countries, TARGIT is nearly halfway
to the accrual goal of 2,232 patients. Follow-up information is
gathered through a web-based data entry system. Separate
protocols are being written to address cosmetic outcome; patient
satisfaction and quality of life; health economics and cost–benefit;
and patient preference.
Conclusion This technique could have enormous implications for
both cost and availability of breast cancer treatment. TARGIT is
currently open to accrual of patients and centres. For further
details please visit www.targittrial.org
Available online http://breast-cancer-research.com/supplements/10/S2S38
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Introduction Two-dimensional radiotherapy (RT) breast plans can
lead to substantial dose inhomogeneity, which may cause
increased normal tissue toxicity. We report the dosimetry results of
our National Cancer Research Network-adopted randomised trial
comparing standard two-dimensional RT with intensity-modulated
radiotherapy (IMRT).
Methods Following 3D imaging, a standard plan was produced for
all patients. Plans were classified as having significant dose
inhomogeneity if they exceeded the upper limit of International
Commission on Radiation Units and Measurements Report 50
(>107% of prescribed dose). Those patients with satisfactory
dose homogeneity were treated with standard RT. Patients with
significant dose inhomogeneity were randomised to standard
breast RT or IMRT. The randomised group were replanned with
forward-planned IMRT.
Results A total of 1,145 patients were recruited from March 2003
to July 2007. One patient was randomised in error and therefore
excluded. Eight hundred and fourteen out of 1,139 (71%) had
significant dose inhomogeneity with standard 2D RT, and were
randomised to IMRT or control; 325/1,139 (29%) had acceptable
dose homogeneity, and were treated with standard 2D RT. The
mean improvement in volumes >107% for IMRT plans was 34 cm3
(P < 0.0001, 95% CI = 26 to 42 cm3). The mean improvement in
volumes <95% for IMRT plans was 48 cm3 (P = 0.0001, 95% CI =
34 to 62 cm3).
The mean difference in breast volume between randomised and
nonrandomised patients was 596 cm3 (P < 0.0001, 95% CI = 530
to 662 cm3). We aim to report the acute and interim late side
effects in spring 2008, if the data are released by the Independent
Data Monitoring Committee.
Conclusion  IMRT improves radiotherapy planning, and patients
with larger breasts are more likely to require this treatment.
However, as there was considerable overlap in the range of breast
volumes between the randomised groups, size alone cannot
predict the need for IMRT. This trial will quantify the clinical benefit
of breast IMRT, in a patient group who consume 30% of RT
resources. It will also provide DNA samples linked with high-quality
clinical outcome data, for a translational study investigating
individual patient variation in normal tissue toxicity. This will bring
us closer to the ultimate aim of individualised RT based on a
patient’s genetic profile.
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Background  During breast cancer growth and development,
angiogenesis is triggered by the interaction between vascular
endothelial growth factor (VEGF) and its receptors VEGF-R1 and
VEGF-R2. In breast cancer, alternative VEGF receptors, the
neuropilins (Np1 and Np2), are often upregulated and serve to
augment the effects of VEGF-R1/VEGF-R2 binding and provide
alternative signalling pathways. Recently, a humanized antibody,
Bevacizumab (Bz), which prevents VEGF binding to VEGF-R1/
VEGF-R2, in combination with chemotherapy demonstrated initial
efficacy (increased progression-free survival) in breast cancer
phase III clinical trials. Eventually, however, the tumours evade
treatment control. This may be because neuropilins are not blocked
by Bz and provide an alternative VEGF signalling pathway in breast
cancer. Therefore the present study aims to evaluate the potential
of enhancing efficacy of Bz treatment by simultaneously blocking
VEGF–neuropilin binding.
Methods  Western blot analysis of VEGF receptors in human
endothelial cells (HUVEC and HuDMEC) and breast cancer cell
lines (MDA-MB-436, MCF-7 and T47D) assessed relative expres-
sions of VEGF-R1, VEGF-R2, Np1 and Np2 in these cells. Micro-
vascular endothelial tubule formation assays were then performed
in vitro where cells were incubated on Matrigel in the presence of
VEGF for 24 hours, and then Bz (1 to 4 mg/ml) and/or anti-Np (50
to 100 ng/ml) antibody were added to the wells. The number of
branch points were quantified in three fields of view/well in three
separate experiments.
Results Western blot analysis revealed Np1 and Np2 expression
in both breast cancer and endothelial cell lines, whereas VEGF-R1
is expressed in MCF-7, MDA-MB-436 and endothelial cells and
VEGF-R2 is only expressed by endothelial cells. HuDMEC
stimulated by VEGF formed tubules in vitro, and the number of
branch points/field of view for VEGF-stimulated controls (43 ± 6)
versus Bz (25 ± 3) versus anti-NP antibody (26 ± 4) versus Bz +
anti-Np antibody (17 ± 3) demonstrated a significant (P < 0.001)
reduction in tubule formation.
Conclusion These data show that anti-Np antibodies increase the
inhibitory effect of Bz and suggest that efficacy of breast cancer
treatment with Bz may be enhanced by addition of a neuropilin
blocking agent.
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The breast tumour kinase Brk (PTK6) is found in over two-thirds of
breast cancer cell lines and tumours but is not expressed in normal
mammary cells. Brk has previously been shown to play a role in
regulating proliferation in breast tumour cells [1]. However, in vivo,
the site of Brk expression in normal tissues is restricted to
nonproliferating cells that are undergoing terminal differentiation
such as those in the gut or the skin [2,3]. This led us to
hypothesise that Brk expression in breast tumours could be
reflective of a differentiation phenotype, especially as a previous
study had shown that involucrin, a marker of terminal keratinocyte
differentiation, was expressed in a subset of tumours [4]. We
therefore examined involucrin expression in breast tumour cells
lines and patient biopsy samples. In addition we investigated
whether inducers of differentiation in keratinocytes such as
prolonged culture in suspension or vitamin D3 treatment could also
affect differentiation of breast tumour cells.
We found that the expression of Brk in cultured cell lines
correlated with involucrin expression. In addition the change in Brk
expression, as a result of culture conditions, was accompanied by
a change in involucrin levels. Moreover, treatment with vitamin D3
resulted in a decrease in cell numbers in the Brk-positive cell lines
relative to the control treatments. The Brk-negative cell line was
unaffected by vitamin D3 treatment.
These data suggest that Brk and involucrin may be coregulated
and that inducers of differentiation such as vitamin D3 could be
considered potential therapeutic strategies.
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C35 is a protein overexpressed in invasive breast cancer. The C35
gene is located on chromosome 17, next to ERBB2/HER2. C35
encodes a canonical immunoreceptor tyrosine-based activation
motif (ITAM) sequence. ITAM-containing proteins have key
signalling roles in the hematopoietic system and in oncogenic
retroviruses. The ITAM interacts with Syk kinase, which mediates
downstream signalling events.
C35-overexpressing breast tumours were found to be of two
subsets. In one subset, C35 is coexpressed with HER2. The second
subset is found within the basal-like carcinoma group. In order to
evaluate the therapeutic potential of targeting C35 ITAM/Syk
signalling, we utilised 3D cell cultures. Transformed cell lines act in a
manner resembling their in vivo behaviour when grown in 3D
cultures, on reconstituted basement membrane. Using this method,
C35-expressing cells formed enlarged structures in both an ITAM-
dependent and Syk-dependent manner. Furthermore, BT474 cells
coexpressing C35 and HER2 formed more normal 3D structures
when treated with a combination of Herceptin and Syk inhibitors.
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Background  Herceptin is active in a subset of patients over-
expressing the epidermal growth factor receptor (EGFR) c-erbB-2
(HER2) but it is not possible to predict which individuals will
respond. Several molecular hypotheses have been proposed for
how Herceptin causes tumour regression: one is that the antibody
binds to HER2 and causes it to be internalised into breast cancers
cells, where it is either degraded or locates to a compartment in
which it can no longer signal (or signal in the same way).
The present research aims to explore possible molecular and
cellular mechanisms involved in resistance of Herceptin. We are
also interested in identifying whether inhibiting other pathways
(such as signalling via HER3) would increase the number of
patients who show a response. We have created a plasmid
containing c-erbB-2 fused to Yellow Fluorescent Protein (c-erbB-
2-YFP) and an epidermal growth factor receptor fused to Green
Fluorescent Protein (EGFR-GFP). The correct sequence was
obtained for both of these and we showed that they react with
specific antibodies using western blotting. We have established a
system in which we can express c-erbB2-YFP with or without
coexpression of the EGFR labelled (or not) with GFP and add
Herceptin chemically coupled to the red fluorescent compound
Alexa Fluor 568 to see if there is an effect in cell trafficking. We
have made a monoclonal antibody called SGP1 that recognises
the extracellular domain of HER3 receptor [1] and we would like to
see whether addition of a HER3-specific monoclonal antibody to
Herceptin will increase its anticancer activity. If so, SGP1 antibody
Available online http://breast-cancer-research.com/supplements/10/S2S40
could be humanised and then both coadministrated with Herceptin
in clinical trials.
Methods  Both constructs c-erbB-2-YFP and EGFR-GFP were
used to transiently transfect COS-7 cells to determine their
biosynthesis and transport to the cell surface. Time-course studies
using low-light fluorescent microscopy have shown that both
receptors are found on the surface of cells between 18 and 24
hours post transfection. We have chemically labelled Herceptin
immunoglobulin (Genentech Inc., South San Francisco, CA, USA)
with Alexa Fluor 568 (Invitrogen Molecular Probes, Inc., CA, USA)
and have shown that this binds only to cells expressing the c-erb-
B2-YFP receptor. The specificity is notably high in relation to
previous experience with similar antibodies as no signal has been
seen on any untransfected cells of several types. Treatment of cells
at 37°C with Herceptin-568 for increasing time periods up to 48
hours was performed. Most of the effects of the drug on receptor
localisation were seen in the first four hours and so in future
experiments we employed this timeframe.
Results  These studies indicate that Herceptin applied to cells
expressing only c-erbB-YFP induces receptor internalisation into a
compartment apparently just under the surface of the plasma cell
membrane, supporting the observations of Austin and colleagues
[2] who explored this by electron microscopy. Addition of
Herceptin-568 to cells expressing the EGFR gave no binding as
expected. However, cotransfection of c-erbB-2 (unlabelled) with
EGFR tagged to GFP gave the unexpected result that the EGFR
was internalised over about 1 hour (significantly slower than the
effect of adding EGFR-Alexafluor). Preliminary results to determine
the effect of the antibody SGP1 on the c-erbB-3 receptor have
shown induced phosphorylation of a 60 kDa protein that is
probably Shc, which already has been identified as one of the main
second messenger proteins recruited by HER3. However, further
studies are needed to fully characterise this protein.
Conclusion  The results from the present work have shown that
both constructs can be expressed in mammalian cells and that
receptor trafficking can be observed and evaluated using two-
colour digital fluorescent microscopy. In addition we have
fluorescently labelled Herceptin, and its ability to bind c-erbB-2 is
retained. We showed that cotransfection with c-erbB-2-YFP and
EGFR labelled (or not) with GFP and addition of the labelled
Herceptin is affected by the presence of EGFR. Our preliminary
results using monoclonal antibody SGP1 have shown that the
presence of HER3 receptor can affect the extent of downregulation.
It may be that multiple targeting of the HER-family receptors will
help to increase the number of patients that respond to the therapy.
Acknowledgement Supported by Breast Cancer Campaign.
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Background  Breast cancer patients commonly receive a
combination of different therapies; however, our understanding of
how such combined treatments work is incomplete. We have
previously shown that sequential administration of the cytotoxic
agent doxorubicin (dox) (Pharmachemie BV, Haarlem, The Nether-
lands) followed by the antiresorptive agent zoledronic acid (zol)
(Novartis Pharma, Basel, Switzerland) synergistically increased
tumour cell apoptosis in vitro, and also increased tumour cell
apoptosis, decreased tumour cell proliferation and reduced sub-
cutaneous in breast tumour growth in vivo. In contrast, pretreating
the cells with zol before dox or adding both drugs simultaneously
did not cause synergy. The aim of the present study was to
determine the mechanism by which sequential administration of
dox followed by zol exerts the increased antitumour effects.
Methods  All experiments were carried out using MDA-MB-436
breast cancer cells, or MDA-MB-436 cells expressing green
fluorescent protein (MDA-G8). Effects of dox on cell membrane
integrity were monitored following propidium iodide (PI) or 7-
amino-actinomycin D (7AAD) staining. Effects of single or
sequential treatment with dox and zol were assessed using
Annexin (apoptosis antibody), TMRE (mitochondrial membrane
potential dye) and 7AAD (permeable membrane dye) staining by
flow cytometry. Uptake of zol was assessed following western
blotting using an antibody to the unprenylated form of Rap1a.
Results Following administration of 1 nM dox for 24 hours, 95% of
the MDA-G8 showed uptake of both PI and 7AAD. The cells
showed no sign of apoptosis and remained viable. Administration
of 25 μM zol for 1 hour to cells pretreated with dox for 24 hours
resulted in increased cell death compared with that caused by
treatment with either dox or zol alone. Accumulation of unpreny-
lated Rap1a was detected following treatment for 1 hour with
lower doses of zol (8 μM) in the dox then zol treated cells,
compared with cells treated with zol alone (12 μM). These data
imply that pretreatment with dox facilitated the uptake of zol.
Conclusion Treatment of MDA-MB-436 cells with 1 nM dox
disrupts cell membrane integrity without reducing cell viability.
Administration of dox 24 hours prior to zol facilitates the uptake of
zol in MDA-MB-436 breast cancer cells.
Acknowledgement Breast Cancer Campaign funded this work.
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Background  Breast cancer patients commonly receive a
combination of different therapies; for patients with late-stage
breast cancer involving metastasis to the bone, a chemo-
therapeutic agent is usually given in combination with the
antiresorptive drug zoledronic acid (zol) (Novartis Pharma, Basel,
Switzerland). We have previously reported that administration of
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doxorubicin (dox) (Pharachemie BV, Haarlem, The Netherlands) 24
hours prior to zol inhibits subcutaneous breast tumour growth,
inhibits tumour cell proliferation and increases apoptosis in vivo.
The aims of the present study were to determine the mechanisms
by which dox and zol exert their synergistic antitumour effects.
Methods  MDA-MB-436-GFP (MDA-G8) cells (0.5 × 108) were
inoculated into the right flank of female MF1 nude mice
(n = 3/array). Mice were treated once per week for 6 weeks with
saline, 2 mg/kg dox, 100 μg/kg zol or dox followed 24 hours later
by zol. Animals were sacrificed 24 hours following final treatment
and one half of each tumour was stored in RNAlater and the other
half in protein lysis buffer. RNA was extracted using a SuperArray
ArrayGrade™ total RNA extraction kit (Tebu-bio, Peterborough, UK)
and biotin-labelled riboprobes were subsequently produced using
a SuperArray TrueLabelling-AMP™ 2.0 kit (Tebu-bio). Four
micrograms of biotin-labelled RNA from each group was hybridised
overnight at 60°C to separate GEArray cell-cycle and apoptosis
pathway-specific microarrays (Superarray.com; Tebu-bio). Gene
expression was analysed using GEAsuite software (Superarray.com;
Tebu-bio) and gene maps were produced using Pathway
Architecture software (Stratagene, CA, USA). Genes were
considered relevant if they showed a twofold or greater change in
gene expression compared with control and they showed direct
interactions on the gene map. Expression of relevant genes was
confirmed by quantitative PCR and protein expression assessed by
western blot.
Results  Molecular analysis of subcutaneous MDA-G8 tumours
showed no effect on tumour cell cycle or apoptosis following
administration of 100 μg/kg zol. Conversely, 2 mg/kg dox caused a
cell-cycle block at G1-S and G2-M with a downregulation of cyclin
E/CDK2 and cyclin B/CDC2; dox alone did not affect apoptosis.
When dox was administered 24 hours prior to zol, however, the
cell cycle was further suppressed, compared with dox alone, there
was a downregulation of cyclin E1, cyclin B, cyclin D1 and cyclin
D3 as well as their related cyclin-dependent kinases CDK2, CDC2,
CDK4 and CDK7. Furthermore, tumours treated sequentially with
dox then zol showed an induction in the apoptotic pathway with an
upregulation in Bax, a downregulation in Bc12 and an increase in
caspase 3 cleavage.
Conclusion In subcutaneous MDA-G8 tumours: administration of
zol does not effect the apoptotic cell cycle pathways,
administration of zol disrupts the cell cycle but has no effect on
apoptosis, and sequential administration of dox followed by zol
results in cell-cycle inhibition and induction of apoptosis.
Acknowledgement Breast Cancer Campaign funded this work.
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Background Many breast cancer survivors are menopausal either
at diagnosis or as a result of a premature therapy-induced
menopause, complaining frequently of climacteric symptoms [1].
The menopause is widely seen as part of the natural ageing
process; however, for many women who have had treatment for
breast cancer; it can be viewed as a further complication, which
can significantly impact on their quality of life as they recover from
cancer treatment [2]. The increased symptoms often coincide with
a time of transition from the completion of intensive treatment to
follow-up care when there can be a perceived decrease in levels of
support [3]. The limited evidence to guide practice both
pharmacologically and nonpharmacologically within breast cancer
has created a confused environment, for both clinicians and
patients [4]. The aim of the present study was therefore to explore
the experiences and expectations of both women with breast
cancer and the health professionals, in relation to the management
of menopausal symptoms in a clinical setting.
Method A qualitative exploratory study using focus groups and in-
depth individual interviews was carried out to collect data from 14
female patients with breast cancer and from 18 health
professionals who worked predominately with breast cancer within
a large cancer centre. The data were coded and organised using
QSR Nvivo 7 Software and were analysed thematically.
Results Three main themes emerged across both groups; namely,
recognising the inevitability, building relationships and moving
forward. The data presented an insight into the complexities of
menopausal symptoms that are experienced by women with breast
cancer within the context of their diagnosis, treatment and ongoing
care, and the contrasting perceptions of the health professionals
who manage their care.
Conclusion  While the findings have highlighted the complex
nature of menopausal symptoms for women with breast cancer, it
has also identified the difficulty of isolating these symptoms from
the whole experience associated with breast cancer from
diagnosis and beyond. There is a need to assess and manage
women both individually and within a multidisciplinary context,
particularly as women continue to see different healthcare
professionals following completion of treatment. This would allow
complex issues that span across the premenopausal,
perimenopausal, or postmenopausal stages, to be identified and
resolved effectively.
Acknowledgement  Funded by the Centre for Integrated
Healthcare, Edinburgh.
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Background The factors leading to breast cancer recurrence are
incompletely understood. We recently carried out a retrospective
Available online http://breast-cancer-research.com/supplements/10/S2S42
study of treatment and outcome for 1,065 breast cancer patients
for which we examined factors correlating with cancer recurrence.
We found that infection of surgical wounds after surgery for primary
disease positively correlated with cancer recurrence [1]. Patients
with wound complications were almost threefold more likely to have
systemic recurrences than those without over the follow-up period
(P  < 0.0001). The aim of our current study is to determine
mechanisms responsible for this correlation. Our approach is based
on two possible theories. First, patients may have an underlying
immune dysfunction that predisposes them to developing both
wound complications and also recurrence. This may be as a result
of the tumour itself suppressing the activity of immune regulatory
cells including dendritic cells, T cells and NK cells via increased
levels of some critical cytokines (for example, vascular endothelial
growth factor, IL-10, IL-6). Secondly, factors released at sites of
wound complications may have direct influences on the remaining
occult tumour cells, thereby increasing the likelihood of metastases.
This model is supported by observations that cytokines released at
sites of infection as part of inflammatory/immune responses are
capable of enhancing growth and survival of tumour cells [2]. Also
there is evidence that bacterial components may stimulate
metastatic growth, most probably via cytokine mediators [3].
Methods and results Patients with primary operable breast
cancer are recruited prospectively. Blood samples are collected
from patients preoperatively, 4 hours and 16 hours postoperatively
and again at 2 weeks, 3 months and 6 months postoperatively. A
variety of investigations are carried out on each sample to establish
the immune status of the patient at that time point, and to identify
potential mediators of crosstalk between the immune system, the
wound and any occult tumour cells. These investigations include:
full blood count; detailed immune cell phenotyping (absolute
numbers/frequency of B-cell, T-cell and NK-cell subtypes using
multicolour flow cytometry); and cytokine profiling (using fluid-phase
cytometric multiplex immunoassays for 27 critical cytokines and
growth factors). Patients are followed up and monitored for
postoperative wound complications and evidence of recurrence. We
shall determine whether patients that develop wound complications
and/or metastases show immune defects from the outset, and
whether systemic changes in immune regulators during wound
complications reflect the development of metastases. Recruitment is
ongoing with samples from >100 patients expected to be collected
and processed by the end of 2007. Preliminary data concerning
immune status and wound complications will be presented.
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Background  Ductal carcinoma in situ (DCIS) is a noninvasive
breast cancer. While debate persists about its most appropriate
treatment, women diagnosed with DCIS are faced with a paradox;
although they are often reassured that the condition has been
caught early and is not life-threatening, they undergo similar
treatments (including mastectomy) to invasive breast cancer
patients [1]. Ongoing research by the authors exploring the
psychosocial impact of DCIS has found that women hold diverse
beliefs about the condition [2]. This work, along with previous
research, suggests that DCIS patients can be confused about the
condition and that the terminology used by health professionals
and the treatment recommendations given to patients may
enhance this misunderstanding [3]. Health professionals’ attitudes
about DCIS may also vary, which in turn could impact on patient
care, satisfaction and risk perceptions of the condition. Previous
research suggests that discrepancies between patient and health
professional perceptions of invasive breast cancer can disrupt
communication and compromise care [4]. Therefore, the present
study aimed to explore health professionals’ perceptions of DCIS,
including the terminology they use with patients and the challenges
the condition presents in their work.
Method Two hundred and ninety-three UK health professionals (for
example, surgeons, breast care nurses, radiologists, oncologists
and radiographers) involved with the diagnosis and treatment of
DCIS patients completed an online survey including demographic
information and items relating to the terminology used to describe
DCIS, risk and perceptions. A number of open-ended questions,
providing qualitative data, were also included.
Results Findings suggest that professionals have diverse beliefs
about DCIS; 35.2% perceived it as breast cancer, whereas 44%
viewed it as a precancer. Oncologists were significantly more likely
to view it as not breast cancer (χ2 = 14.83, df = 6, P = 0.022).
Participants were asked to rate the risk associated with DCIS for
patients’ overall long-term health. The results suggest that breast
care nurses, surgeons and oncologists considered it to be less
serious than radiologists, radiographers and pathologists. Overall,
however, 80% rated DCIS as a low (39.6%) or intermediate risk
(41.3%), but despite this relatively positive prognosis 46.8% of
health professionals found explaining DCIS to patients more
difficult than invasive breast cancer. The qualitative findings
indicate that explaining the condition and the lack of consistent
terminology between health professionals was a key challenge.
Conclusion The findings suggest that there is considerable variation
in both health professionals’ perceptions of DCIS and the
terminology they use. This is likely to have a substantial impact on
patients’ experiences and perceptions, which is the focus of ongoing
research by the authors. The nature and impact of these variations
warrant further exploration and debate with both health professional
and patient groups in order to inform the provision of appropriate
care and information to meet the needs of DCIS patients.
Acknowledgement  Funded by a PhD studentship grant from
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preferences of women aged 70 years and over: a study in
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Background  Tens of thousands of women are diagnosed with
breast cancer each year in the UK. Because the risk of developing
the disease increases with age, more than one-third of cases are
diagnosed in women aged 70 years and over. In addition,
improvements in treatment have meant that many women,
diagnosed before the age of 70, are surviving into older age.
Despite this, the breast cancer experiences of women in the age
group of 70 years plus have been largely neglected [1], alongside
their information and support needs and preferences. So whilst it is
recognised that women in this age group are less likely to use
existing information and support opportunities [2], it is not known
why this is so.
This presentation will report on a study that is using one-to-one
interviews and focus groups to explore the breast cancer
experiences of women aged 70 years and over, particularly when
other health conditions are also present, and their information and
support needs and preferences. Preliminary findings will be
offered, alongside some developing recommendations for
information and support mechanisms that are informed by, and
better meet, the needs and preferences of women with breast
cancer aged 70 years and over.
Acknowledgement Funded by Macmillan Cancer Support.
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Background  There is increasing concern that the longer-term
psychological and information needs of individuals found to carry
genetic mutations predisposing them to an increased risk of
developing breast/ovarian cancer are not being met. The present
study sought to explore preferences for an ongoing support
network for mutation carriers.
Methods Sixteen female BRCA1/2 mutation carriers within the All
Wales Medical Genetics Service attended one of three focus
groups. A topic guide was used to explore patients’ current and
ongoing information and psychological support needs, and
preferences for the content, nature and format of support group or
network. Data were transcribed and thematically analysed.
Results  The results reflected a diverse range of experiences
amongst participants. Many patients reported adequate support
from the genetic service both upon receipt of test results and in the
longer term, whilst others were not aware that ongoing support
was available. Many participants believed they and family members
would benefit from increased psychological support and
information. General consensus was reached that a support
network, incorporating elements including a traditional support
group alongside matching schemes, web-based chat forums and
professional-led workshops, would be the best approach. It was
felt important that such an initiative should have professional input.
Conclusion The data will inform the development of an appropriate
support network for mutation carriers to help them adapt to living
with their genetic risk and cope with their worries for themselves
and family. The results of the study will also inform the
development of similar support networks for other at-risk patients.
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assess the impact of the type and timing of breast
reconstruction on quality of life following mastectomy
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Background  Breast reconstruction is performed to improve the
quality of life and body image for women facing mastectomy.
Whilst significant anecdotal evidence and surgical dogma exists
regarding the optimal reconstructive practice, a comprehensive
MEDLINE literature review has revealed a paucity of well designed,
statistically powered studies to address the impact of either the
type or the timing of breast reconstruction on these key patient-
reported outcomes. There is little high-quality evidence to support
the benefit of immediate versus delayed breast reconstruction, for
example, or to suggest the superiority of autologous over implant-
assisted reconstructions in terms of improvements in quality of life
or body image, particularly in the context of postoperative
radiotherapy (RT). There is also very limited evaluation of the
impact of latissimus dorsi (LD) breast reconstruction, although this
is the procedure most commonly offered by oncoplastic breast
surgeons in the UK. There is currently, therefore, very little to guide
patients or their surgeons in making important decisions regarding
their reconstructive options.
Study aim The Quality of Life following Mastectomy and Breast
Reconstruction (QUEST) study aims to apply rigorous scientific
methodology to definitively address causality and to address key
reconstructive questions, thus ultimately providing patients and
their surgeons with high-quality evidence as the basis for truly
informed consent.
Study design The QUEST study is the first multicentre statistically
powered randomised controlled trial to assess the impact of the
type and timing of the most commonly offered form of breast
reconstruction on quality of life following mastectomy. The study
consists of two parallel randomised controlled trials, with study
entry determined by a preoperative assessment of the requirement
for postoperative RT (see Figure 1). Women unlikely to require
postoperative RT will be randomised to either autologous or
implant-assisted LD breast reconstruction, while those requiring
RT will be randomised to either immediate or delayed extended LD
procedures. These approaches are consistent with current
accepted reconstructive practice. The use of a randomised
methodology in the context of patient-centred procedures of this
kind has been much criticised on the basis of additional patient
stress and the view that patients who consent to randomisation are
Available online http://breast-cancer-research.com/supplements/10/S2S44
likely to differ significantly from the population as a whole, thus
limiting the generalisability of the results. The QUEST study,
however, addresses this issue by recruiting patients declining or
not eligible for randomisation to a prospective cohort study, thus
creating a comprehensive cohort and allowing the impact of the
decision-making process to be assessed.
Patients Women requiring mastectomy for invasive breast cancer,
ductal carcinoma in situ, atypical ductal hyperplasia, lobular
carcinoma in situ or other premalignant condition who request LD
breast reconstruction are eligible for inclusion in the study.
Sample size A power calculation has suggested that 150 patients
will be required in each study arm to detect an effect size of 0.4 at
the 5% level with 90% confidence. As a randomised trial in breast
reconstruction is a challenging prospect, the main study will be
preceded by a 12-month feasibility study of the same design to
assess patient recruitment to each study arm.
Conclusion  As the survival rate from breast cancer increases,
quality of life becomes an increasingly significant outcome. This is
an exciting, innovative and challenging project, but it is only
through the use of rigorous scientific methodology that definitive
evidence can be produced. Women facing mastectomy deserve
truly informed decision-making regarding their reconstructive
options. This is the QUEST.
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and body image following immediate latissimus dorsi
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Background  Immediate breast reconstruction (BR) is currently
advocated by the National Institute of Clinical Excellence on the
basis of improved psychosocial outcomes with benefit of a single
operative intervention. Tissue-based procedures are largely
preferred due to cosmetic superiority, particularly in the context of
postoperative radiotherapy (RT). The impact of this approach on
quality of life (QoL), however, has never been fully evaluated. We
present a pilot prospective longitudinal study that questions this
practice.
Methods Patients undergoing immediate latissimus dorsi (LD) BR,
the most commonly offered reconstructive procedure in the UK,
completed validated QoL questionnaires (EORTC C30+BR23/
FACT B+4) together with the Body Image Scale preoperatively
and at 3 months, 6 months, 12 months and 24 months post
surgery. QoL and body image were compared in women under-
going extended (ELD) and implant-assisted (LDI) procedures ±
postoperative RT.
Results Sixty-two women underwent 46 (74%) implant-assisted
and 16 (26%) extended LD BR with RT in 13 (28%) and seven
(44%) cases, respectively. One hundred and ninety-four question-
naires were completed with a median follow-up of 6 months (range
3–24 months). The QoL in all groups declined initially before
improving, with patients undergoing implant-assisted procedures
reporting a more rapid return to baseline levels of QoL than those
in the extended group (Figure 1). Body image was superior in the
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The QUEST study flow chart. ADH, atypical ductal hyperplasia; DCIS,
ductal carcinoma in situ; ELD, extended latissimus dorsi; LCIS, lobular
carcinoma in situ. *Prospective patients will undergo preoperative
evaluation of the breast (mammogram/ultrasound scan/MRI and core
biopsy) and axilla (ultrasound scan and fine-needle aspiration of
suspicious nodes or preoperative sentinel lymph node biopsy) to
determine whether they are likely to require postoperative radiotherapy
(RT) according to each centre’s local RT guidelines (for example,
multifocality, grade 3, lymphovascular invasion and nodal involvement).
**Delayed reconstructions must be performed within 12 months of
randomisation. ***Patients in the delayed arm will complete baseline
questionnaires prerandomisation and at 3 months and 6 months post
mastectomy, then prereconstruction (usually approximately 12 months
postoperative). Following reconstruction, follow-up will be as per the
other arms – 3 months, 6 months, 12 months and annually for 5 years.
Figure 1 (abstract P88)
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extended group when compared with LDIs at 12 months, but QoL
was comparable (Figure 2). Irradiation of ELD but not LDI
reconstructions produced dramatic and persistent deteriorations in
both QoL and body image.
Conclusion  Body image is superior following tissue-based
reconstruction, but this difference is not reflected by superior QoL.
Combining ELD with RT, however, has a profound effect on both
body image and QoL. Surgeons should consider patient-reported
outcomes as well as cosmesis when recommending surgical options.
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Background Early mammographic screening (under the age of 50)
is offered to many women in the UK who are at moderate or high
risk of developing breast cancer because of their family history of
the disease [1]. While studies are underway to establish the
clinical effectiveness of early mammographic screening [2],
relatively little is understood about the impact of early and regular
surveillance on the psychological wellbeing of women [3], and
even less about the impact of being diagnosed with breast cancer
while on a screening programme. This qualitative study explores
the emotional effect that the diagnosis of breast cancer had on
women, and the value they placed on having joined the family
history screening programme, both pre and post diagnosis.
Methods In-depth interviews were undertaken with 12 women in
the UK, aged 35 to 50, diagnosed with a screen-detected breast
cancer while on a mammographic surveillance programme because
of their family history of breast cancer. The interviews include
explorations of women’s motivations for joining the early screening
programme, their views about the value of mammography, and the
process of and their reactions to their cancer detection.
Results The interviews revealed different convictions of the likelihood
of developing breast cancer, but all women gained a strong sense of
reassurance from the possibility of the early detection of a cancer
through undergoing regular mammography. A number of women
relied solely on mammography to detect abnormalities, often reluctant
to examine their breasts due to the fear of finding a symptom.
Reactions to the diagnosis of a cancer ranged from relief to intense
shock. While all women were very positive about having undergone
mammography, not all wanted to continue with screening. For some,
prophylactic mastectomy was preferable, to reduce future cancer risk,
and to alleviate anxieties about the detection of another cancer at
each subsequent screen. Our study shows that for this group of
women, detection of their cancer was ultimately a positive experience.
They perceived surveillance to have achieved its goal of detecting a
cancer at a stage when treatment was likely to be effective, and the
future described was often one free of the fear of cancer that they had
carried with them for many years.
Clinical implications Not all women diagnosed with breast cancer
will have a pronounced negative reaction to their diagnosis; the
period during which they are under threat of developing the disease
may be a time of psychological preparation, thus enabling an easier
adjustment to the diagnosis. Women may seek bilateral mastectomy
as their treatment of choice, although their cancer my warrant a less
radical approach. Surgeons need to be aware of the fears associated
with future screening. Identification of women who are averse to self-
examination may allow the development of strategies to overcome this
avoidance. Women who have experienced the process of diagnosis
and treatment may be in an ideal position to provide a mentoring
system to women on the family history screening programme who are
very distressed at the possibility of being diagnosed with breast
cancer. Their perceptions of being able to cope should a breast
cancer be detected may be improved through such contact.
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Background Annual mammographic screening from the age of 40
is recommended for women in the UK whose family history places
Available online http://breast-cancer-research.com/supplements/10/S2
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them at a lifetime risk of developing breast cancer of ≥1:6 [1].
While the clinical benefits of screening younger women at
increased risk are not established, emerging evidence suggests
screening may lead to increased survival [2]. However, little is
understood of the emotional impact of screening on women with a
family history. This is particularly important in view of the increased
likelihood of recall for further tests in women under 50 years old
compared with those over 50 years old [3]. A recent questionnaire
study of the psychological impact of mammographic screening on
women under 50 years old with a family history of breast cancer
showed that, contrary to expectations, women who were recalled
for further tests prior to an all-clear result reported significantly
more positive feelings post result about screening than women not
recalled [4]. This complementary qualitative study explored the
value women placed on having joined a programme of regular
screening, and sought to understand the reactions of women who
had received an initial all-clear result and who had received an all-
clear result following further tests.
Methods  In-depth interviews were performed with 58 women,
aged 35 to 50, undergoing mammographic surveillance due to
their family history of breast cancer, and who had taken part in the
questionnaire survey. Women with initial all-clear results (36
women) and women with all-clear results after further testing (22
women) were recruited. Interview topic areas included experiences
of breast cancer within the family, motivations for joining the
programme, likelihood of developing breast cancer, views of
mammography, emotional responses to the screening process and
results, and views about the overall value of participating in the
programme. All interviews were transcribed verbatim and analysed
thematically.
Results Participating in the programme reflected a strong desire
within the women to be proactive about their risk of breast cancer,
particularly if delay in diagnosis was a factor in their relatives’
disease. Regardless of their individual experiences of cancer within
the family, faith in the ability of mammography to detect a cancer at
an early stage gave reassurance that a cancer diagnosis could lead
to a positive outcome. Many women placed a much greater faith in
mammography than in their own ability to detect an abnormality,
particularly at the very early stages of a symptom developing. A
high degree of reassurance and relief was described by women
receiving an initial all-clear result, although for a small number this
relief was slightly tempered by doubts about the accuracy of their
result. Of the women recalled for further tests, most experienced
immediate distress; for some, this remained throughout the
process of further testing. The subsequent all-clear result was
often followed by an increased feeling of security and reassurance,
and the women appeared to place an even greater faith in
screening than those receiving an initial clear result. Far from being
a negative component of screening, recall was interpreted as proof
that mammography worked. Recall for a nonmalignant symptom, or
for an unclear mammogram, enhanced belief in the detection of
any future malignancy. Women’s concerns about being at risk of
developing breast cancer appear to be alleviated by participating in
an annual surveillance programme. Irrespective of their screening
result, their stories demonstrated the significance of mammo-
graphy in enabling them to establish a sense of being in control of
their family history.
Clinical implications These findings highlight the emotional
benefits to many women of participating in a family history
screening programme. Counselling women prior to joining could
include detailed discussions of the effectiveness of mammography,
which may need to be reiterated with screening results. The
importance of remaining breast aware between screens should be
reinforced. These findings are important in the context of the
introduction of a national screening programme for women under
50 years old with a family history of breast cancer, and the
increased likelihood of recall in this group compared with women
over the age of 50.
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Background It is not yet known whether the benefits of regular
screening for women with a family history of breast cancer (FHBC)
outweigh the harms. One of the harms associated with having a
mammogram is recall for further tests such as additional imaging
and biopsies [1]. This has been shown to cause significant anxiety
in the short term, and possibly the long term, in women in routine
screening [2]. Given the greater cancer worry in women with a
FHBC [3], it is possible they may be particularly adversely affected
by a recall. This multicentre, prospective study investigated both
the positive and negative psychological effects of regular
mammographic screening in women <50 years with a family
history of breast cancer [4].
Methods Women who received an immediate all-clear result after
mammography (n = 1,174) and women who were recalled for
further tests prior to receiving an all-clear result (false positive)
(n = 112) completed questionnaires: 1 month before mammo-
graphy, and 1 month and 6 months after receiving final results. The
questionnaires included measures of cancer worry, psychological
consequences and perceived benefits of breast screening.
Results See Figure 1. Women who received an immediate all-clear
result experienced a decrease in cancer worry and negative
psychological consequences immediately post result, whereas
women who were recalled for further tests did not. By 6 months
this cancer-specific distress had reduced significantly in both
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groups. Changes in levels of distress were significantly different
between the two groups, but in absolute terms the differences
were not large. Recalled women reported significantly greater
positive psychological consequences of screening immediately
post-result, and were also more positive about the benefits of
screening compared with women who received an immediate all-
clear result.
Conclusion  For women receiving an immediate all-clear result,
participating in annual mammographic screening is psychologically
beneficial. Furthermore, women who are recalled for further tests
do not appear to be psychologically harmed by screening.
Women’s positive views about mammography suggest that they
view any distress caused by recall as an acceptable part of
screening.
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Background  Phytoestrogens are plant-derived, bioactive sub-
stances with a chemical structure similar to that of 17β-oestradiol.
Women previously treated for breast cancer may increase their
phytoestrogen intake to avoid conventional hormone replacement
therapy or because of a belief that they may help avoid recurrence
[1,2]. There is no recommended daily intake and there are some
concerns about phytoestrogen safety in this group, although the
evidence is conflicting and more research is needed [3,4].
Methods Three hundred and sixteen women each completed a 4-
day food and drink diary (14 of whom also completed a 7-day
weighed intake diary 6 weeks previously). The 55 most recently
recruited women collected their urine for 24 hours whilst
completing their diaries and were interviewed by telephone
regarding their food choices since diagnosis.
Results A new dietary analysis database was created using peer-
reviewed published data and analysing 34 additional foods and
beverages for which there were no published results. The
urinanalysis results contributed validation data. A summary of the
dietary intake data is shown in Table 1. There was a lack of primary
analytical data on the phytoestrogen profile of many foods and
beverages routinely consumed by this study population. However,
food frequency data from the highest quartile show the important
contribution of nonsoya foods to high intakes (Table 2). Telephone
Available online http://breast-cancer-research.com/supplements/10/S2
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Summary of intake data by receptor status and antioestrogenic drug prescription
First Second Third Fourth 
Total phytoestrogen intake (μg/1,000 kcal) (n = 316) n quartile quartile quartile quartile
Receptor status
Mean 8,388 ER-negative 42 11 (14%) 11 (14%) 13 (16%) 7 (9%)
Range 126 to 77,703 ER-positive 182 40 (51%) 42 (53%) 48 (61%) 52 (66%)
Quartile ranges Not available 92 28 (35%) 26 (33%) 18 (23%) 20 (25%)
First quartile <3,817 Antioestrogenic drugs
Second quartile 3,817 to 6,798 No prescription 109 30 (38%) 30 (38%) 25(32%) 24 (30%)
Third quartile 6,799 to 10,255 Tamoxifen or arimidexa 200 47 (59%) 47 (59%) 52 (65%) 54 (68%)
Fourth quartile >10,255 Other/missing 7 2 (3%) 2 (3%) 2 (3%) 1 (2%)
aAstraZeneca, London, UK.S48
interviews were completed by 39 subjects. For most women,
having breast cancer had not changed their diet. Health concerns
unrelated to cancer, the needs of other family members, cooking
on a budget and physical appearance all seemed more important
than the impact of the cancer diagnosis.
Discussion  Variation in phytoestrogen intakes and metabolite
excretion reflect food preferences, dietary analysis database
limitations and likely variations in existing knowledge combined
with a lack of routine access to dietary information. In the absence
of definitive advice, more immediate health and social concerns
influence food choice rather than past breast cancer diagnosis.
Conclusion No data previously existed on intake in this potentially
vulnerable group and these data will help evaluate the health
implications related to such phytoestrogen consumption patterns.
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Background Since 2004, Burton-upon-Trent’s NHS Hospital Breast
Care Unit has run a homeopathy service providing an alternative
therapy for symptoms affecting women during and after treatment of
their primary disease. The majority suffer from menopause-type
symptoms arising from breast cancer treatment. Such symptoms can
be bad enough to affect long-term compliance with drug regimes.
Patients receive a course of treatment from a qualified homeopath,
consisting of a series of patient-centred consultations plus
individualised homeopathic medicines. The present study aimed to
evaluate the benefit gained by women attending the homeopathic
service between April 2005 and March 2007.
Methods Routine data gathered at each homeopathic consultation
included a validated patient-generated and assessed outcome
measure (MYMOP2), in which patients choose their worst
symptoms, and score them and their general wellbeing on a seven-
point Lickert scale from 0 (very good) to 6 (very bad). A change
>0.8 is considered clinically significant improvement.
Results Initial and final MYMOP2 data were collected from 104
women, mean age 51.2 years, range 19–74 years. The most
frequently chosen worst symptoms were hot flushes (46%), breast
pain (19%), depression/anxiety (10%) and aches/pains (9%). The
mean worst symptom score at presentation was 4.1 ± 0.126, and
at the end of the course was 2.34 ± 0.16 (P < 0.001), with 73%
reporting an improvement ≥1. General wellbeing at presentation
scored 3.2 ± 0.13 and at the end 2.3 ± 0.15 (P < 0.001).
Conclusion These results indicate that homeopathy can offer a
valuable addition to mainstream conventional therapy for breast
cancer patients, possibly helping to improve compliance and
therefore long-term survival.
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The cancer stem cell hypothesis suggests that targeting stem-like
cells in cancer will improve current therapeutic strategies. In vitro
culture of mammospheres (MS), colonies that are analogous to
neurospheres, has been used to study factors affecting the self-
renewal and growth of ductal carcinoma in situ (DCIS) in 29
cases. The MS culture system demonstrates a small subset of
DCIS cells with self-renewal clonogenic capacity showing 1.5 ±
0.1% MS forming efficiency (MFE), which is greater than normal
breast MFE, 0.5 ± 0.1% (P < 0.0001). DCIS MS demonstrated an
increased growth rate compared with normal, yielding MS >60 μm
within 3 days rather than 7 days. The MFE was greater in high (1.6
± 0.1%) compared with low (1.1 ± 0.1%, P = 0.012) histological
grade DCIS, suggesting a link between the number of MS-initiating
cells and recurrence rates.
Since normal breast MS formation was known to depend on
epidermal growth factor (EGF) and Notch receptor signalling, we
investigated these pathways in DCIS MS. Only high-grade DCIS
MFE was decreased in the presence of the EGF receptor inhibitor,
Gefitinib, when no EGF was present in the media (1.36 ± 0.16%
to 0.56 ± 0.2183, P = 0.0017). This suggests high-grade DCIS
secrete growth factors that signal via the EGF receptor. Notch was
aberrantly activated in DCIS compared with normal breast,
demonstrated by increased levels of activated Notch intracellular
domain (NICD) and downstream targets Notch 4 and Hes-1. A γ-
secretase inhibitor, DAPT, which inhibits the activating cleavage of
Notch receptors, reduced DCIS MFE from 0.88 ± 0.07% to 0.51
± 0.08% (P = 0.0005). A Notch 4 receptor neutralising antibody
reduced DCIS MFE, 0.97 ± 0.1% to 0.2 ± 0.05%, resulting in no
MS formation in two out of six cases (P < 0.0001). Furthermore,
presence of NICD by immunohistochemistry predicted recurrence
Breast Cancer Research    May 2008 Vol 10 Suppl 2 Breast Cancer Research 2008
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Main food sources of phytoestrogens
From highest 
quartile Daidzein Genistein Glycitein Formononetina Biochanin Aa Coumestrola Matairesinola Secoisolariciresinola
Main  food  Cereal  Cereal Soya  Fruit, Legumes, Fruit,  Tea  Tea 
group source foods foods products vegetables blackcurrants vegetables (black leaves),  (black leaves), 
cereal foods fruit, vegetables
aLimited data available on content in some foods.S49
in patients with 5 years’ follow up after surgery (n = 50,
P = 0.012).
These data indicate that Notch and EGF receptor signalling
pathways are important in DCIS MS formation, and therapeutic
inhibition of the Notch signalling may increase recurrence-free
survival after surgery.
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Background  Women who inherit a germline mutation in the
BRCA2 gene are predisposed to breast cancer [1]. Therapies
targeted specifically at these cancers have so far remained elusive.
Recently, inhibition of poly-ADP-(ribose)-polymerase-1 (PARP-1)
was shown to cause high levels of death in cells and xenografts
deficient in BRCA2 [2-4].
Methods  We have conditionally deleted Brca2 and  p53 within
murine mammary epithelium, resulting in the development of
naturally arising tumours from 6 months of age. These tumours
have been treated in situ with a highly potent inhibitor of PARP-1,
either alone or in combination with carboplatin. The tumour size
was followed by regular measurement with calipers.
Results  Daily exposure to 50 mg/kg PARP-1 inhibitor caused
significant regression or growth inhibition in the majority of
Brca2/p53-deficient tumours, in comparison with p53-deficient or
pten-deficient control tumours. Combination treatment with
carboplatin did not enhance initial tumour regression compared
with carboplatin treatment alone. However, prolonged treatment
with PARP-1 inhibitor, after an initial 28-day combination therapy,
increased the time to tumour relapse compared with 28 days of
carboplatin monotherapy or combination therapy.
Conclusion  This is the first preclinical study to show in vivo
hypersensitivity of naturally arising Brca2-deficient mammary tumours
to PARP-1 inhibition monotherapy and combination therapy.
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